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Summary 
Anxiety and depression disorders represent common, serious and growing health problems 
world-wide. The neurobiological basis of anxiety and depression, however, remains poorly 
understood. Further, there is a clear need for the development of better treatments for these 
disorders. Emerging data with genetic and pharmacological tools supports a role for GABAB 
receptors in both anxiety and depression. GABAB receptors are metabotropic GABA 
receptors that are comprised of two subunits, GABAB1 and GABAB2, which form 
heterodimers. The GABAB(1) gene is transcribed into two predominate isoforms, GABAB(1a) 
and GABAB(1b) which differ in sequence primarily by the inclusion of a pair of sushi domains 
(or short consensus repeats) in the GABAB(1a) N-terminus. Both isoforms heterodimerize with 
GABAB2 subunits to form functional receptors. The  two GABAB(1) isoforms and the 
GABAB(2) subunit constitute the majority of the molecular diversity of the GABAB receptor. 
However, in the absence of any isoform-selective ligands for research, the behavioural 
function of mammalian GABAB1 receptor isoforms has been inscrutable.  
Recently mice deficient in GABAB(1a)  and GABAB(1b) isoforms were generated. 
Aspects of anxiety- and depression-related behaviour may be modelled in mice, by using 
traditional animal models, and by examining specific biological and behavioural components 
of the human symptomatology, or ‘endophenotypes’. A preliminary aim of this thesis was to 
determine the utility of GABAB(1) isoform-deficient mice for the dissection of GABAB(1a) and 
GABAB(1b) isoform-mediated behaviour. The main aim of this thesis was to test the 
hypothesis, using a combination of traditional and endophenotype murine models, that 
GABAB(1) receptor isoforms play an important role in the mediation and anxiety and 
depression-related behaviour.  
 
GABAB(1) Isoforms in GABAB Receptor Function B
Preparatory work in this thesis examined the influence of genetic background on GABAB  
receptor-mediated responses. Genetic background, in the form of different mouse strains,  had 
a strong, differential effect on the classic responses to GABAB receptor activation; 
hypothermia and ataxia. This underlined the necessity of including multiple experimental 
endpoints in the examination of GABAB receptor function in subsequent work with GABAB(1) 
isoform-deficient mice. Importantly, this study also demonstrated that the BALB/c mouse 
strain was an appropriate genetic background for carrying the GABAB(1) isoform mutations. 
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Initial studies with GABAB(1) isoform-deficient mice demonstrated that they were free 
of gross sensory-motor deficits that may preclude their application in behavioural tasks. 
Furthermore,  GABAB(1a) and GABAB(1b) diverged in their influences on locomotor responses 
to novelty and circadian activity, although the GABAB receptor agonists baclofen or γ-
hydroxybutyrate (GHB) were not specific for either isoform and were unable to discriminate 
these differences. These findings demonstrated that the GABAB(1) isoforms had differential 
influences on behaviour. Together these studies demonstrated that the GABAB(1a)-/- and 
GABAB(1b)-/- mice were applicable for testing the hypothesis that the GABAB(1) isoforms were 
differentially implicated in anxiety and depression related behaviour.  
 
GABAB(1) Isoforms in Endophenotypes of Anxiety and Depression 
Deletion of GABAB(1a) and GABAB(1b) isoforms had profound, differential impacts on the 
acquisition (GABAB(1a)) and extinction (GABAB(1b)) of aversive memories, as determined in a 
conditioned taste aversion paradigm.  These effects, however, were not accompanied by 
differences in innate anxiety, as assessed in a comprehensive test battery of unconditioned 
anxiety tests, including autonomic (stress-induced hyperthermia), active (marble burying) and 
passive exploratory avoidance (staircase, light-dark box, elevated plus maze, elevated zero 
maze) behavioural readouts. There was no evidence for a specific influence of either isoform in 
these tests. This indicated that the GABAB(1) isoforms themselves did not have a defining role 
in innate anxiety.  
 GABAB(1a)-/- and GABAB(1b)-/- mice diverged in their cognitive phenotypes. GABAB(1a)-
/- mice were impaired in tasks of working spatial and recognition memory, but not in passive 
avoidance. GABAB(1b)-/- mice were also impaired, to a lesser degree, in a working spatial 
memory task, but showed preservation of working recognition memory and passive avoidance. 
Long term recognition memory, however, was also impaired in these mice. 
The GABAB(1a) isoform was specifically implicated in depression-related behaviour, as 
indicated by reduced immobility in a classic test of antidepressant-like behaviour – the forced 
swim test. This was most probably mediated via the striking interactions of the GABAB(1a) 
isoform with the serotonergic system, as illustrated in particular by the profound 
desensitisation of presynaptic 5-HT1A receptors in GABAB(1a)-/- mice. A lack of effect on 5-
HT1A receptor expression in GABAB(1a)-/- mice, as indicated by normal 5-HT1A 
autoradiography densities, suggested an intracellular mechanism for this desensitisation.  
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Together these studies demonstrated that the GABAB(1) isoforms are functionally 
important variants of the GABAB receptor, with specific relevance in depression and to 
aversive learning and memory processes that underlie cognitive symptoms in anxiety disorders. 
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Chapter 1 
 
General Introduction 
 
μελανχολια 
Hippocrates, c. 460 BC–c. 370 BC 
 
“I was walking along a path with two friends—the sun was setting—suddenly the sky turned 
blood red—I paused, feeling exhausted, and leaned on the fence—there was blood and 
tongues of fire above the blue-black fjord and the city—my friends walked on, and I stood 
there trembling with anxiety—and I sensed an infinite scream passing through nature.” 
Edvard Munch, 1863 - 1944
 
Anxiety disorders and depression have been synonymous with human civilization for 
centuries, and now constitute a fast-growing world-wide pandemic, and yet the causative 
factors and underlying mechanisms of these disorders still remain poorly understood. 
Psychiatric disorders are thus amongst the most challenging and impenetrable diseases to 
treat, with most current pharmacotherapies being the far from ideal benzodiazepine and 
monoaminergic-based drugs first discovered nearly 50 year ago. GABAB receptors were the 
last of the major neurotransmitter receptors to be cloned. Pharmacological and genetic 
deletion studies have indicated that the GABAB receptor is a promising target in anxiety and 
depression, although tools with which to probe the intricate and complex functions of this 
ubiquitously-expressed receptor have only relatively recently begun to be developed. The 
GABAB receptor is a heterodimer of two subunits, GABAB(1) and GABAB(2). Two isoforms of 
the GABAB(1) subunit are predominant in the brain, GABAB(1a) and GABAB(1b), and as such 
comprise the majority of the molecular diversity of the GABAB receptor. However, with no 
ligands with which to probe the physiological roles of these isoforms, the impact of these 
isoforms on GABAB receptor functions or in GABAB receptor mediated influences on anxiety 
and depression has been a mystery.  
The aim of this thesis was to use newly generated genetic tools – mice deficient in the 
GABAB(1a) and GABAB(1b) isoforms, in combination with behavioural analysis and 
pharmacological techniques, to evaluate the impact of the GABAB(1) receptor isoforms in 
models of anxiety and depression. 
Chapter 1  10 
_________________________________________________________________________________ 
1.1 The GABAB Receptor B
 
Discovery and Structure of the GABAB Receptor B
 
γ-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain. There are 
two distinct classes of GABA receptor through which GABA produces its effects: the 
GABAA receptor pentamer, which mediates fast inhibitory neurotransmission via a gated 
chloride ion channel, and the metabotropic GABAB receptor which modulates slower 
inhibitory responses (Cooper et al. 2003). Unlike the ionotropic GABAA receptors, GABAB 
receptors predominantly mediate their effects though activation of guanine nucleotide-binding 
proteins (G proteins). Although aberrations in GABA neurotransmission have long been 
implicated in the pathophysiology of psychiatric disorders, the role of GABAB receptors in 
these disorders has, until recently, been largely ignored (Cryan and Kaupmann 2005). 
The first specific GABAB receptor ligand was synthesised in 1962: β-chlorophenyl-
GABA, or baclofen, a derivative of GABA; although it was some time later that the receptor 
itself was identified. Two stereoisomers of baclofen exist, although only one is active: L-
baclofen. Baclofen was introduced in to the market in 1972 as Lioresal© for the control of 
spasticity and muscle rigidity associated with spinal cord injury, multiple sclerosis, 
amyotrophic lateral sclerosis, and cerebral palsy (Bowery 1993), an indication for which it is 
still in clinical use, more than 30 years later (Brogden et al. 1974). Indeed baclofen remains 
the only GABAB receptor-mediated therapeutic in the clinic. The existence of the GABAB 
receptor itself was first proposed by Norman Bowery and colleagues in the early 1980s, 
following from their biochemical description of a GABA-mediated response insensitive to the 
GABAA antagonist bicuculline, but sensitive to baclofen (Bowery et al. 1980). This became 
known as the GABAB receptor (Bowery et al. 1981). 
Cloning of the GABAB receptor, however, proved elusive and was not completed until 
> 15 years after Bowery’s discovery. As such, it was the last of the major neurotransmitter 
receptors to be cloned. The necessity for selective, high affinity ligands and the complex 
architecture of the receptor itself certainly contributed to this delay, and indeed made the 
cloning of this receptor a formidable challenge (Bettler et al. 2004; Froestl et al. 2003). Once 
soluble, selective, high-affinity ligands were derived, GABAB receptor cDNAs were isolated 
by expression cloning using the high-affinity radiolabelled GABAB receptor antagonist 
[125I]CGP64231 (Froestl et al. 2003; Kaupmann et al. 1997). Two isoforms (then proposed as 
splice variants) were discovered, and designated GABABR1a and GABABR1b (Kaupmann et 
al. 1997). The two isoforms differed in sequence only by an extended sequence in the 
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extracellular NH2-terminus (N-terminus) of the GABAB(1a) isoform, which harboured two 
domains known as ‘Sushi motifs’ or ‘short consensus repeats’ (see section 1.4). Both 
GABAB(1a) and GABAB(1b) were comprised of the extracellular N-terminus, a seven 
transmembrane region and an intracellular COOH-terminus (C-terminus) region. They each 
share structural similarities with metabotropic glutamate receptors (mGluRs), Ca+2-sensing 
receptors (CaS), vomeronasal and taste receptors, and as such have been categorized with 
these receptors as members of the Family 3 (or Family C) G-protein coupled receptors 
(GPCRs) (Bettler et al. 2004; Foord et al. 2005; Kaupmann et al. 1997). When expressed in a 
recombinant system however, agonist binding affinities and effector coupling of the 
GABAB(1) proteins were substantially below that of native receptors (Kaupmann et al. 1997).  
In the year after the cloning of the GABAB(1) gene, a second, structurally similar, 
member of the GABAB receptor family: the GABAB(2) subunit was described concomitantly 
by a number of research groups (Jones et al. 1998; Kaupmann et al. 1998a; Kuner et al. 1999; 
Martin et al. 1999; Ng et al. 1999; White et al. 1998). Furthermore, the reduced agonist 
affinity seen with recombinant expression of GABAB(1) proteins were explained by the 
discovery that when expressed alone, the GABAB(1) subunits were retained in the endoplasmic 
reticulum (ER), (Couve et al. 1998). Co-expression of the GABAB(1) and GABAB(2) subunits 
recovered both the surface expression, agonist binding affinity and for the most part, effector 
coupling in recombinant systems (see (Bettler et al. 2004)). The mechanism by which the 
subunits interacted to enable cell surface expression was subsequently shown to be via the 
masking of an ER retention motif (RSRR) in the C-terminus of the GABAB(1) subunit by the 
C-terminus of the GABAB(2) subunit, through the formation of a coiled-coil heteromer 
association between the two C-termini (Margeta-Mitrovic et al. 2000; Pagano et al. 2001) 
(although other regions in the transmembrane and extracellular domains also contribute to 
dimerisation - see (Bettler et al. 2004; Cryan and Kaupmann 2005)). Together these studies 
indicated that GABAB receptors were functional heterodimers, the first such described for G 
protein-coupled receptors (Fig. 1). This previously unreported phenomenon almost certainly 
contributed to the difficulties encountered in the initial attempts to clone the GABAB receptor.  
The ligand binding domain for GABAB receptor agonists and competitive antagonists 
has been mapped to the GABAB(1) subunit. This domain conforms as a hinged, double-lobed 
structure that closes with ligand binding, and are thus termed the Venus flytrap modules 
(Bettler et al. 2004; Kubo and Tateyama 2005). The GABAB(2) subunit contains the same type 
of ligand binding domain, but to date no GABAB receptor ligands have been found which 
interact with this site (Bettler et al. 2004). The main function of the GABAB(2) subunit (in 
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addition to masking the RSRR domain of GABAB(1)) appears to be the mediation of GABAB 
receptor G-protein coupling (Thuault et al. 2004), although GABAB(1) is clearly necessary to 
optimize the coupling efficiency (see (Bettler et al. 2004)). 
 
 
 
 
Fig. 1. The GABAB receptor is a heterodimer comprised of GABAB B(1) (blue) and GABAB(2) (pink) 
subunits. Heterodimerisation is facilitated by coiled-coil interactions between the C-termini of the two 
subunits. The agonist and competitive antagonist ligand binding domain is present only on the 
GABAB(1) subunit, while G protein coupling and positive modulator binding is mediated by the GABAB(2) 
subunit. Two isoforms of the GABAB(1) subunit exist: GABAB(1a) (1a) and GABAB(1b) (1b) which differ in 
their N-termini by the inclusion of two Sushi motifs in the GABAB(1a) isoform. From Cryan and 
Kaupmann (2005) Trends Pharmacol Sci: 26 (1): 36-43. 
 
The relatively limited molecular diversity of GABAB receptors, being comprised 
predominantly of the GABAB(1a) or GABAB(1b) isoforms dimerised with the GABAB(2) 
subunit, came as a surprise to many researcher in the field, and is still considered today to be 
at odds with the reported variability and range of responses to GABAB receptor ligands 
(Bettler et al. 2004; Huang 2006; Marshall et al. 1999). However, the nature of GABAB 
receptor effector interactions, and the anatomical expression profile of this receptor almost 
certainly contribute greatly to this diversity.  
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GABAB Receptor Expression and Effector Systems B
 
GABAB receptors predominantly mediate their effects via G protein coupling, via the Giα and 
Goα G protein subtypes (Asano and Ogasawara 1986; Campbell et al. 1993; Greif et al. 2000; 
Menon-Johansson et al. 1993; Morishita et al. 1990). However, evidence also exists for direct, 
non-G protein mediated actions of GABAB receptors, for example via interactions with the 
transcription factor ‘activating transcription factor 4’ (ATF4, also known as cAMP response 
element binding protein 2 (CREB2)) (Nehring et al. 2000; Vernon et al. 2001; White et al. 
2000) or with mGluR1 receptors (Tabata et al. 2004). The expression profile and thus 
anatomically determined effector coupling of GABAB receptors certainly contributes to the 
diversity of GABAB receptor-mediated responses. GABAB receptors are expressed as 
presynaptic heteroreceptors, at post- and extra-synaptic sites and as interneuron autoreceptors 
(see (Bettler et al. 2004; Bowery et al. 2002; Cryan and Kaupmann 2005); Fig. 2).  
 
 
 
Fig. 2. GABAB receptors are expressed as presynaptic heteroreceptors, coupling via G proteins to 
voltage-gated Ca  channels and modulating neurotransmitter release, and postsynaptically where 
they couple to inwardly-rectifying K  channels to modulate slow inhibitory postsynaptic potentials 
They are also expressed as autoreceptors, mediating GABA release, and at extrasynaptic sites. From 
Cryan and Kaupmann (2005) Trends Pharmacol Sci: 26 (1): 36-43. 
B
+2
+
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Presynaptic receptors 
Presynaptic GABAB receptors inhibit the release of a number of different neurotransmitters 
(see (Bowery 1993) and (Bonanno and Raiteri 1993) for reviews), mainly by reducing 
calcium influx through high-voltage P/Q and N-type Ca+2 channels (for examples see (Amico 
et al. 1995; Cardozo and Bean 1995; Menon-Johansson et al. 1993; Mintz and Bean 1993; 
Moldavan et al. 2006; Pfrieger et al. 1994; Poncer et al. 1997)), both of which are strongly 
implicated in neurotransmitter release (Wu and Saggau 1997). Presynaptic GABAB receptors 
may also influence L- and T-type Ca+2 channels, although both inhibition and activation of 
these channels by GABAB receptors has been reported (see (Bettler et al. 2004)). In addition, 
direct influences of GABAB receptors on exocytotic release machinery have also been 
proposed (Capogna et al. 1996; Kolaj et al. 2004; Scanziani et al. 1992). There are also 
indications that at the presynaptic terminal, GABAB receptors interact with inwardly-
rectifying K+ channels (Kir3 or GIRK channels), although the channel subunit composition 
likely differs from the postsynaptically expressed GIRKs (Bettler et al. 2004). 
 
Postsynaptic Receptors 
Postsynaptic GABAB receptors couple to Kir3 channels, which when activated induce K+ 
efflux, hyperpolarisation and mediate slow inhibitory postsynaptic currents (IPSC) (Kolaj et 
al. 2004; Luscher et al. 1997; Schuler et al. 2001). Evidence for this comes, in particular, from 
experiments with mice deficient in either Kir3.2 or the GABAB(1) subunit, both of which do 
not show the normal baclofen-induced outward currents in hippocampal neurons (Luscher et 
al. 1997; Schuler et al. 2001). Other postsynaptic K+ currents may also be activated by 
GABAB receptors, such as fast-inactivating voltage-gated K+ channels and small-conductance 
Ca+2- activated K+ channels (SK channels) (see (Bettler et al. 2004)). There is also some 
evidence to suggest that postsynaptic GABAB receptors may suppress N-type high-voltage-
activated calcium conductances (Kolaj et al. 2004). 
In addition to coupling with ion channels via G proteins, GABAB receptors negatively 
couple to adenylyl cyclase via Gαi and Gαo proteins, as evidenced, most often, by GABAB 
receptor-activated inhibition of forskolin-stimulated cAMP release (for examples see (Gjoni 
et al. 2006; Hashimoto and Kuriyama 1997; Nishikawa et al. 1997; Wojcik and Neff 1984), 
and see (Bettler et al. 2004; Bowery 1993; Bowery et al. 2002) for reviews). GABAB 
receptor-activated stimulation of adenylyl cyclase has also been reported (Hashimoto and 
Kuriyama 1997; Ren and Mody 2006). Mechanisms by which this latter effect has been 
proposed to occur include a reliance on crosstalk between the βγ subunits of co-expressed 
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stimulatory (Gs) G proteins (Bettler et al. 2004), or alternatively via GABAB receptor-
dependent Ca+2 activation of Ca2+/calmodulin, which in turn directly stimulates adenylyl 
cyclases I and/or VIII (Ren and Mody 2006). GABAB receptor inhibition of presynaptic 
cAMP has also been implicated in presynaptic plasticity via a retardation of vesicle 
recruitment, most probably mediated by a failure in a Ca2+ / cAMP-dependent vesicle priming 
step (Sakaba and Neher 2003). Finally, GABAB receptors have also been implicated in other 
second messenger pathways including the mitogen-activated protein kinase (MAPK) and 
protein kinase C (PKC) pathways (Kubota et al. 2003; Ren and Mody 2003; Taniyama et al. 
1992). 
 
Anatomical Expression Profile 
GABAB receptors in general are widely expressed throughout the central nervous system. It 
has been postulated that nearly every neuron in the brain expresses GABAB receptors to some 
degree (Bischoff et al. 1999). The cerebral cortex (especially Layer 6b), thalamus, Purkinje 
processes in the molecular layer of the cerebellum, pyramidal cell layer of CA1-CA3 of the 
hippocampus, granular cell layer of the dentate gyrus, medial habenular nucleus, superficial 
layers of the dorsal horn of the spinal cord and motor neurons in the ventral horn, show 
particularly strong expression (Bischoff et al. 1999; Bowery et al. 1987; Charles et al. 2001; 
Fritschy et al. 1999; Kaupmann et al. 1997; Liang et al. 2000). The anatomical expression 
profile of the two GABAB(1) isoforms overlaps to a large degree with the GABAB(2) subunit, 
(Bettler et al. 2004) supporting the requisite heterodimerisation necessary for the expression 
of functional receptors. 
 
Functions of GABAB Receptors B
 
Well known physiological and pathophysiological roles of GABAB receptors, largely 
discerned from research with baclofen, include addiction, spasticity, epilepsy, 
gastroesophageal reflux disease, pain, cognition, anxiety and depression (for reviews see 
(Bettler et al. 2004; Bowery et al. 2002; Cryan and Kaupmann 2005), and see section 1.4  
GABAB Receptors in Anxiety and depression for further discussions on anxiety, depression 
and cognition,). 
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Hypothermia and Ataxia: In vivo Probes of GABAB Receptor Function 
Other well known effects of GABAB receptor activation include marked hypothermia (Cryan 
et al. 2004; Frosini et al. 2004; Gray et al. 1987; Humeniuk et al. 1995; Perry et al. 1998; 
Queva et al. 2003; Schuler et al. 2001; Serrano et al. 1985; Zarrindast and Oveissi 1988) and 
deficits in motor coordination (Brogden et al. 1974; Cryan et al. 2004; Frosini et al. 2004; 
Gassmann et al. 2004; Gray et al. 1987; Kasture et al. 1996; Schuler et al. 2001; Smith and 
Vestergaard 1979). These effects are well preserved in a wide range of species including 
mice, rats, rabbits and man. GABAB receptor activation also induces increases in plasma 
growth hormone, prolactin, adrenocorticotropin hormone (ACTH) and cortisol (or 
corticosterone in rodents) in a range of species. This indicates roles for the GABAB receptor 
in motor control, thermoregulation and endocrine modulation (Cavagnini et al. 1977; Davis et 
al. 1996; Hausler et al. 1993; Kimura et al. 1993; Koulu et al. 1979; Orio et al. 2001). GABAB 
receptor agonist-induced hypothermia, locomotor incoordination and endocrine measures are 
all relatively non-invasive, cross-species translatable and simple experimental measures to 
obtain that can provide information about the functional in vivo state of GABAB receptor. In 
combination with GABAB receptor agonist challenges, they show great utility as in vivo 
probes of GABAB receptor function in various experimental and clinical conditions.  
Criteria for the valid application of pharmacological probes of central neurotransmitter 
in vivo function have been proposed (Checkley 1980), and include: 
1. The response should result from the stimulation of a receptor, and be inhibited by 
drugs that block that receptor. The same response should occur with administration of 
all drugs that stimulate that receptor, and should not be inhibited by drugs that block 
other receptors; 
2. The receptor should be centrally located; 
3. Factors that can influence the response must be held constant (for example 
environmental, circadian, stress, hormonal rhythms); 
4. Time-course studies are advocated over single time-point studies in case peak 
responses are missed; 
5. Conscious animals should be used. 
 
In this way, baclofen indeed has been used to probe GABAB receptor function in 
animals and in clinical studies. For example, baclofen-induced locomotor impairment, 
antinociception and hypothermia have been used to probe GABAB receptor function in 
rodents following chronic antidepressant treatments (Borsini et al. 1986; 1988; Gray et al. 
1987; McManus and Greenshaw 1991). In clinical trials, blunted growth hormone to baclofen 
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has been seen in major depression (Marchesi et al. 1991; O'Flynn and Dinan 1993) (but see 
(Davis et al. 1997; Monteleone et al. 1990), alcoholism; heroin addiction (Vescovi et al. 1998; 
Volpi et al. 1992), and social phobia (Condren et al. 2003).  
This approach for probing GABAB receptor function is also applicable for use in 
mutant mice, as illustrated by studies with GABAB(1)-/- and GABAB(2)-/- mice. In these mice, 
the absence of hypothermia and ataxic responses to baclofen confirmed a total loss of  in vivo 
GABAB receptor-mediated responses (Gassmann et al. 2004; Queva et al. 2003; Schuler et al. 
2001). Furthermore, with mutant mice this approach can be gainfully utilised in the evaluation 
of proposed agonists. For example, GABAB(1)-/- mice did not show hypolocomotor or 
hypothermic responses to the weak GABAB receptor agonist and drug of abuse, γ-
hydroxybutyrate (GHB), indicating GHB normally exerts it in vivo effects through the 
GABAB receptor and not via a postulated GHB receptor (Kaupmann et al. 2003).  
 
1.2 Anxiety and Depression  
 
Anxiety and depression disorders represent common, serious and growing health problems 
world-wide (Kessler et al. 2005a; Miller 2006; Murray and Lopez 1997; Wong and Licinio 
2001). The disorders share high levels of comorbidity (Kessler et al. 2005b; Merikangas et al. 
2003), and those suffering from these disorders not only face debilitating disruptions to their 
psychological well-being, but are at high risk for suicide (Licinio and Wong 2005) and 
somatic conditions such as heart disease, gastrointestinal disorders and obesity (Harter et al. 
2003; Rumsfeld and Ho 2005; Sheps and Sheffield 2001). The causative factors underlying 
anxiety and depression, however, remain poorly understood (Cryan and Holmes 2005; Wong 
and Licinio 2001; Wong and Licinio 2004), and it is clear that improvements in understanding 
these factors and the development of better treatments are needed (Cryan and Holmes 2005; 
Holmes and Cryan 2006; Wang et al. 2005). 
Anxiety and depression disorders are characterised by a broad range of diverse, 
overlapping symptom clusters (Merikangas et al. 2003) and are classified into numerous 
categories and subcategories, based mainly on the subjective descriptions of symptoms (Lam 
et al. 2006; Wong and Licinio 2001) (Table 1 & 2). For example, two symptom criteria for 
major depression include: 1) depressed mood as indicated by self report or by observation 
(e.g. appears tearful); 2) feelings of worthlessness or excessive or inappropriate guilt (which 
my be delusional), not merely self-reproach or guilt about being sick (DSM-IV 1994; Lam et 
al. 2006; Wong and Licinio 2001) (see Table 1 for other DSM-IV symptom criteria). Anxiety 
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disorders are subdivided in to a number of categories, distinguished from one another mainly 
by the nature of the anxiety or of the stimulus producing the anxiety (Cryan and Holmes 
2005; Lam et al. 2006). They include generalized anxiety disorder, panic disorder (with or 
without agoraphobia), specific phobia, social phobia, obsessive–compulsive disorder and 
post-traumatic stress disorder, each with both distinct and overlapping symptom criteria 
(DSM-IV 1994; Lam et al. 2006) (See Table 2 for a summary).  
The subjective nature of these definitions are considered by many in the field to 
provide challenges in clinical diagnosis (Hasler et al. 2004; Lam et al. 2006; Schulze et al. 
2005; Wong and Licinio 2001), and although it is clear that some of the features of 
psychiatric disorders in humans cannot be modelled in mice (Tables 1 & 2), these definitions 
certainly contribute to challenges in modelling aspects of depression and anxiety disorders in 
mice and other experimental animals (Cryan and Holmes 2005; Cryan and Mombereau 2004; 
Holmes and Cryan 2006; Phillips et al. 2002; Tarantino and Bucan 2000). 
 
1.3 Mutant Mice and Murine Modelling of Anxiety and Depression  
 
The Endophenotypes Approach 
 
Recently, there has been a move to describe psychiatric disorders by dissecting the 
symptomatology into objectively measurable components. That is, into individual 
behavioural, physiological or neurochemical endpoints - termed ‘endophenotypes’ 
(Gottesman and Gould 2003; Hasler et al. 2004). The promotion of endophenotypes has arisen 
primarily with the aim of strategising an approach to discover the genetic and neurobiological 
architecture of psychiatric diseases. This comes from the conceptual basis that the number of 
genes required to produce less complex, definable traits may be fewer (and therefore more 
easily discovered) than those involved in producing a more complex trait such as those seen 
in psychiatric diagnostic criteria (Gottesman and Gould 2003; Hasler et al. 2004). In addition, 
the endophenotypes approach is clearly more applicable for use in animal models (Cryan and 
Holmes 2005; Gottesman and Gould 2003; Hasler et al. 2004; Holmes and Cryan 2006). 
Mice as experimental animals hold many practical and economic advantages over 
other laboratory species for use in animal modeling of human disorders. They are easy to 
breed, have a short generation turnover, and low maintenance costs in terms of housing. It is 
their unique amenability to genetic manipulations, however, that has seen the dramatic 
increase in the popularity of mice in psychiatric and other research, including anxiety and 
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depression (see (Cryan and Holmes 2005; Holmes and Cryan 2006; Jacobson and Cryan 
2007; Joyner and Sedivy 2000; Phillips et al. 2002; Tarantino and Bucan 2000)). Further 
more, the availability of different inbred mouse strains, many of which are essentially 
isogenetic, are a particular advantage as they allow assessment of a manipulation-induced 
phenotypes against a reduced background variability (Festing 2004; Jacobson and Cryan 
2007). As such, there have been numerous attempts to model psychiatric disease symptoms 
and endophenotypes in mice.  
Proposed essential criteria for a valid animal model of a psychiatric disease include 
that it is: ‘reasonably analogous’ to the human disorder in its manifestations or 
symptomatology; causes a behavioural change that can be monitored objectively; produces 
behavioural changes that are reversed by the same treatment modalities that are effective in 
humans; and is reproducible between investigators (McKinney and Bunney 1969). These 
criteria overlap well with the endophenotype approach in terms of setting experimental 
endpoints that are objectively measurable, repeatable and show analogy to human 
symptomatology. Examples of some of the psychological and behavioural endophenotypes of 
depression and anxiety, and how they may be modelled in mice are shown in Tables 1 and 2 
(see (Cryan and Holmes 2005; Cryan and Mombereau 2004; Cryan and Slattery 2007) for 
reviews). 
 
Table 1. Modelling symptoms of major depression* in mice  
Symptom How might symptom be modelled in mice? 
Depressed mood Cannot be modelled 
Markedly diminished interest or pleasure in 
everyday activities (anhedonia) 
Reduced intracranial self-stimulation, progressive 
ratio responding for positive reward (for example, 
sucrose) and social withdrawal 
Large changes in appetite or weight Abnormal loss in body weight after exposure to chronic stressors 
Insomnia or excessive sleeping Abnormal sleep architecture (measured using electroencephalogy) 
Psychomotor agitation or slowness of movement Difficulty in handling and alterations in various measures of locomotor activity and motor function 
Fatigue or loss of energy 
Reduced activity in home cage, treadmill/running 
wheel activity, nest building and active waking 
electroencephalogram 
Indecisiveness or diminished ability to think or 
concentrate 
Deficits in working and spatial memory and 
impaired sustained attention 
Difficulty performing even minor tasks, leading to 
poor personal hygiene Poor coat condition during chronic mild stress 
Recurrent thoughts of death or suicide Cannot be modelled 
Feelings of worthlessness or excessive or 
inappropriate guilt  Cannot be modelled 
*Symptoms used in the Diagnostic and Statistical Manual-IV diagnosis of major depression 
From Cryan and Holmes, (2005) Nat Rev Drug Discov 4 (9): 775-90 
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Table 2. How symptoms of anxiety disorders* might be modelled in mice  
 
Symptom How might symptom be modelled in mice? 
Avoidance of places from which escape could be 
difficult (agoraphobia) Increased avoidance of exposed, well-lit areas 
Sudden onset of intense fearfulness, often with 
respiratory distress and fear of ‘going crazy’ 
(panic attack) 
Increased flight from a predator 
Anxiety provoked by social situations, leading to 
avoidance behaviour (social phobia) Low social interaction with unfamiliar conspecific 
Anxiety provoked by a specific feared object, 
leading to avoidance behaviour (specific phobia) Conditioned taste avoidance 
Re-experiencing a traumatic event, leading to 
increased arousal and avoidance of stimuli 
associated with the event (post-traumatic stress 
disorder) 
Increased freezing response to fear-conditioned 
cue or context 
Anxiety-provoking obsessions and anxiety-
reducing compulsions (obsessive–compulsive 
disorder) 
Increased marble burying and excessive 
grooming 
Difficulty concentrating or mind going blank 
(generalized anxiety disorder) Impaired sustained attention 
Sleep disturbance/insomnia  Abnormal sleep architecture (measured using electroencephalogy) 
Autonomic hyperarousal (tachycardia, blushing, 
sweating and frequent urination) 
Radiotelemetric measurement of heart rate 
dynamics during anxiety-provocation, such as 
increased stress-induced hyperthermia 
Flashbacks of traumatic events  Impairment in extinction of fear memory  
Cognitive bias towards ambiguous or weak threat 
cues Increased fear conditioning to partial threat cue 
Heightened startle response, particularly in 
threatening contexts 
Increased acoustic startle response and fear-
potentiated startle response 
Separation anxiety  Increased ultrasonic vocalizations in pups separated from their mother 
Feelings of losing control or going crazy during a 
panic attack  Cannot be modelled 
*Symptoms used in the Diagnostic and Statistical Manual-IV diagnosis of anxiety disorders. 
From Cryan and Holmes, (2005) Nat Rev Drug Discov 4 (9): 775-90 
 
Traditional Mouse Models and Tests in Anxiety Research 
 
With regard to traditional animal models of anxiety, it should be noted that fear and anxiety 
are normal, adaptive responses to danger. Pathological anxiety has therefore been considered 
by some as an extreme state of the same continuum, and many animal models have been 
designed with this in mind (Cryan and Holmes 2005). Animal models of anxiety disorders 
can be broadly categorized into two categories: unconditioned and conditioned (see 
following section: “Modelling Cognitive Symptoms of Depression and Anxiety in Mice”, 
page 23, for discussions on the latter). 
The most common anxiety tests in the unconditioned category have capitalized on the 
conflict between natural avoidance behaviours and the exploratory drive of rodents, to 
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develop ethologically based behavioural tasks (Rodgers et al. 1997a). Examples of these 
tasks include the aversion to the open central area of novel open fields (see (Prut and 
Belzung 2003)), avoidance of brightly lit spaces in the light-dark box test (Crawley 2000), 
and avoidance of elevated and/or open spaces in the elevated plus maze (Crawley 2000; 
Holmes 2001; Rodgers 1997), elevated zero maze (Lee and Rodgers 1990; Shepherd et al. 
1994), the staircase test (Simiand et al. 1984), and the mirrored arena (mirrored chamber test) 
(see (Belzung and Griebel 2001; Crawley 2000; Cryan and Holmes 2005; Rodgers 1997; 
Rodgers et al. 1997a) for reviews). Another test in this category is the four-plate test, which 
is based on the conflict between exploratory drive and avoidance of punishment (as shocks 
are delivered though the floor plates when mice move on to a new plate). All of these tests 
rely on a passive avoidance strategy of the animal to provide an indication of anxiety. The 
marble-burying and defensive burying (for example, of a shock-probe) tests, in contrast, 
requires the engagement of active behaviours for the expression of anxious behaviours and 
thus are interesting inclusions in test batteries (Broekkamp et al. 1986; Sluyter et al. 1996; 
Sluyter et al. 1999; Spooren et al. 2000).  
Exploratory based tests are sensitive to interference by locomotor activity - for 
example a genetic mutation which alters baseline locomotor activity in mice may produce 
false negatives, or false positives, in exploratory paradigms (Cryan and Holmes 2005). The 
so-called ‘ethological parameters’, that is, species-specific behaviours and postures adapted 
during exploration and risk assessment, can be included as measures in many of the 
aforementioned tests: reductions in the number of stretch-attend postures, head-dipping over 
the edges of elevated apparatuses and rearing have been interpreted as heightened anxious 
responses in various apparatuses (Belzung 1999; Homanics et al. 1999; Rodgers 1997; 
Rodgers and Johnson 1995; Shepherd et al. 1994). Ethological parameters are thought to be 
less influenced by locomotor activity, although their particular advantage in animal models, 
however, originates from their basis in the evaluation of risk assessment behaviours, and thus 
are thought to model endophenotypes of apprehension and excessive vigilance seen in 
patients with anxiety disorders (Blanchard et al. 2003; Cryan and Holmes 2005; Rodgers et al. 
1997a). The ethological approach has been taken further in the Mouse Defense Test Battery 
(MDTB), where mice are exposed to a predator threat, and panic, defensive threat/attack and 
risk assessment behaviours assessed, which are sensitive to panicolytic and anxiolytic 
pharmacotherapies, respectively (Blanchard et al. 2003).  
Other examples of tests used in mice that also relatively independent from bias 
introduced by alterations in locomotor activity include the Vogel punished drinking test, 
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novelty suppressed feeding, separation-induced ultrasonic vocalisations and stress-induce 
hyperthermia (SIH) (Holmes and Cryan 2006). The SIH test in particular is an ideal inclusion 
in an anxiety test battery as it provides and indication of autonomic responses to stress, and is 
a translational model across strains and species (including mice and humans; see 
(Bouwknecht et al. 2006)). 
 
Traditional Mouse Models and Tests in Depression Research 
 
Currently the lack of understanding about the causative factors and the pathophysiology of 
depression in humans has prevented the development of an animal models from a pure 
aetiological basis (Cryan and Slattery 2007). Descriptions of currently used tests are 
summarised in Table 3. In depression research, the most widely utilized mouse models and 
tests are based on alterations in stress-induced coping strategies. This derives from the 
observation that stress and trauma, or the uncontrollability of stress (‘lack of coping’), often 
pre-disposes human depression (Cryan and Holmes 2005; Kessler 1997). Examples of tests 
based on this construct include the learned helplessness, forced swim test (FST) and tail 
suspension tests (Table 3). These tests all show responsiveness to a range of clinical 
antidepressant treatments and are therefore often referred to as tests of antidepressant-like 
activity (Cryan and Slattery 2007). The FST is currently the most widely used test in murine 
antidepressant research, and is also often used in the phenotypic analysis of mutant mice (see 
(Cryan and Holmes 2005; Cryan and Mombereau 2004; Jacobson and Cryan 2007; Slattery 
and Cryan 2006) for overall reviews). Care must be taken to assess the locomotor phenotype 
of mutant mice used in all of the above tests, as abnormal locomotor activity produced by a 
genetic mutation may bias results (Cryan and Holmes 2005; Holmes and Cryan 2006; 
Jacobson and Cryan 2007). 
The chronic mild stress (CMS) paradigm, which also relies on repeated exposure to 
stressful stimuli (Monleon et al. 1995; Willner 2005; Willner et al. 1987), has shown transient 
popularity of recent. An advantage of this model is that the experimental outcomes are usually 
based on hedonic measures, such as intake of a preferred sweet solution or intracranial self 
stimulation (ICSS), and thus may model aspects of anhedonia seen in human depression 
(Harkin et al. 2002; Moreau 1997; Papp et al. 1996). In mice, deterioration of coat condition 
also appear to be a sensitive measure (Griebel et al. 2002; Santarelli et al. 2003). The test is 
also sensitive to chronic antidepressant treatment (Cryan and Holmes 2005; Cryan and 
Mombereau 2004; Willner 2005). The greatest disadvantage of the CMS model, however, lies 
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in the lack of reproducibility between different laboratories (Cryan and Holmes 2005; 
Jacobson and Cryan 2007) and see Psychopharmacology 134(4)).  
 
Table 1 Traditional mouse models used in depression research 
 
Animal model  Description Reviewed in: 
Learned helplessness 
Animals exposed to inescapable shocks subsequently 
fail to escape when able to. Antidepressant treatment 
increases the number of escapes, not all animals 
develop this helpless behaviour 
(Maier and 
Watkins 2005; 
Weiss et al. 
1981) 
Forced swim test  Rodents, placed in an inescapable container of water swim more following antidepressant administration 
(Borsini 1995; 
Petit-Demouliere 
et al. 2005) 
Tail suspension test 
Rodents, chiefly mice, when hung from the tail will 
adopt an immobile posture. Antidepressant treatment 
increases the time animals spend in active behaviours 
(Cryan et al. 
2005) 
Olfactory bulbectomy 
Removal of the olfactory bulbs causes a constellation 
of behavioural and neurochemical alterations, which 
are only reversed by chronic antidepressant treatment 
(Harkin et al. 
2003; Song and 
Leonard 2005) 
Chronic mild stress  
Animals are subjected to a variety of unpredictable 
stressors, which leads to a constellation of symptoms, 
that are reversed by antidepressant treatment 
(Willner 2005) 
Neonatal clomipramine 
administration 
When exposed to neonatal clomipramine, adult 
animals display a number of symptoms analogous to 
depression, including decreased reward seeking, 
aggressiveness and sexual behaviour. Antidepressant 
treatment can reverse behaviours 
(Vogel et al. 
1990) 
Adapted from Cryan and Slattery (2007) Curr Opin Psychiatry 20 (1): 1-7. 
 
 
Modelling Cognitive Symptoms of Anxiety and Depression in Mice 
 
Human anxiety and depression and are accompanied by specific cognitive deficits. Anxiety 
disorders are characterised by specific cognitive deficits such as misappraisal and over-
attention to threatening stimuli in panic disorder, generalized anxiety disorder and phobias, 
and persistence of traumatic memories in post-traumatic stress disorder (DSM-IV 1994; Lang 
et al. 2000). Approaches to modelling these aspects in animals have mainly focused on 
conditioned tests of anxiety, such as Pavlovian fear conditioning (Cryan and Holmes 2005; 
Kim and Jung 2006). In this paradigm, fear-related behaviours are induced by exposure to a 
previously innocuous stimulus (the conditioned stimulus (CS), for example, an auditory tone) 
that has been associated, through repeated pairings, with an innately aversive stimulus (the 
unconditioned stimulus (US), for example, footshocks) (Cryan and Holmes 2005; Davis 1990; 
Maren 2001). The tasks may be further delineated into testing contextual (fear associated with 
the place of conditioning, which is hippocampally-dependent) and cued (fear associated with 
a tone cue, and is amygdala-dependent) fear responses (Barad 2005; Bouton and Moody 
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2004). Freezing, startle, tachycardia, defensive burying and ultrasonic vocalizations have 
mainly been used as experimental outputs in these tests (see (Cryan and Holmes 2005) for a 
review). Interestingly, disturbances in sleep have also recently been shown to be a sensitive 
readout of fear conditioning in mice (Sanford et al. 2003a; Sanford et al. 2003b), which is 
highly relevant to the endophenotype of sleep dysfunction that is a diagnostic criterion in both 
depression and certain anxiety disorders (DSM-IV 1994). 
Both the acquisition and extinction of fear memories can be investigated with fear 
conditioning. Extinction is the decline in fear observed with repeated, unreinforced exposure 
to the CS, and is considered a new form of learning in which new associations with the CS, in 
the absence of reinforcement by the US, dominate the original association (Berman and Dudai 
2001; Myers and Davis 2002; Reilly and Bornovalova 2005). Investigations into the 
neurobiology of extinction in particular, have been applied to the modelling of anxiety 
disorders with persistent aversive memory and associations, such as post-traumatic stress 
disorder and panic disorder (Barad 2005; Cryan and Holmes 2005; Delgado et al. 2006; 
Ledgerwood et al. 2005; Ressler et al. 2004). 
Conditioned taste aversion (CTA) is well known as an aversive, associative learning 
and memory paradigm (Akirav 2006; Akirav et al. 2006; Berman and Dudai 2001; Bermudez-
Rattoni 2004; Lamprecht et al. 1997) and has recently been applied to the study of anxiety 
disorders associated with altered emotional learning and memory (Cryan and Holmes 2005; 
Guitton and Dudai 2004; Yasoshima and Yamamoto 2005). In CTA, an otherwise innocuous 
(or even preferred) taste is paired, most commonly, with experimentally induced malaise such 
as that induced by intraperitoneal injection of Lithium chloride. Similarly to fear conditioning, 
both the acquisition and extinction of the aversive association can be assessed. The test is also 
largely independent of influences on locomotor output (which may be problematic in tests 
relying on outputs such as freezing or flight). In addition to the amygdala, a well known hub 
in anxiety circuitry, CTA is also reliant on the insular cortex (Bermudez-Rattoni 2004; Bures 
1998b), which has recently been highlighted as a highly important structure in many (if not 
all) human anxiety disorders (Paulus and Stein 2006). This suggests that CTA may be well 
suited to the investigation of the neurobiological basis of anxiety disorders with a strong 
cognitive component.  
In depression, cognitive deficits include impaired planning, executive function and 
increased attention towards negative stimuli (Elliott et al. 2002). In theory, classic mouse 
cognitive tests of attention, working and reference, spatial and non-spatial memory could be 
used to study cognitive endophenotypes of depression (Cryan and Holmes 2005; Holmes and 
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Cryan 2006). Examples of tests could include the 5-choice serial reaction time task for 
attention (Patel et al. 2006; Wrenn et al. 2006), spatial alternation in T or Y mazes for 
working memory (Reisel et al. 2002) or Morris water maze or multi-armed food-rewarded dry 
mazes for spatial reference memory (Crawley 2000; Crawley and Paylor 1997). With regard 
to alterations in executive and prefrontal cortical function, an intra-dimensional and extra-
dimensional set shifting test based on the Wisconsin card-sorting test that was developed for 
the assessment of prefrontal cortex cognitive functioning in rats (Birrell and Brown 2000), has 
recently been adapted for mice, and may show promise for application in depression-related 
research in the future (Brigman et al. 2005; Garner et al. 2006). In practice, there are very few 
such studies investigating alterations in cognitive processes in murine depression-related 
research. In one recent example, chronic mild stress and learned helplessness paradigms 
impaired the rate of acquisition and the memory probe of the hidden platform position in the 
Morris water maze of spatial memory (Song et al. 2006). Furthermore, these deficits were 
ameliorated by chronic treatment with imipramine or fluoxetine. Stress-induced increases in 
corticosterone and decreases in hippocampal brain-derived neurotrophic factor (BDNF) and 
CREB, which were also reverse by chronic antidepressant treatment, were thought to 
contribute to the mechanisms underlying these deficits (Song et al. 2006). 
 
Modelling Depression and Anxiety: Conclusions 
 
Overall, it is clear that there are many animal models and tests which may be applied to the 
study of the neurobiology of anxiety and depression. There are certain caveats and cautions 
that must be taken into account in the application of each of these tests. Genetic background, 
in the form of a carefully selected mouse strain, is of high importance (Crawley 2000; 
Jacobson and Cryan 2007). Possible abnormal locomotor phenotypes produced by a genetic 
mutation have been discussed, but potential alterations in other sensory-motor modalities 
must also be taken into account (for example, pain sensitivity in tests where foot shocks are 
delivered, or impairment in taste or olfactory senses in food-motivated or reward-based test). 
Previous test history, interactions with early-life environment and compensatory changes for 
constitutive genetic mutations may also influence results in anxiety and depression models 
(Holmes and Cryan 2006; Holmes et al. 2005). As such, a test-battery approach has been 
advocated for the detecting genuine phenotypes in anxiety and depression research with 
mutant mice, as reliance on fewer tests may give rise to erroneous interpretations depending 
on specific idiosyncrasies of individual tests or mutations (Cryan and Holmes 2005). Despite 
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these caveats, mutant mice have been greatly important for the evaluation of the function of 
specific genes and their down-stream molecular, circuit-related and behavioural influences 
(Cryan and Holmes 2005; Phillips et al. 2002; Tarantino and Bucan 2000). Mutant mice in 
particular are invaluable for the dissection of the functional role of a molecule that cannot be 
approached using more traditional strategies – perhaps the best example being that when 
pharmacological tools are unavailable or have poor selectivity for a particular receptor 
subtype (Cryan and Holmes 2005). 
 
1.4 GABAB Receptors in Anxiety and Depression B
 
GABAB Receptors and Anxiety B
 
There are a number of indications from preclinical and clinical studies with baclofen that 
implicate the GABAB receptor in anxiety (Couve et al. 2000; Cryan and Kaupmann 2005; Pilc 
and Nowak 2005). Baclofen showed anxiolytic effects in several preclinical studies including 
ultrasonic vocalisation in rat pups (Nastiti et al. 1991), punished drinking (Ketelaars et al. 
1988; Shephard et al. 1992), Geller-Seifter conflict test (Ketelaars et al. 1988), elevated plus 
maze (Andrews and File 1993) and in rats dependent on either diazepam or alcohol in the 
social interaction and elevated plus maze tests after drug withdrawal (File et al. 1991a; File et 
al. 1991b; File et al. 1992). Baclofen has also shown anxiolytic activity in some clinical 
settings, for example during alcohol withdrawal in alcoholics (Addolorato et al. 2002a; 
Addolorato et al. 2002b; Addolorato et al. 2006; Ameisen 2005; Flannery et al. 2004), and in 
panic disorder (Breslow et al. 1989), post-traumatic stress disorder (Drake et al. 2003) and in 
patients suffering from acute spinal trauma (Hinderer 1990). 
Not all studies, however, have reported anxiolytic actions for baclofen (for a 
preclinical example see (Dalvi and Rodgers 1996), for reviews see (Couve et al. 2000; Millan 
2003)). One postulated mechanism for this variability relates to the actions of GABAB 
receptor agonists at GABAB autoreceptors. Activation at this site would be expected to 
suppress the release of GABA, and thus could influence anxiety via subsequent actions at the 
GABAA receptor (Dalvi and Rodgers 1996; Millan 2003). It is also clear that the dose-
window for baclofen that is free of motor-impairing (and hypothermic) effects is very narrow, 
and as such, limit its application in both research and in the clinical treatment of affective 
disorders (Cryan and Kaupmann 2005).  
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The strongest evidence for the role of GABAB receptors in anxiety, however, probably 
comes from recent genetic deletion studies in mice and the development of GABAB receptor 
positive modulators (Cryan and Kaupmann 2005). Constitutive deletion of either the 
GABAB(1) or GABAB(2) receptor subunits in mice results in a complete loss of typical GABAB 
receptor function, spontaneous seizures, hyperalgesia, hyperlocomotion and memory 
impairment (Gassmann et al. 2004; Prosser et al. 2001; Schuler et al. 2001). Furthermore, 
these mice show a highly anxious phenotype in exploratory-based tests of anxiety 
(Mombereau et al. 2004a; Mombereau et al. 2005; Mombereau et al. 2004b). Specifically, 
GABAB(1)-/- mice show profound anxiety relative to wild-type controls in the light-dark box 
and staircase tests (Mombereau et al. 2004a; Mombereau et al. 2004b), while GABAB(2)-/- 
mice are also anxious in the light dark box (Mombereau et al. 2005). 
Positive modulators of the GABAB receptor, such as CGP7930 and the more potent 
GS39783, enhance both the potency and the maximal efficacy of GABA at GABAB receptors 
in native and recombinant receptor preparations, but have little or no intrinsic action (Dupuis 
et al. 2006; Urwyler et al. 2005; Urwyler et al. 2001; Urwyler et al. 2003). These compounds 
have recently been shown to interact with the 7-transmembrane domain of the GABAB(2) 
subunit, rather that at the ligand binding domain residing on the GABAB(1) subunit (Binet et 
al. 2004; Dupuis et al. 2006). When applied in vivo, GABAB receptor positive modulators 
potentiate the effects of GABAB receptor agonists, supporting their in vitro profile (Carai et 
al. 2004). GABAB receptor positive modulators by themselves do not show the motor 
impairing and hypothermic profile characteristic of GABAB receptor agonists (Cryan et al. 
2004). Importantly with regard to anxiety, GS39783 by itself has an anxiolytic profile in 
rodents, thus providing further support for a role of the GABAB receptors in anxiety (Cryan et 
al. 2004).  
 
GABAB Receptors and Depression B
 
In addition to the role in anxiety, there is strong evidence from animal studies that GABAB 
receptors are implicated in depression and the action of antidepressants, and that GABAB 
receptor antagonists may be an attractive target for the development of novel antidepressants 
(see (Couve et al. 2000; Cryan and Kaupmann 2005; Pilc and Nowak 2005; Slattery and 
Cryan 2006)). It is now over 20 years ago since Pilc and Lloyd (1984) observed that in rats, 
GABAB receptor binding in the frontal cortex was up-regulated after chronic (but not acute) 
antidepressant treatment. From these findings they hypothesised that GABAB receptors may 
be involved in the mechanisms underlying depression and the action of antidepressants (Pilc 
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and Lloyd 1984). Other animal studies have since demonstrated similar findings with GABAB 
receptor function or expression following antidepressant treatments, including models of 
electroconvulsive shock therapy (Gray et al. 1987; Gray and Green 1987; Lloyd et al. 1985; 
Sands et al. 2004b). Indeed, chronically administered GABAB receptor antagonists, such as 
CGP36742 and SCH50,911, also up-regulate GABAB receptor binding sites (Malcangio et al. 
1993; Pibiri et al. 2005), and to a similar degree as chronically administered desipramine, 
further suggesting a potential application for GABAB receptor antagonists in antidepressant 
therapy (Pratt and Bowery 1993). 
In animal models of depression or antidepressant-like action, GABAB receptor 
antagonists show an antidepressant-like profile in the rat and mouse FST (Mombereau et al. 
2004a; Nowak et al. 2006), in addition to the learned helplessness (Nakagawa et al. 1999; 
Nowak et al. 2006), olfactory bulbectomy and chronic mild stress paradigms (Nowak et al. 
2006). Furthermore, genetic deletion of either the GABAB(1) or GABAB(2) receptor subunits 
induced an antidepressant-like phenotype in the forced swim test (FST) in mice (Mombereau 
et al. 2004a; Mombereau et al. 2005).  
There are very few clinical studies examining GABAB receptor function in depressed 
patients. Mixed results are reported from studies examining GABAB receptor function in 
depressed patients, using probes such as baclofen-induced growth hormone secretion or the 
dexamethasone suppression test (see (Slattery and Cryan 2006) for a review). However, in 
one, small clinical trial with depressed patients, baclofen was reported to exacerbate 
depressive symptoms (Post et al. 1991). Clearly more clinical studies are required to examine 
GABAB receptors in depression (and preferably using GABAB receptor antagonists). 
 
GABAB Receptor-Serotonin Interactions Mediate Aspects of Antidepressant Activity 
The mechanisms underlying the antidepressant-like behavioural effects of GABAB receptor 
antagonists have been shown to depend on an interaction with the serotonin (5-HT) system, as 
demonstrated by the abolition of the antidepressant-like effects of the GABAB antagonist 
CGP56433A in the rat forced swim test by pre-treatment with the tryptophan hydroxylase 
inhibitor para-chlorophenylalanine (pCPA) (Slattery et al. 2005a). Indeed, nearly all of the 5-
HT cell bodies in the dorsal and medial raphé nuclei (DRN and MRN) have been shown to 
express GABAB receptors (Abellan et al. 2000a; Serrats et al. 2003; Varga et al. 2002). 
Activation of GABAB receptors with baclofen, either systemically, or locally at the DRN, 
influences 5-HT neuron firing rate and 5-HT release at the level of the raphé nuclei and in 
postsynaptic structures (Abellan et al. 2000a; Abellan et al. 2000b; Tao et al. 1996). The 
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direction of this influence, however, differed between these aforementioned studies by 
Abellan and Tao. In further studies by the former group, GABAB receptors were shown to be 
expressed both at postsynaptic sites on serotonin containing neurons, and presynaptically at 
GABAergic terminals synapsing with 5-HT neurons (Serrats et al. 2003). Thus, they proposed 
that activation of post-synaptic GABAB receptors located on serotonergic neurons could 
explain the baclofen-induced inhibition of 5-HT release described by Tao et al., (1996), while 
activation of presynaptic GABAB autoreceptors by baclofen could result in disinhibition of 
serotonin neurons, and an increase in firing rate and serotonin release (Abellan et al. 2000b; 
Serrats et al. 2003).  
 
GABAB Receptors and Cognitive Processes Associated with Anxiety and 
Depression 
B
 
As previously discussed, anxiety and depression are both characterised by symptomatic 
deficiencies in specific cognitive functions (for example from DSM-IV-TR: reduced ability to 
think or concentrate, or indecisiveness in major depression; and difficulty in concentration or 
mind going blank in generalized anxiety). It is therefore interesting to note that GABAB 
receptors have been strongly implicated in cognitive function, and in the purported underlying 
cellular correlate of memory, long-term potentiation (LTP) (see (Bowery et al. 2002; Davies 
and Collingridge 1996; Davies et al. 1991; Froestl et al. 2004)). In animal studies, GABAB 
receptor antagonists improved performance in hippocampally-dependent spatial learning and 
memory (Helm et al. 2005; Nakagawa and Takashima 1997; Staubli et al. 1999) and in 
passive and active avoidance tasks (Getova and Bowery 1998; Mondadori et al. 1994; 
Mondadori et al. 1993). Furthermore, the GABAB receptor antagonist SGS742 was recently 
investigated as a cognitive enhancer in a Phase II clinical trial for Alzheimer’s disease 
(Froestl et al. 2004). In contrast, GABAB receptor agonists generally (but not always: 
(Castellano et al. 1993; Escher and Mittleman 2004; Saha et al. 1993)) impair learning and 
memory (for examples in animal models, see (Cryan et al. 2004; Erickson et al. 2006; Galeotti 
et al. 1998; McNamara and Skelton 1996; Nakagawa et al. 1996; Nakagawa and Takashima 
1997; Pitsikas et al. 2003; Tang and Hasselmo 1996)). Further evidence is provided by the 
phenotype of GABAB(1)-/- and GABAB(2)-/- mice, which are profoundly impaired in passive 
avoidance performance in a gene dose-dependent manner (Gassmann et al. 2004; Pagano et 
al. 2001). 
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1.5 The Mystery of the Sushi Repeats: GABAB(1) Receptor Isoforms 
 
As stated earlier, GABAB(1a) and GABAB(1b) are the most abundantly expressed variants of the 
GABAB(1) subunit (Kaupmann et al. 1997), both of which form functional heterodimers with 
the GABAB(2) subunit (Benke et al. 1999; Kaupmann et al. 1998a). As such, the GABAB(1a) 
and GABAB(1b) isoforms comprise an enormous proportion of the molecular diversity of the 
GABAB receptor. Up until very recently, however, there has been a dearth of specific tools 
with which to probe the functional roles of these two isoforms in physiology and behaviour.  
In recombinant studies, many groups have failed to ascribe differential 
pharmacological attributes to the GABAB(1a) and GABAB(1b) isoforms, despite the use of 
different experimental endpoints such as production of inositol phosphates (Brauner-Osborne 
and Krogsgaard-Larsen 1999), competitive binding (Green et al. 2000; Kaupmann et al. 
1998a; Malitschek et al. 1998) or coupling to Kir3 channels (Kaupmann et al. 1998a). There 
have been a few reports to the contrary, for example indicating isoform-differential G protein 
coupling to Kir3 channels (GABAB(1a,2) preferentially mediated Kir3 activity via Goα, while 
GABAB(1b,2) coupled to both Giα and Goα variants) (Leaney and Tinker 2000). Some reports 
have also suggested that the anticonvulsant gabapentin interacts differentially with GABAB(1) 
isoforms, although as attempts to repeat these findings in other laboratories have been 
unsuccessful, these findings remain controversial (see (Bettler et al. 2004) for a review).  
There are, however, other lines of evidence to support the notion that GABAB(1a) and 
GABAB(1b) are highly important variants mediating GABAB receptor responses. For example, 
GABAB(1a) and GABAB(1b) isoforms both show high levels of evolutionary conservation, as 
demonstrated by their expression in a wide range of vertebrate species including the human, 
rat, mouse chicken, frog and zebrafish. Interestingly, no evidence was found for the presence 
of GABAB(1a) or GABAB(1b) receptor isoforms in the fruit fly Drosophila melanogaster or the 
nematode Haemonchus concortus. GABAB(1) and GABAB(2) orthologs, however, are present 
in Drosophila, but the characteristic sushi motifs of GABAB(1a) are not present (see (Bettler et 
al. 2004)).  
Although originally postulated to be splice variants, both GABAB(1a) and GABAB(1b) 
are transcribed directly from different promoter regions of the Gabbr1 gene (Steiger et al. 
2004). The human gene coding the GABAB(1a) isoform is comprised of 23 exons. The first 
five exons are specific only to the GABAB(1a) isoform and harbour the GABAB(1a) 5’-
untranslated region (UTR) (exon 1), a signal peptide, and the two Sushi domains (Steiger et 
al. 2004). The N-terminus of GABAB(1b) is produced immediately upstream from the sixth 
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intron of GABAB(1a) (Bettler et al. 2004; Steiger et al. 2004) (Fig. 3). The remaining exons are 
common to both isoforms (Bettler et al. 2004; Steiger et al. 2004). As such, GABAB(1a) and 
GABAB(1b) isoforms differ in amino acid sequence only at the extracellular N-terminus 
domain - the 147 amino acids of the GABAB(1a) isoform being replaced by a truncated 18 
amino acid sequence in the GABAB(1b) isoform (Kaupmann et al. 1997) (Fig. 3). In particular, 
the two sushi domains in the GABAB(1a) N-terminus are absent in the GABAB(1b) isoform 
(Bettler et al. 1998; Blein et al. 2004; Hawrot et al. 1998). Transcription of the two isoform 
mRNAs are differentially influenced by ATF4/CREB2 and depolarization-sensitive upstream 
stimulatory factor (USF) (Steiger et al. 2004). Other (splice) variants of the GABAB(1) subunit 
have also been reported in the literature, including GABAB(1c), GABAB(1c-a), GABAB(1c-b), 
GABAB(1d) GABAB(1e) GABAB(1f) (see (Bettler et al. 2004; Billinton et al. 2001; Cryan and 
Kaupmann 2005)). They vary in structure from the GABAB(1a) and GABAB(1b) isoforms 
mainly in the number or sequence of the N-terminus or in the C-terminus RSRR domain. 
However, many of these GABAB(1) splice variants are either not evolutionarily conserved 
across different species, or not expressed in native tissues, and as such the functional 
relevance of these variants remains controversial (Bettler et al. 2004; Cryan and Kaupmann 
2005). 
 
Fig. 3. Top: Structure of the human Gabbr1 gene showing specific GABAB(1a) (red) and GABAB(1b) 
(blue) exons, the common exons encoding both GABAB(1a) and GABAB(1b) isoforms (purple), 
transcription start sites (arrows), ATG translation initiation codons, and translational stop codon 
(asterisk) (scale is indicated above right). Bottom: Promoter patterns for the generation of GABAB(1a) 
(GABABR1a) and GABAB B(1b) (GABABBR1b) mRNA, showing exons (boxes) and their size (number of 
base pairs, below). The GABAB(1a) mRNA contains five exons at the 5’ -end which are absent in the 
GABAB(1b) transcript. Exon 1 contains the GABAB(1a) 5’-UTR. Exon 6’ is the alternative first exon for 
GABAB(1b) and contains the GABAB(1b) 5’ -UTR and the GABAB(1b) -specific coding region. The N 
terminus (NH2 ) and first transmembrane domain (TM1) are labeled (arrows). From Steiger et al., 
(2004) J Neurosci 24(27): 6115-26. 
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The function of the sushi domains in the GABAB(1a) isoform N-terminus have been a 
mystery, until very recently, and have prompted much speculation as to their function with 
regard to the GABAB receptor. Sushi repeats have mostly been found in proteins that are 
involved in cell-cell adhesion, and prior to their identification in the GABAB(1a) isoform, had 
not previously been described in association with a neurotransmitter receptor (Bettler et al. 
2004). The function of the sushi repeats in GABAB receptors was therefore speculated to 
convey protein-protein interactions at the GABAB(1a) N-terminus (Couve et al. 2000), and 
possibly to direct pre- and postsynaptic trafficking of GABAB(1) receptor isoforms (Bettler et 
al. 2004; Blein et al. 2004).  
 Many studies have demonstrated that GABAB(1a) and GABAB(1b) isoforms show 
marked differences in their pattern of anatomical distribution and relative abundance in 
different structures of the brain and spinal cord (Benke et al. 1999; Billinton et al. 1999; 
Bischoff et al. 1999; Fritschy et al. 1999; Kaupmann et al. 1998b; Liang et al. 2000; 
Malitschek et al. 1998; Poorkhalkali et al. 2000; Princivalle et al. 2000; Towers et al. 2000). 
This was particularly well demonstrated in the cerebellum, where there was good agreement 
between studies that the GABAB(1a) isoform was predominantly expressed in the granule cell 
layer, while the GABAB(1b) isoform was expressed mainly in the Perkinje cells (Billinton et al. 
1999; Bischoff et al. 1999; Fritschy et al. 1999; Kaupmann et al. 1998b; Liang et al. 2000; 
Poorkhalkali et al. 2000).  
Perhaps the most comprehensive neuroanatomical study conducted to investigate the 
expression of the two isoforms to date was that of Bischoff et al., (1999). Using isoform-
specific and pan in situ hybridization probes, in combination with autoradiographic binding of 
the GABAB receptor antagonist [3H]CGP54626, relative levels of GABAB(1a) and GABAB(1b) 
isoform expression were quantified in 87 structures and nuclei, and in four white matter 
regions. The greatest disparity in expression of the two isoforms were shown in the septal 
areas, where expression of GABAB(1b) was greater than that of the GABAB(1a) isoform. This 
profile was repeated in the majority of thalamic nuclei examined. In contrast, the midbrain 
and brainstem nuclei, including the substantial nigra pars reticulate, ventral tegmental area, 
locus ceruleus and DRN, showed a dominant expression of the GABAB(1a) isoform over the 
GABAB(1b) isoform. In the cortex, GABAB(1a) tended to be somewhat dominant in most layers, 
and most strikingly in L4 of the parietal cortex. In L6, however, the GABAB(1b) isoform was 
dominant (Bischoff et al. 1999). The divergent expression profile of the two isoforms lead 
many researchers to speculate that the two isoforms localised differentially to pre- and 
postsynaptic locations (Benke et al. 1999; Billinton et al. 1999; Bischoff et al. 1999; 
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Kaupmann et al. 1998b; Liang et al. 2000; Poorkhalkali et al. 2000; Princivalle et al. 2000; 
Towers et al. 2000). However, solid evidence for this was never directly demonstrated 
(Bettler et al. 2004), due in particular to a lack of high quality, isoform-specific antibodies 
suitable for electron microscopy (Vigot et al. 2006). 
GABAB receptor isoforms also demonstrate a differential expression in development. 
Fritschy et al., (1999) showed that GABAB(1a) was expressed at higher levels than GABAB(1b) 
in the rat neonatal brain membranes, but steadily decreased during maturation. In contrast 
GABAB(1b) was expressed at relatively lower levels in the neonate, increased transiently 
around post natal day 10, then declined again toward maturity, but was still the dominant 
isoform in the adult (Fritschy et al. 1999). These result were similar to an earlier study by 
Malitschek et al., (1988) who showed that from post natal days 2 to 7, GABAB(1a) in the 
cortex was significantly higher than GABAB(1b), while from days 14 to adulthood, the 
expression levels of GABAB(1a) decreased and that of GABAB(1b) rose. 
Further indications for distinct physiological roles of the GABAB(1) isoforms comes 
from the differential induction of GABAB(1a) and GABAB(1b) isoforms in neurological disease, 
disease models and in response to antidepressant pharmacotherapies. Specifically, GABAB(1a) 
and GABAB(1b) isoform expression was altered in different regions of the hippocampus of 
patients with temporal lobe epilepsy (Princivalle et al. 2003). In an animal model of 
Parkinson’s disease, GABAB(1a) was preferentially induced over GABAB(1b) in the basal 
ganglia of rats following lesion of the nigro-striatal pathway (Johnston and Duty 2003). 
GABAB(1a) was also enhanced over GABAB(1b) in the hippocampus and spinal cord of rats 
following chronic treatment with the antidepressants desipramine or fluoxetine (McCarson et 
al. 2006; Sands et al. 2004a; Sands et al. 2004b) (although chronic amitriptyline increased 
both GABAB(1a) and GABAB(1b) equally in the spinal cord (McCarson et al. 2006)). Chronic 
immobilisation stress or repeated testing for withdrawal to a thermal stimulus also enhanced 
GABAB(1a) expression in the spinal cord (McCarson et al. 2006). 
Together the evolutionary conservation, differential control of transcription, and 
variation in anatomical, developmental and induced expression of GABAB(1a) and GABAB(1b) 
isoforms tantalizingly suggest that these isoforms are highly relevant and functionally distinct 
variants of the native GABAB receptor. However, solid evidence for differential subcellular 
localization (e.g., pre- versus postsynaptic), or indeed for distinct physiological properties of 
the two isoforms, was not provided in the aforementioned studies. Furthermore, no isoform-
selective ligands exist, thus precluding in vivo pharmacological investigations of the 
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contributions of GABAB1a and GABAB1b to physiological or behavioural functions, such as 
anxiety or depression.  
 
1.6 Sushi Demystified: GABAB(1a)-/- and GABAB(1b)-/- Mice 
 
In order to better characterise the roles of the two GABAB receptor isoforms, mice deficient in 
the GABAB(1a) and GABAB(1b) have recently been generated (Vigot et al. 2006). Given that 
the two isoforms arise from differential promoter usage of the same Gabbr1 gene, traditional 
knockout techniques were not applicable. Instead, the research group of Prof Bernhard Bettler 
at the University of Basel, in collaboration with Dr. Klemens Kaupmann and co-workers at 
the Novartis Institutes for BioMedical Sciences in Basel, adopted an elegant point mutation 
knock-in strategy to convert the start codons for GABAB(1a) and GABAB(1b), respectively, into 
stop codons (Fig. 4). To generate the mutant mice, BALB/c gene targeting constructs with 
mutated initiation codons and a floxed neomycin cassette for the selection of transfected 
embryonic stem cells, were electroporated into BALB/c embryonic stem cells. Homologous 
recombination events were diagnosed, and targeted embryonic stem cells injected into 
C57BL/6  blastocysts, which were then implanted into foster mothers. Chimeric progeny were 
crossed with BALB/c mice to generate heterozygotic founding mice.  The neomycin cassette 
was excised by crossing founder mice with BALB/c mice expressing Cre- recombinase under 
control of  the cytomegalus virus promoter.  Pups born from these matings were then scored 
for Cre-mediated loss of the neomycin cassette and bred to homozygosity. 
In each of the GABAB(1a)-/- and GABAB(1b)-/- mutants, both GABAB(1a) and GABAB(1b) 
mRNA transcripts were expressed, as predicted. However, specific and total loss of 
GABAB(1a) and GABAB(1b) proteins was achieved in each specific mutant, respectively, thus 
validating that the conversion of start to stop codons prevented translation of the specific 
isoform proteins. Furthermore, GABAB(1a)-/- and GABAB(1b)-/- mice were viable, reproduced 
normally and did not show any overt physical abnormalities, indicating potential applicability 
for subsequent behavioural analysis. 
The pharmacology of natively expressed GABAB(1a,2) and GABAB(1b,2) heterodimers, 
as assessed in cortical membranes obtained from the GABAB(1b)-/- and GABAB(1a)-/- mice 
respectively, was for the most part similar (Vigot et al. 2006). Inhibition of [125I]CGP64213 
antagonist binding by GABA and L-baclofen did not differ between the two mutant strains, 
supporting the similar results found with recombinant studies (see section 1.5). Likewise, 
[3H]-baclofen binding in cortical membranes was attenuated, but to a similar degree, in both 
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mutants. G protein coupling, as determined using GABA-stimulated GTPγ [35S] binding in 
cortical membranes, was also attenuated in both mutants, but slightly more so in the 
GABAB(1b)-/-.   
 
 
 
Fig. 4. Generation and genetic architecture of GABAB(1a)-/- (1a-/-) and GABAB(1b)-/- (1b-/-) mice. White 
boxes denote exons encoding the N terminus of GABAB(1a), Ma denotes the position of the GABAB(1a) 
start codon. The grey box denotes the exon for the N terminus of GABAB(1b), Mb denotes the position 
of the GABAB(1b) start codon. Hatched boxes denote shared downstream exons (only exon 6 is 
shown). S denotes the knockin conversion of the respective start codons, Ma and Mb, to stop codons. 
The black bar denotes the position of the floxed neomycin cassette inserted for selection of 
transfected embryonic stem cells (introduced in the introns between exons 2a/3a for GABAB(1a)-/- or 
between exons 5a/1b for the GABAB(1b)-/-. White arrows denote a loxP site that is left behind after Cre-
mediated excision of the neomycin cassette. From Vigot et al.,(2006) Neuron 50, 589–60. 
 
 
Subsequent analysis of the mutant neuroanatomy, however, comprehensively 
demonstrated a pre- versus postsynaptic expression profile for GABAB(1a) and GABAB(1b) 
isoforms respectively (Perez-Garci et al. 2006; Shaban et al. 2006; Vigot et al. 2006). 
Ultrastructural analysis of the hippocampi and amygdalae of GABAB(1a)-/- and GABAB(1b)-/- 
mice, conducted with pan-GABAB(1) immunogold labelling and electron microscopy, showed 
that in GABAB(1a)-/- mice the remaining GABAB(1b) isoform was mostly located at 
postsynaptic sites opposite from glutamatergic terminals, and to a certain degree at extra 
synaptic sites. In contrast, in the GABAB(1b)-/- mice, the remaining GABAB(1a) isoform was 
predominantly located at glutamatergic terminals (Shaban et al. 2006; Vigot et al. 2006). This 
expression profile was supported by studies with GFP-transfected GABAB(1a) or GABAB(1b) 
isoforms in CA1 pyramidal neurons of rat hippocampal organotypic cultures. Although both 
transfected isoforms were present in dendritic processes, GABAB(1b)-GFP was the dominant 
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isoform present in dendritic spines, while in contrast, GABAB(1a)-GFP targeted axons (Vigot 
et al. 2006).  
In electrophysiological studies in the hippocampus GABAB heteroreceptors were 
absent at Schaffer collateral terminals onto the CA1 in GABAB(1a)-/- mice, but were preserved 
in GABAB(1b)-/- mice. When examining autoreceptor function, baclofen reduced IPSC 
amplitudes in CA1 pyramidal neurons of both GABAB(1a)-/- and GABAB(1b)-/- mice, indicating 
that both isoforms fulfilled autoreceptor functions. In contrast, CA1 pyramidal slow IPSCs, as 
mediated by Kir3.2 inwardly rectifying channels were intact in GABAB(1a)-/- mice, but greatly 
reduced in GABAB(1b)-/- mice, demonstrating that GABAB(1b) was indeed the predominant 
isoform mediating GABAB receptor mediated IPSCs (Vigot et al. 2006). Similar results were 
obtained in the lateral amygdala, again showing a specific presynaptic heteroreceptor function 
of GABAB(1a,2), a postsynaptic function of GABAB(1b,2), and both isoforms fulfilling 
autoreceptor functions (Shaban et al. 2006). In L5 cortical neurons, GABAB(1b,2) also fulfilled 
a postsynaptic function, although the predominant autoreceptor was GABAB(1a,2) (Perez-Garci 
et al. 2006). This latter finding is of particular significance as it suggests that GABAB(1) 
autoreceptor expression can vary between the GABAB(1) isoforms in a region-dependent 
manor.  
Deletion of the respective GABAB(1) isoforms had profound impacts on 
neurophysiological processes of GABAB(1a)-/- and GABAB(1b)-/- mice. Hippocampal LTP 
induction at CA3-CA1 synapses was significantly impaired in GABAB(1a)-/- mice (Vigot et al. 
2006), which mirrored the findings with GABAB(1)-/- mice (Schuler et al. 2001). In contrast, 
LTP in GABAB(1b)-/- mice was normal. The deficits in LTP shown by GABAB(1a)-/- mice were 
proposed to result from adaptive changes causing a reduction in the proportion of AMPA 
silent synapses (Vigot et al. 2006). In the amygdala, the ultrastuctural location of the 
GABAB(1) isoform determined the nature of LTP in the lateral amygdala (LA). Specifically, in 
GABAB(1a)-/- mice, loss of GABAB(1a) heterosynaptic inhibition removed the necessity for 
costimulation of the thalamic and cortical afferent inputs for the induction of cortico-LA 
presynaptic LTP (Shaban et al. 2006). In L5 cortical pyramidal neurons, GABAB(1b,2) 
receptors on distal dendrites mediated the postsynaptic inhibition of calcium action potentials 
(Ca+2-AP), which otherwise, in the absence of inhibition, forward-propagate to generate a 
burst of axonal action potentials at the cell soma (Perez-Garci et al. 2006)  
Overall the studies by Perez-Garci et al., (2006), Shaban et al., (2006) and Vigot et al., 
(2006) demonstrated that GABAB(1a) and GABAB(1b) isoforms showed highly specific and 
differential ultrastructural organisation and neurophysiological roles, most probably mediated 
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by differential trafficking directed by the presence of sushi repeats on the GABAB(1a) isoform 
(Vigot et al. 2006).  
 
1.7 Thesis Objectives and Methodological Approach  
 
Given the role of GABAB receptors in anxiety and depression, and the differential localisation 
and electrophysiological effects mediated by the GABAB(1a) and GABAB(1b) isoforms, it was 
hypothesized that these isoforms would have a differential impact on specific behaviours 
relevant to anxiety and depression. The aim of this thesis was therefore to determine the 
contribution of the GABAB(1) receptor isoforms to endophenotypes of depression and anxiety-
related disorders, by evaluating newly generated mice deficient in the GABAB(1a) or 
GABAB(1b) subunit isoforms in behavioural, in vivo pharmacology and biochemical models.  
The first experiment in this series of studies (Chapter 2) aimed to evaluate GABAB 
receptor function in different mouse strains using the classic GABAB receptor agonist, L-
baclofen. This provided information as to the degree of genetic contribution to GABAB 
receptor-related responses, and a validation of the BALB/c mouse strain as an appropriate 
background strain to carry the deletion of the GABAB(1) isoforms. Furthermore, it established 
a methodological approach for the subsequent evaluation of residual GABAB receptor 
function in GABAB(1) isoform-deficient mice, principally by demonstrating the importance of 
utilizing multiple behavioural endpoints in the assessment of GABAB receptor function.  
In initial work with the GABAB(1a)-/- and GABAB(1b)-/- mice it was important to first 
evaluate basic somatosensory and locomotor functions of the mutant mice (Chapter 3). This 
allowed determination of whether or not gross phenotypic alterations accompanied the 
isoform deletion which may either bias responses, or preclude application, in other tests. In 
this study, residual GABAB receptor responses were also assessed in GABAB(1a)-/- and 
GABAB(1b)-/- mice using methods identified in Chapter 2. This allowed determination of the 
relative contribution of the isoforms to classic GABAB receptor agonist-induced responses.  
GABAB(1a)-/- and GABAB(1b)-/- mice were then examined in tests modelling different 
components of anxiety and depression-related disorders (Chapters 4-6). Mice were evaluated 
in a test of aversive learning and memory and, importantly, in the extinction of this memory 
using a CTA paradigm (Chapter 4). This methodological approach was taken as extinction of 
conditioned aversive learning tasks in animals are thought to model aspects of human anxiety 
disorders with a cognitive components, such as post-traumatic stress disorder and panic 
disorder (Cryan and Holmes 2005; Delgado et al. 2006; Ledgerwood et al. 2005; Ressler et al. 
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2004). GABAB(1a)-/- and GABAB(1b)-/- mice were further investigated in a battery of tests of 
unconditioned anxiety, and basic hypothalamic-pituitary-adrenal axis HPA characteristics 
measured, to determine the contribution of the GABAB(1) isoforms in innately anxious 
behaviour (Chapter 5).  
Evaluation of the impact of the GABAB(1) isoforms in depression-related behaviour 
are described in Chapter 6, in which GABAB(1) isoform-deficient mice were examined in 
classic tests of antidepressant-like activity: the forced swim test. This study included an 
investigation of whether serotonin-GABAB receptor interactions may contribute to the 
antidepressant-like phenotype of GABAB(1a)-/- mice. 
Finally, to further understand the contribution of GABAB(1) isoforms in cognitive 
endophenotypes GABAB(1a)-/- and GABAB(1b)-/- mice were investigated in cognitive tests of 
recognition, spatial working and avoidance memory (Appendix 1, Chapter 7).  
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2.1 Abstract 
 
Rationale: Comparison of different mouse strains can provide valuable information about the 
genetic control of behavioural and molecular phenotypes. Recent evidence has demonstrated 
the importance of GABAB receptors in anxiety and depression. Investigation of the 
phamacogenetics of GABAB receptor activation may aid in the understanding of mechanisms 
underlying the role of GABAB in affect. Objectives: The aim of current study was to 
determine the relative sensitivity of different mouse strains to GABAB receptor agonism in 
two models of GABAB receptor function, namely hypothermia and motor incoordination. 
Methods: Mice each from 11 strains (BALB/cByJIco, DBA/2JIco, OF1, FVB/NIco, CD1, 
C3H/HeOuJIco, 129/SvPasIco, NMRI, C57BL/6JIco, A/JOlaHsd and Swiss) were trained to 
walk on a rotarod for 300 s. On the following day mice received 0, 3, 6 or 12 mg/kg of L-
baclofen p.o. Rectal temperature and rotarod performance were measured at 0, 1, 2 and 4 
hours after drug application. Results: L-baclofen produced a significant dose-dependent 
hypothermia and ataxia in most, but not all, mouse strains examined. The magnitude and 
duration of response was influenced by strain, with mice of the 129/SvPasIco strain showing 
largest hypothermic response to 12 mg/kg L-baclofen and C3H/HeOuJIco the lowest, whereas 
the BALB/cByJIco strain demonstrated greatest ataxic response on the rotarod, and NMRI the 
least. Interestingly, some strains (notably C3H/HeOuJIco) had marked differential 
hypothermic and ataxic responses, with minimal body temperature responses to L-baclofen 
but significant ataxia on the rotarod observed. Conclusion: There is differential genetic 
control on specific GABAB receptor populations that mediate hypothermia and ataxia. 
Further, these studies demonstrate that background strain is an important determinant of 
GABAB receptor mediated responses, and that hypothermic and ataxic responses may be 
influenced by independent genetic loci. 
 
2.2 Introduction 
 
Comparison of different mouse strains provides valuable information about  the importance of 
genetic background in behavioural and pharmacodynamic phenotypes. Such information is 
important when considering which strains of mice are most suitable for both genetic 
manipulation studies and pharmacological analyses (Crawley 2000; Crawley et al. 1997). 
Recent studies have demonstrated widespread differences in the sensitivity of mice strains to 
GABAA / benzodiazepine receptor ligands (Griebel et al. 2000), and serotonergic and 
noradrenergic antidepressants (Lucki et al. 2001) in animal models of anxiety and depression. 
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Emerging genetic and pharmacological evidence suggests a role for the metabotropic 
GABAB receptor as a therapeutic target for anxiety and depression (Cryan and Kaupmann 
2005; Mombereau et al. 2004a). These receptors were first pharmacologically characterized as 
receptors insensitive to the GABAA antagonist bicuculline by Bowery et al., (1980), and 
designated as GABAB receptors in 1981 (Bowery et al. 2002; Bowery et al. 1981). 
Presynaptic GABAB receptors modulate neurotransmitter release by depressing Ca2+ influx 
via voltage-activated Ca2+ channels (Bowery et al. 2002). Postsynaptic GABAB receptors 
predominantly couple to inwardly rectifying K+ channels (Luscher et al. 1997) and mediate 
slow inhibitory postsynaptic potentials (Bowery et al. 2002). GABAB receptor proteins are 
abundantly expressed in the brain and are localized in many neuronal cell types including 
interneuron populations, as well as in certain glial cells, where they form functional 
heterodimers. 
The prototypical GABAB receptor agonist baclofen (ß-p-chlorophenyl-GABA) was 
first synthesized in 1962 and shown to exert potent muscle relaxant and analgesic properties 
(see (Froestl et al. 2003). Baclofen has been invaluable in elucidating the role of GABAB 
receptors in various disorders including epilepsy, cognition, pain, gastroesophageal reflux 
disease and addiction (Bowery et al. 2002). Further, baclofen (Lioresal®) has been in clinical 
use for the treatment of spasticity for over 30 years (Brogden et al. 1974). Baclofen induces 
marked hypothermia and deficits in motor coordination, and these have been widely used as 
behavioural/physiological indices of GABAB receptor activation in rodents (Brogden et al. 
1974; Cryan et al. 2004; Gray et al. 1987; Lehmann et al. 2003; Schuler et al. 2001). Despite 
this, to our knowledge, there is no data investigating whether these responses are under the 
same genetic control. Indeed recent strain comparisons in mice suggest that individual 
behavioural responses to GABAA receptor ligands (ethanol, diazepam and pentobarbital), 
including motor in-coordination and hypothermia, have differential genetic determinants 
(Crabbe et al. 1998; Crabbe et al. 1994; Crabbe et al. 2002).  
The aim of these studies, therefore, were to investigate if genetic influences exist in 
the response profile of 11 different mouse strains to L-baclofen, in tests for hypothermia and 
motor in-coordination, by recording temperature and rotarod endurance in parallel. It was also 
of interest to see if the pharmacodynamics of both responses differed within each given strain. 
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2.3 Methods  
 
Animals 
Forty to 41 naive male mice from each of 11 strains were obtained from four different 
suppliers. Iffa Crédo (Charles River), France, bred and supplied the inbred FVB/NIco, 
BALB/cByJIco, C57BL/6JIco, DBA/2JIco, C3H/HeOuJIco, 129/SvPasIco and outbred OF1 
mice strains; Janvier, France, supplied the outbred strain Swiss (IOPS Orl); Charles River, 
Germany supplied the outbred CD1 mice; and Harlan, Netherlands, supplied the inbred 
A/JOlaHsd and outbred NMRI strains. All mice weighed between 15-20 grams on arrival at 
the laboratory and were tested within 3 weeks. Mice were group-housed 5 per cage on 
sawdust in macrolon cages with one red, triangular, polycarbonate Mouse House® (Nalgene) 
per cage and tissue paper nesting materials. Housing was at a constant room temperature of 
22-24°C in a 12 h light:dark cycle with lights on at 6 A.M. Food pellets and tap water were 
available ad libitum. All animal experiments were conducted during the light phase, with 
dosing beginning between 9:30 and 11 A.M. The rotarod and a radio were used to provide 
acclimatising and background noise prior to and throughout all experimentation. All animal 
experiments were conducted in accordance with the Veterinary Authority of Basel Stadt, 
Switzerland. 
 
Rotarod 
The rotarod apparatus consists of a 28 mm diameter rod partitioned into 5 available lanes 58 
mm wide to accommodate individual mice. The rod was positioned 30 cm above a surface 
and rotated at a constant speed of 12 rpm. Each day the rod lanes were tightly lined with fresh 
paper towelling. The test was carried out as previously described (Cryan et al. 2004; Dunham 
and Miya 1957). 
 
Rectal Temperature 
Rectal temperature was measured with a lubricated ELLAB Instruments thermistor probe 
inserted 20 mm in to the rectum. Mice were hand-held by the tail base and inverted against 
the cage wall during temperature recording, and the probe held in place until a stable 
temperature measurement was achieved (about 15 seconds). Care was taken to ensure 
minimal disturbance to other mice in the cage until all 5 mice in each cage had been 
measured. 
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Procedure 
Mice strains were tested in two cohorts of about 20 animals on separate days, with the 
exception of the FVB/NIco and CD1 strains, where all mice were tested on a single day. Two 
days prior to testing, the Mouse House® and tissue paper nesting materials were removed 
from each cage to reduce possible inter- and intra-cage variations in mouse body temperatures 
on the day of testing. On the day prior to testing, mice were acclimatized to the rectal 
thermistor probe by performing a single body temperature measurement and were then trained 
to walk on the rotarod for 300 s. Rotarod training was performed in two to four sessions, 
depending on the innate ability demonstrated by each strain to walk on the rotarod. Mice were 
returned to the home cage for an interval of about 30 minutes between training sessions. The 
number of falls during training was recorded for each mouse. 
On the day of testing, mice were moved to the experimental lab at least 2 hours before 
dosing. One hour before dosing, rectal temperature was taken. At time 0 hr, rectal temperature 
was taken for all animals in a cage, and then the animals placed on the rotarod for 300 
seconds to re-establish training and provide an experimental baseline. All rotarod data were 
disregarded from animals falling more than once at this time point; however, animals were 
placed on the rod at all time-points to mimic the conditions of full participants. Drug 
treatments were still administered and temperature data were still collected from these 
animals. All animals were immediately dosed with their allocated treatment on completing 
300 seconds on the rotarod. One, 2 and 4 hours thereafter rectal temperature and endurance on 
the rotarod were recorded.  
Occasionally, mice clung to the rotarod for full revolutions without attempting to walk 
on top of the rod. Animals that clung to the rod in this manner for ≥80% of the time that they 
spent on the rod were thus considered ataxic and were allocated a score of 0 s endurance. 
Animals that clung to the rod for full revolutions totalling less than 80% were 
correspondingly recorded for the amount of time they spent actively walking on the rod.  
An index of the degree of hypothermia was calculated by totalling the differences 
between control (pre-dose) rectal temperature and the temperatures at 1, 2 and 4 h post 
treatment for each animal. An index of the degree of ataxia was calculated by determining the 
difference between cumulative total time on the rotarod 1, 2 and 4 h after drug or vehicle 
application as a proportion of the total possible (i.e. percent reduction from 900 seconds). 
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Drugs 
L-baclofen (the active enantiomer of baclofen) was synthesised in-house (Novartis Pharma). 
Baclofen doses were prepared fresh daily as a suspension in 0.5% methylcellulose in water. 
Vehicle or baclofen were administered orally to deliver a final dose of 0, 3, 6 and 12 mg/kg in 
a volume of 10ml/kg. The experimenter was blinded to drug treatments during the entire 
experimental procedure.  
 
Statistics 
Mouse strain effects on basal rectal temperature (taken 1 h before drug administration on the 
day of testing) were analysed with one-way analysis of variance (ANOVA) followed by 
Fishers LSD post hoc comparisons. Within-strain analysis of the effect of baclofen treatment 
on body temperature employed a two-way repeated measures ANOVA (with dose and time as 
factors) followed by Fishers LSD post hoc comparisons. The cumulative effect of each 
baclofen dose within each strain on the degree of hypothermia was analysed with one-way 
ANOVA followed by Fishers LSD post hoc comparisons.  
The relationship between mean strain basal body temperature and hypothermia with 
baclofen at 12 mg/kg, as well as the correlation between mean strain hypothermia and ataxia 
at 12 mg/kg, were analysed using Pearson product moment correlation. This method has been 
previously reported to estimate the degree of shared genetic control between traits (Crabbe et 
al. 2002; Hegmann and Possidente 1981). 
The effect of strain on falls from the rotarod during training were analysed by 
Kruskal-Wallis one-way ANOVA on ranks, due to failure of normality in assumption testing, 
followed by Dunn’s method for post hoc comparisons. Within-strain analysis of the effects of 
baclofen dose on endurance on the rotarod was analysed using Kruskal-Wallis one-way 
ANOVA on ranks within time, due to failures in normality and equal variance testing, 
followed by Dunn’s Method for post hoc comparisons. The cumulative effect of dose within 
each individual strain on rotarod endurance after drug or vehicle application was analysed 
with  Kruskal-Wallis one-way ANOVA on ranks, due to failure in normality testing, followed 
by Dunn’s Method for post hoc comparisons.  
Effect of strain on ataxia (summed endurance at 1, 2 and 4 h post-drug or vehicle 
application) and hypothermia (summed ΔT°C) were analysed with one-way ANOVA 
followed by Fishers LSD Method for post hoc comparisons. All statistical analyses were 
performed using SigmaStat© for Windows version 2.03, 1992-1997, SPSS Inc. 
Chapter 2  45 
_________________________________________________________________________________ 
 
2.4 Results 
 
General 
Inter-animal aggression in FVB/NIco resulted in 10 of these animals being removed from the 
study before experimentation began, giving a final n of 30 animals. Inter-male aggression has 
been described in this mouse strain previously (Mineur and Crusio 2002; Pugh et al. 2004). 
There were 11 incidences of animals in the C57BL/6JIco strain clinging to the rotarod 
for ≥ 80% of their endurance. There were three such incidences in the DBA/2JIco strain, three 
in the FVB/NIco strain, one in the OF1 strain, two in the CD1 strain, five in the 129/SvPasIco 
strain and six in the Swiss mice. In the A/JOlaHsd mice there were five incidences of clinging 
for 80% or more of their endurance, and three incidences of full-revolution clinging that 
lasted for less than 80% of the endurance time, interspersed with attempts to walk on the rod. 
Only animals receiving baclofen demonstrated rod-clinging behaviour.  
 
Effects of baclofen on hypothermia 
Strains differed in basal body temperature [ANOVA: F(10, 429) = 5.41, P<0.001], with the 
FVB/NIco strain showing the highest basal body temperature ranking of the 11 strains 
investigated, and the BALB/cByJIco the lowest (Table 1).  
 
Table 1. Basal rectal temperature of different mouse strains (taken 1 h before start of the experiment). 
Strain Temperature (°C) † Rank-order n 
FVB/NIco 36.42  (± 0.12)a 1 31 
CD1 36.24  (± 0.12)a 2 40 
NMRI 36.23  (± 0.10)a 3 40 
Swiss 36.17  (± 0.07) ab 4 40 
A/JOlaHsd 35.97  (± 0.09) bc 5 48 
OF1 35.93  (± 0.06) bc 6 40 
C57BL/6JIco 35.93  (± 0.08)bc 7 40 
C3H/HeOuJIco 35.92  (± 0.08) bc 8 41 
129/SvPasIco 35.85  (±  0.11)cd 9 39 
DBA/2JIco 35.82  (± 0.09)cd 10 40 
BALB/cByJIco 35.65  (± 0.10)d 11 41 
 
†Data shows means ± SEM. Means with different superscripts are significantly different (P < 0.05). 
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Body temperature responses of the strains were differentially affected by baclofen 
dose and the time of measurement after dosing (Figure 1). This resulted in a drop in body 
temperature in most strains. When analysed as a two-way repeated measure ANOVA, with 
time and dose as factors, body temperatures in BALB/cByJIco [Dose: F (3, 132) = 30.52, 
P<0.001] and C57BL/6JIco [Dose: F(3, 108) = 11.95, P<0.001] were affected only by the 
highest dose of baclofen used (12 mg/kg), whereas DBA/2JIco [Dose: F(3, 108) = 15.19, 
P<0.001], FVB/NIco [Dose: F(3, 81) = 16.67, P<0.001], 129/SvPasIco [Dose: F(3, 105) = 
44.68, P<0.001], A/JOlaHsd [Dose: F(3, 132) = 30.52, P<0.001] and the out-bred strains 
NMRI [Dose: F(3, 108) = 7.97, P<0.001], Swiss [Dose: F(3, 108) = 12.06, P<0.001], CD1 
[Dose: F(3, 108) = 6.14, P<0.01] and OF1 [Dose: F( 3, 108) = 12.98, P<0.001] all showed 
hypothermic responses to both 6 and 12 mg/kg baclofen (Figure 1).  
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Fig. 1 (a-k). Mean (+ SEM) body temperature responses to baclofen at 0, 3, 6 and 12 mg/kg  p. o. in 
11 different mouse strains at -1, 0, 1, 2 and 4 h relative to the time of drug application. Inset graphs 
are mean (+ SEM) summed total body temperature change from baseline within animal, pooled over 
time for each different baclofen dose. *,  **,  *** Groups that differed significantly compared to vehicle-
treated mice (P < 0.05, <0.01, and <0.001, respectively). 
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Peak hypothermic responses to baclofen were reached by 1 hour post-dosing for the 
strains DBA/2JIco [Interaction: F(9, 108) = 14.13, P<0.001], FVB/NIco [Interaction: F(9, 81) 
= 11.19, P<0.001] and NMRI [Interaction: F(9, 108) = 2.64, P<0.01], whereas 
BALB/cByJIco [Interaction: F(9, 111) = 12.65, P<0.001]), C57BL/6JIco [Interaction: F(9, 
108) = 6.29, P<0.001], 129/SvPasIco [Interaction: F(9, 105) = 19.31, P<0.001], A/JOlaHsd 
[Interaction: F(9, 132) = 18.36, P<0.001] and the three outbred strains CD1[Interaction: F(9, 
108) = 8.23, P<0.001], OF1 [Interaction: F(9, 108) = 8.76, P<0.001] and Swiss [Interaction: 
F( 9, 108) = 5.57, P<0.001] showed peak hypothermia at two hours post-dosing. The body 
temperature of all strains had returned to normal within 4 hours of dosing, with the exception 
of BALB/cByJIco, DBA/2JIco and 129/SvPasIco when given the 12 mg/kg baclofen dose 
only. Interestingly, the C3H/HeOuJIco strain showed no body temperature responses to 
baclofen at any dose or time point investigated [Dose: F(3, 111) = 0.77, P = 0.52; Interaction: 
F(9, 111) = 0.89, P = 0.54]. 
Pearson’s product moment correlation of strain means showed no significant 
relationship between basal body temperature and hypothermic responses to 12 mg/kg baclofen 
(r = 0.19, P = 0.58). When assessed as a cumulated hypothermic response to baclofen over 
time and within strain (Figure 1 insets), again it can be seen that BALB/cByJIco mice [F(3, 
37) = 19.41, P<0.001] respond significantly only to the 12 mg/kg dose of baclofen. Similar 
effects were observed with the out-bred CD1 [F(3, 36) = 3.72, P<0.05] and Swiss [F(3, 36) = 
2.98, P<0.05] strains, with the latter strain showing only relatively small cumulative 
hypothermia to baclofen. C57BL/6JIco [F(3, 36) = 7.17, P<0.001], DBA/2JIco [F(3, 36) = 
25.81, P<0.001], FVB/NIco [F(3, 27) = 11.90, P<0.001], 129/SvPasIco [F(3, 35) = 51.74, 
P<0.001], A/JOlaHsd [F(3, 45) = 20.83, P<0.001] and the outbred OF1 [F(3, 36) = 7.45, 
P<0.001] and NMRI [F(3, 36) = 5.51, P<0.01] strains show a significant incremental increase 
in hypothermia with increasing doses of baclofen above 3 mg/kg. However the incremental 
increase in response in the C57BL/6JIco to the lower doses of baclofen were relatively small 
in comparison with that observed in other strains (Table 1). Again C3H/HeOuJIco, when 
assessed in this manner, had a blunted body temperature response to all of the doses of 
baclofen used in this experiment [F(3, 37) = 0.72, P = 0.55]. 
 
Effects of baclofen on rotarod endurance 
Strains differed in the number of falls accumulated during rotarod training (Kruskal-Wallis: H 
= 125.3, P<0.001), with the 129/SvPasIco falling most often, and the NMRI strain the least 
(Figure 2). 
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Fig. 2. Median (± 25% quartile, white box ; ± 75% quartile, error bar) number of falls from the rotarod 
during training sessions, medians with different superscripts are significantly different (P<0.05). 
 
Endurance on the rotarod, like body temperature, was affected differently and 
temporally across the strains by baclofen (Figure 3). Similar to the hypothermic effects,  
BALB/cByJIco (1h: H = 28.63, P>0.001, 2 h: H = 28.58, P<0.001) and C57BL/6JIco (1 h: H 
= 18.57, P>0.001, 2 h: H = 12.68, P<0.01) were ataxically affected only by baclofen at 12 
mg/kg. Although unlike their temperature responses, this was also the case for FVB/NIco (1 
h: H = 11.85, P<0.01; 2 h: H = 14.89, P<0.01), and the out-bred strains OF1 (1 h: H = 11.52, 
P<0.01), CD1 (1 h: H = 19.78, P<0.001; 2 h: H = 9.18, P<0.05) and Swiss (1 h: H = 17.61, 
P<0.001; 2 h: H = 18.32, P<0.001). The DBA/2JIco (1 h: H = 22.26, P<0.001; 2 h: H = 12.47, 
P<0.01), 129/SvPasIco (1 h: H = 27.13, P<0.001; 2 h: H = 26.79, P<0.001), and A/JOlaHsd (1 
h: H = 23.18, P<0.001; 2 h: H = 13.92, P<0.01) mice showed responses to both 6 and 12 
mg/kg. NMRI was the only strain which did not display significant ataxia to any doses of 
baclofen or at any time point investigated in the study. Of note, the C3H/HeOuJIco strain also 
showed significant responses to baclofen on the rotarod (1 h: H = 16.74, P<0.001; 2 h: H = 
12.24, P<0.01), in comparison to no effect on body temperature. All mice strains had returned 
to a normal level of coordination not statistically different from baseline within 4 h after 
dosing.  
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Fig. 3 (a-k). Mean (+ SEM) time spent on the rotarod (up to a maximum of 300 s per time point) 
following baclofen at 0, 3, 6 and 12 mg/kg p. o. in 11 different mouse strains 0, 1, 2 and 4 h after drug 
application. Inset graphs are mean (+SEM) percentages of  summed total time spent on the rotarod 1, 
2 and 4 h after drug or vehicle application relative to the maximum possible duration (900 s) for the 
different baclofen doses. Statistical analyses were performed on raw summed data. *,  **,  *** Groups 
that differed significantly compared to vehicle-treated mice (P < 0.05, <0.01, and <0.001, respectively). 
 
Confirmation of the ataxic responses to only the highest dose of baclofen were 
demonstrated by analysing summed endurance (Figure 3 insets) for the inbred strains 
BALB/cByJIco (H = 26.33, P<0.001), C57BL/6JIco (H = 19.78, P<0.001), FVB/NIco (H = 
11.99, P<0.01), C3H/HeOuJIco (H = 11.42 , P = 0.01), and the outbred strains OF1 (H = 
14.27, P<0.01), CD1 (H = 19.12, P<0.001) and Swiss (H = 24.52, P<0.001). Likewise, 
summed endurance for NMRI (H = 6.41, P = 0.09) failed to demonstrate significant ataxic 
responses to any of the doses of baclofen used when analysed in this way. Although the 
NMRI strain approached statistical significance for ataxia at the highest dose of baclofen used 
(P = 0.06), the reduced endurance on the rod at 12 mg/kg was small – about an 11% mean 
reduction from the possible cumulated time spent on the rod at the three rotarod sessions after 
dosing (Figure 4a). DBA/2JIco (H = 19.79, P<0.001), 129/SvPasIco (H = 28.07, P<0.001), 
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and A/JOlaHsd (H = 20.35, P<0.001) mice, in comparison, show significant dose-related 
ataxia to both the 6 and 12 mg/kg doses of baclofen (Figure 3 insets). 
 
Ranking of strains for sensitivity to baclofen 
Comparison of the different strains for summed hypothermic sensitivity to 12 mg/kg baclofen 
revealed a significant effect of strain [F(10, 100) = 10.05, P<0.001] allowing the ranking of 
strains from least to most sensitive (P<0.05, Table 2, Figure 4a). There was also an influence 
of strain on the ataxic sensitivity to 12 mg/kg of baclofen [F(10, 96) = 7.71, P<0.001], with 
post hoc analysis again allowing ranking of the different strains from least to most sensitive 
(P<0.05, Table 2, Figure 4a).  
The rank order of ataxia, from least to most sensitive strains, differed from the 
hypothermic sensitivity rank order (Figure 4b). Mean strain hypothermic sensitivity and 
ataxia to 12 mg/kg baclofen were not significantly correlated (r = 0.35, P = 0.30). 
 
 
Table 2. Rank orders of strain sensitivity (from least to most sensitive) to baclofen (12 mg/kg ) on the 
basis of hypothermic body temperature response (ΔT from baseline within animal (°C) summed over 4 
h), and ataxic responses on the rotarod (total summed endurance on the rotarod over three 5-min 
sessions at 1, 2 and 4 hours after drug or vehicle application) 
 
Hypothermia Time on Rotarod 
Strain Σ(ΔT)† Rank Strain Σ Endurance (s)† Rank 
C3H/HeOuJIco 1.42 (±1.74)a 1 NMRI 801 (±42)a 1 
Swiss -0.69 (±0.56)ab 2 OF1 717 (±53)ab 2 
NMRI -2.12 (±1.10)bc 3 CD1 567 (±53)bc 3 
C57BL/6JIco -2.63 (±0.70)bc 4 FVB/NIco 531 (±88)cd 4 
CD1 -3.44 (±1.11)cd 5 C57BL/6JIco 497 (±75)cd 5 
A/JOlaHsd -4.14 (± 0.75)cde 6 A/JOlaHsd 778 (± 54)cd 6 
OF1 -4.56 (±1.16)cdef 7 Swiss 478 (± 57)cd 7 
BALB/cByJIco -5.88 (±1.41)def 8 C3H/HeOuJIco 442 (±67)cde 8 
DBA/2JIco -6.45 (±0.80)ef 9 DBA/2JIco 365 (±63)de 9 
FVB/NIco -7.16 (±1.85)f 10 129/SvPasIco 297 (±48)e 10 
129/SvPasIco -10.32 (±0.78)g 11 BALB/cByJIco 283 (±38)e 11 
 
† Data shown are means (± SEM). Means with different superscripts are significantly different (P < 0.05) 
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2.5 Discussion 
 
The present study shows that baclofen produces different degrees of hypothermia and ataxia 
in the eleven mouse strains investigated. In addition, the strains most sensitive to the 
hypothermic responses were not necessarily the same as those giving the greatest ataxia and 
vice versa. These findings point to a differential genetic influence on various GABAB receptor 
mediated responses in vivo, which may have marked implications regarding choice of strain 
for genetic and pharmacological studies influenced by GABAB receptor function. 
GABAB receptors have long been known to influence body temperature in mammals. 
Previous studies have demonstrated baclofen-induced hypothermia in C57BL/6 mice (Gray et 
al. 1987), C57BL/6:129Sv hybrid mice (Queva et al. 2003), BALB/c mice (Humeniuk et al. 
1995; Schuler et al. 2001), OF1 mice (Cryan et al. 2004), rats (Serrano et al. 1985; Zarrindast 
and Oveissi 1988), rabbits (Frosini et al. 2004) and in man (Perry et al. 1998). The weak 
GABAB receptor agonist and GABA metabolite, γ-hydroxybutyrate (GHB), has also been 
shown to produce a reduction in body temperature (Kaupmann et al. 2003). The GABAB 
receptor antagonist CGP35348 blocks the hypothermic response to baclofen in rats (Jackson 
and Nutt 1991) and in BALB/c mice (Humeniuk et al. 1995). Furthermore, GABAB(1) or 
GABAB(2) receptor subunit-deficient mice do not demonstrate any hypothermic response to 
GABAB receptor agonists, although their basal body temperature is lower than that of their 
wild-type litter mates (Gassmann et al. 2004; Kaupmann et al. 2003; Queva et al. 2003; 
Schuler et al. 2001). 
Results from the present study indicate that although baclofen can induce hypothermia 
in many mice strains, the degree of hypothermia produced is dependent on their genetic 
background. Further, this response may be absent altogether, as we observed in the 
C3H/HeOuJIco strain (Table 2, Figure 1f, Figure 4a). Variations in the body temperature 
response profiles of different mouse strain have also been previously reported for 
pentobarbital (Crabbe et al. 2002), ethanol (Crabbe et al. 1994), diazepam (Crabbe et al. 1998) 
and morphine (Belknap et al. 1998). Although it is not necessarily expected that different 
drugs will give similar hypothermic responses in different strains, it is interesting to note that 
in our studies the C3H/HeOuJIco strain body temperature was unaffected by baclofen, and in 
the study of Belknap and colleagues (1998) the C3H/HeJ strain did not show any hypothermia 
to morphine. Conversely, the 129/SvPasIco strain in this study responded with a high degree 
of both ataxia and hypothermia to baclofen, and the 129P3/J (formerly 129/J; (Festing et al. 
1999) strain was shown to be highly susceptible to the hypothermic and ataxic effects of 
pentobarbitone in comparison with other strains (Crabbe et al. 2002). However, it should be 
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noted that extensive genetic variability between the 129 substrains exist  (Simpson et al. 1997; 
Threadgill et al. 1997), which makes drawing comparisons about like-phenotypes within this 
strain more complicated. 
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Fig 4. Relative ataxic and hypothermic sensitivity to the highest dose of baclofen (12 mg/kg) in 11 
different mouse strains. A) Pale grey bars: mean (+ SEM) percent reduction in total time spent on 
rotarod from a possible maximum of 900 s (300 s at each of the three post-drug time points tested) 
following baclofen dosing. Black bars: mean (+ SEM) change in temperature (ΔT), for each mouse 
relative to own control, summed over the 4 time points tested, following baclofen dosing. B) Schematic 
showing disparity of rank order in mouse strain hypothermic and ataxic sensitivity to baclofen (least 
sensitive = 1, most sensitive = 11). 
 
Baclofen has also long been known to produce motor discoordination in a range of 
species, for example in BALB/c (Gassmann et al. 2004; Schuler et al. 2001), OF1 (Cryan et 
al. 2004) and C57BL/6 mice (Gray et al. 1987), rats (Kasture et al. 1996; Smith and 
Vestergaard 1979) and rabbits (Frosini et al. 2004). Clearly, it is these muscle relaxant effects 
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that have made baclofen the drug of choice for treatment of spasticity in man (Bowery et al. 
2002). The results of the present study indicate that indeed, as for hypothermia, the severity of 
baclofen-induced ataxia in mice is highly dependent on the background strain, and may be 
absent altogether, as in the case of the NMRI strain (Table 2, Figure 3i, Figure 4a). Other 
strains, such as C3H/HeOuJIco, DBA/2JIco, 129/SvPasIco and BALB/cByJIco, show 
relatively severe ataxic responses to baclofen. Interestingly, recent studies (Rustay et al. 
2003a) have demonstrated that the BALB/cByJ and DBA/2 strains (and also FVB/N) failed to 
show ataxia with 2 g/kg of ethanol on the accelerating rotarod. However, on a fixed speed 
rotarod (rotating at 10 rpm), which is a similar speed to that used in our study (12 rpm), all 
mice strains investigated were similarly impaired by the three doses (1, 2 and 3 g/kg) of 
ethanol studied (Rustay et al. 2003a). Crabbe and co-workers have also investigated the ataxic 
effects of the GABAA allosteric modulators ethanol (Crabbe et al. 1994), pentobarbital 
(Crabbe et al. 2002) and diazepam (Crabbe et al. 1998) in different mouse strains. Overall, 
when comparing the strains used in these aforementioned studies with the strains most similar 
to those used in our studies, there appears to be little consistent agreement on ataxic ranking. 
This is to be expected to a certain degree as the primary sites of drug action differ between 
these studies. Additionally, we acknowledge that caution must be taken when comparing 
rotarod data amongst different laboratories, as parameters such as rotarod speed, or 
accelerating versus fixed speed protocols can influence animal performance and hence the 
interpretation of result (Rustay et al. 2003b).  
Multiple mechanisms may underlie the different ataxic and hypothermic responses to 
baclofen in the mouse strains. Firstly, it is possible that genetic influence on pharmacokinetics 
and metabolism of baclofen may influence the different sensitivity between strains. Certainly, 
variations in mouse strain responses to pentobarbital and diazepam appear to be at least 
somewhat influenced by differences in pharmacokinetics, although pharmacodynamic 
contributions were much greater (Crabbe et al. 1998; Crabbe et al. 2002). To our knowledge, 
there is no inter-strain comparison of the pharmacokinetics of GABAB receptor agonists. 
However, when making within-strain comparison of GABAB receptor-mediated responses, 
there is unlikely to be a major pharmacokinetic influence. We purposely investigated 
simultaneously, two distinct responses in the same animals in an effort to minimize any 
potential interpretation of a pharmacokinetic basis for the effects. Thus the differential 
responses of baclofen on motor in-coordination and temperature in certain strains, such as the 
C3H/HeOuJIco and NMRI , are largely due to pharmacodynamic influences. 
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It may be postulated that strains with different basal temperature set points could 
respond to hypothermia-induction in a congruent fashion. However, poor correlations 
between the strain mean hypothermic responses and basal body temperature illustrate that 
these two parameters are not significantly related at least with regard to baclofen. Just as basal 
body temperature varies with strain, so to does innate ability on the rotarod, in terms of both 
baseline performance and ability to learn the task over time (Bothe et al. 2004; Brooks et al. 
2004; McFadyen et al. 2003; Tarantino et al. 2000). Additionally, widespread strain 
differences in cognitive ability have been reported (Crawley 2000; Crawley et al. 1997). 
Hence it is plausible that strain learning ability on rotarod could influence performance in the 
present study. However, the baselines at time zero, the day after training, with the exception 
of animals of the A/JOlaHsd strain, were stable showing that the mice had learned the task 
adequately. The generally poor performance of the A/J strain on the fixed speed rotarod has 
also been demonstrated in other studies (Rustay et al. 2003a). Nevertheless, given the fact that 
GABAB receptors modulate cognitive performance (although the specific mechanisms are still 
not fully understood; Bowery et al. 2002; Schuler et al. 2001), one cannot totally rule out 
potential cognition-altering effects of baclofen on rotarod performance.  
Potential regional differences in GABAB receptor expression may also play a role in 
the altered hypothermic or ataxic responses to baclofen in the different mouse strains. Body 
temperature is coordinated primarily by the anterior hypothalamus and preoptic area (Boulant 
2000; Frosini et al. 2004), and is mediated at least partially through GABAB receptors in these 
regions (Jha et al. 2001; Pierau et al. 1997; Yakimova et al. 1996). The posterior 
hypothalamus and brainstem nuclei are also implicated in body temperature regulation. In the 
rat, the GABAB(1a) receptor isoform  is relatively heavily expressed in the supraoptic nucleus 
of the hypothalamus (Liang et al. 2000), and the GABAB(1) receptor subunit is predominantly 
expressed (over that of the GABAB(2) receptor subunit) in most serotonergic and 
catecholaminergic neurons of the brainstem nuclei that are involved in regulation of 
autonomic functions (Burman et al. 2003). 
GABAB receptors are also widely expressed in many neuroanatomical structures 
involved in motor control and coordination such as the cerebellum, thalamus, striatum, 
sensory motor cortex and spinal cord (see (Benke et al. 1999; Bowery et al. 2002; Chen et al. 
2004; Fritschy et al. 2004; Liang et al. 2000; Waldvogel et al. 2004). Given such an 
expression profile it would be expected that baclofen could induce motor impairment at 
numerous different anatomical levels. Indeed, baclofen has been proposed to have direct 
actions on various regions known to influence motor in-coordination including the motor 
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cortex (Frosini et al. 2004), substantia nigra (Chan et al. 1998; Turski et al. 1990), cerebellum 
(Dar 1996) and at the spinal level (Bettler et al. 2004). Detailed information on specific cross 
strain differences in GABAB receptor expression patterns have not been reported to date. 
However, it is conceivable that variations in GABAB receptor expression and abundance in 
motor- and temperature-related anatomical regions may underlie strain differences in 
sensitivity to baclofen. 
Finally, other neurotransmitter systems can influence body temperature and ataxia. 
The neurochemistry of temperature control is complex, and certainly involves many 
neurotransmitter receptor systems including 5-HT1A (Cryan et al. 1999; Hedlund et al. 2004), 
5-HT2C, dopamine D2 receptors (Cryan et al. 2000), 5-HT7 (Hedlund et al. 2004), GABAA 
receptor ethanol, benzodiazepine, and barbiturate binding sites (Crabbe et al. 1998; Crabbe et 
al. 1994; Crabbe et al. 2002); cholinergic (Unal et al. 1998); noradrenergic (Myers et al. 1987) 
and the opioid receptor system (Adler et al. 1988; Belknap et al. 1998). On the other hand, the 
glutamate, dopamine, adrenergic and cholinergic systems are the main neurotransmitters 
associated with motor control in mice (Svensson et al. 1995). GABAB has long been known to 
interact with monoaminergic systems, as demonstrated by baclofen-induced increases in 
striatal dopamine (Carlsson et al. 1977), and attenuation of baclofen-induced increases in 
noradrenaline turnover by the α2-adrenergic receptor agonist clonidine (Sawynok and Reid 
1986). The interactions between GABAB and 5-HT have been shown particularly at the level 
of the dorsal raphe nucleus (Judge et al. 2004; Mannoury la Cour et al. 2004), and may occur 
through presynaptic GABAB heteroreceptor inhibition of 5-HT release, or possibly though G-
protein coupling interactions between 5-HT1A and GABAB receptor complexes (Mannoury la 
Cour et al. 2004). It is noteworthy that although GABAB may influence serotonergic-mediated 
effects, the reverse, at least as determined via hypothermic responses to GABAB and 5-HT1A 
agonists, may not necessarily hold true. Gray et al., (1987) demonstrated that serotonin 
depletion via ICV 5,7-dihydroxytryptamine administration abolished the hypothermic effect 
of the 5-HT1A receptor agonist 8-OH DPAT, but did not alter baclofen-induced hypothermia. 
Of particular relevance to motor control, GABAB receptor agonism has also been shown to 
influence neostriatal glutamatergic excitability, most likely through inhibition of presynaptic 
glutamate release via GABAB inhibition of Ca+2 channels (Barral et al. 2000). Finally, large 
strain differences in monoamine systems also exist, for example in brain 5-HT, noradrenaline 
and dopamine levels in C57BL/6 and BALB/c mice (Daszuta and Barrit 1982; Daszuta et al. 
1982a; Daszuta et al. 1982b) and these divergences may indirectly influence strain responses 
to baclofen. 
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The present study indicates that baclofen can have distinct, independent effects 
(including no effect at all) on ataxia and hypothermia within a given strain. This is 
demonstrated in particular by mice in the NMRI strain, which showed hypothermia without 
significant ataxia, and by mice of the C3H/HeOuJIco strain, which exhibited ataxia without 
simultaneous hypothermia, in response to the same dose of baclofen (Table 2, Figure 4a). This 
is of particular interest for two reasons: 1) it demonstrates the importance of genetic 
background in responses to GABAB receptor activation, and; 2) it suggests that hypothermia 
and ataxia may be under independent genetic control (despite activation of a common 
receptor). The study of inbred mouse strains assists in identification of specific genetic 
influences on given behaviours, as inbred mice from the same strain are essentially 
genetically identical i.e. homozygous for each gene. Thus, fluctuations in the mean responses 
of diverse strains are a reflection of differences in genetic makeup (Crabbe et al. 2002). 
Genetic background has been shown to influence the sensitivity of mice to many drugs 
(Crawley 2000; Crawley et al. 1997) and the present study shows that this is true also for the 
response of mice to baclofen. It should be cautioned, however, that epigenetic factors have 
also been shown to have a strong influence on behaviour (Francis et al. 2003) and these also 
may alter the responses to baclofen. Clearly our data also suggests that it is prudent to 
investigate multiple responses (both behavioural and physiological) when investigating 
pharmacological effects following genetic manipulations such as targeted deletions, as using a 
single parameter may not indicate whether or not the responses to a given ligand are truly 
changed, as demonstrated here with hypothermia and ataxia. 
Recently, GABAB receptor positive modulators have been identified (Urwyler et al. 
2003) which lack the hypothermic and ataxic properties of baclofen (Cryan et al. 2004). 
Allosteric positive modulation of metabotropic receptors provide a novel means for the 
pharmacological manipulation of G-protein-coupled receptors acting at a distinct site apart 
from the orthosteric binding region of the receptor protein. The prototypical GABAB positive 
modulator GS39783 has shown potential as anti-addictive and anti-anxiety agent (Cryan et al. 
2004; Smith et al. 2004). Future studies must determine whether similar strain differences are 
manifested in behaviours related to these disorders as occurs with baclofen-induced 
responses. 
Overall, our data clearly show a strong genetic influence on GABAB receptor-
mediated responses. Such genetically determined effects may directly influence the 
therapeutic efficacy of GABAB agonists and suggest that perhaps pharmacogenetic factors 
should be considered in patients prescribed baclofen. These findings also have implications 
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for the selection of mouse strains for research investigating the role of GABAB in physiology 
and  behaviour. Further, these studies demonstrate that hypothermic and ataxic responses may 
be influenced by independent genetic loci. 
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3.1 Abstract 
 
GABAB receptors agonists produce hypothermia and motor in-coordination. Two GABAB(1) 
receptor subunit isoforms exist, but because of lack of specific molecular or pharmacological 
tools, the relevance of these isoforms in controlling basal body temperature, locomotor 
activity or in vivo responses to GABAB receptor agonists has been unknown. Here we use 
mice deficient in the GABAB(1a) and GABAB(1b) subunit isoforms to examine the influence of 
these isoforms on both baseline motor behaviour and body temperature and on the motor-
incoodinating and hypothermic responses to the GABAB receptor agonists L-baclofen and γ-
hydroxybutyrate (GHB). GABAB(1b)-/- mice were hyperactive in a novel environment and 
showed slower habituation than either GABAB(1a)-/- or wild-type mice. GABAB(1b)-/- mice were 
hyperactive throughout the circadian dark phase. Hypothermia in response to L-baclofen (6 
and 12 mg kg -1) or GHB (1 g kg -1), baclofen-induced ataxia as determined on the fixed-
speed rotarod, and GHB-induced hypolocomotion were significantly, but for the most part 
similarly, attenuated in both GABAB(1a)-/- and GABAB(1b)-/- mice. We conclude that L-baclofen 
and GHB are non-selective for either GABAB(1) receptor isoforms in terms of in vivo 
responses. However, GABAB1 receptor isoforms have distinct and different roles in mediating 
locomotor behavioural responses to a novel environment. Therefore GABAB(1a) and 
GABAB(1b) isoforms are functionally relevant molecular variants of the GABAB(1) receptor 
subunit, which are differentially involved in specific neurophysiological processes and 
behaviors. 
 
3.2 Introduction 
 
GABAB receptors are heterodimeric G protein-coupled receptors composed of GABAB(1) and 
GABAB(2) subunits. They are located pre- and postsynaptically, where they modulate 
neurotransmitter release and slow inhibitory postsynaptic potentials, mainly via actions on 
presynaptic Ca+2 channels and postsynaptic inwardly rectifying K+ channels, respectively, and 
are also expressed as interneuron autoreceptors (Couve et al., 2000; Bettler et al., 2004). 
GABAB receptors are implicated in epilepsy, addiction, pain and gastrointestinal disease 
(Bettler et al., 2004). Emerging data also supports a role for GABAB receptors in anxiety, 
depression (Mombereau et al., 2004a, 2005; Cryan and Kaupmann, 2005) and cognition 
(Bowery, 2006). These findings promote further investigations into the mechanisms of action 
of the GABAB receptors because of their potential importance as a therapeutic target (Bettler 
et al., 2004; Cryan and Kaupmann, 2005). 
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The Gabbr1 gene is transcribed from two different promoter sites to generate two 
predominant isoforms in the brain: GABAB(1a) and GABAB(1b) (Steiger et al., 2004), both of 
which can heterodimerise with the GABAB(2) subunit to form functional receptors (Bettler et 
al., 2004). The two isoforms differ in sequence only by the inclusion of a pair of sushi 
domains (also called short consensus repeats) at the N-terminus on the GABAB(1a) isoform, 
which are absent in the GABAB(1b) isoform (Blein et al., 2004). Other GABAB(1) receptor 
splice variants have been reported in recombinant systems, although many of these variants 
are either not expressed in native tissues, or are not evolutionarily conserved across different 
species, and as such the functional relevance of these variants remains controversial (Bettler 
et al., 2004; Cryan and Kaupmann, 2005). Therefore, the molecular diversity of native 
GABAB receptors has therefore been regarded as being relatively limited, which is at odds 
with the reported variability in the nature of responses to GABAB receptor ligands (Marshall 
et al., 1999; Bettler et al., 2004; Huang, 2006).  
In recombinant systems, many studies attest to a lack of pharmacological differences 
between the GABAB(1a,2)  and GABAB(1b,2) isoforms (Kaupmann et al., 1998a; Malitschek et 
al., 1998; Brauner-Osborne and Krogsgaard-Larsen, 1999; Green et al., 2000), although there 
are also a few findings to the contrary, that differences exist in the pharmacology of the 
receptor isoforms (see (Bettler et al., 2004). However, to date, research tools with which to 
probe the in vivo pharmacology of GABAB(1a) and GABAB(1b) isoforms have not been 
available. The anatomical expression profile of GABAB(1a) and GABAB(1b) receptor isoforms 
diverges in many structures (Benke et al., 1999; Bischoff et al., 1999; Liang et al., 2000; 
Fritschy et al., 2004), which has given rise to speculation that the isoforms may have 
functional heterogeneity, possibly meditated by differential synaptic localisation (Bettler et 
al., 2004). Furthermore, many studies have shown pharmacological differences between 
hetero- and autoreceptors, and some GABAB receptor ligands have been postulated to act 
preferentially at either presynaptic or postsynaptic locations (fore reviews see Bowery et al, 
2002 and Bettler et al, 2004). However, the possible contribution of these different isoforms 
to characteristic in vivo responses to GABAB receptor activation, such as hypothermia and 
motor performance in response to baclofen (Gray et al., 1987; Jacobson and Cryan, 2005), are 
currently unknown. 
Recently, mice deficient in the GABAB(1a) and GABAB(1b) subunit isoforms have been 
generated using a knock-in genetic approach (Vigot et al., 2006). Electron microscopy and 
electrophysiological characterisation of the mice revealed that, at least in the hippocampus 
(Vigot et al., 2006) and in the lateral amygdala (Shaban et al., 2006), the GABAB(1a) isoform 
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was predominantly a presynaptic heteroreceptor, while the GABAB(1b) isoform was mainly 
located postsynaptically, and both were autoreceptors (Shaban et al., 2006; Vigot et al., 2006). 
In addition, this distribution has been shown to generalise to layer 5 cortical neurons, where 
the GABAB(1b) isoform was also shown to be predominantly postsynaptically located, while 
GABAB(1a) was the main isoform represented at presynaptic terminals of local interneurons 
synapsing on the dendritic tuft (Perez-Garci et al., 2006). As such, GABAB(1a)-/- and 
GABAB(1b)-/- mice provide an ideal tool with which to investigate the roles of the two 
GABAB(1) isoforms in the in vivo pharmacology of GABAB receptor agonist-induced 
responses. Therefore, the aim of the present study was to determine the influence of the two 
GABAB(1) isoforms on both on motor-incoodinating and hypothermic responses to the 
GABAB receptor agonists baclofen and γ-hydroxybutyrate (GHB), and on baseline locomotor 
behaviour and body temperature. 
 
3.3 Materials and Methods 
 
Animals and Housing 
The generation (Vigot et al., 2006) and breeding strategy (Jacobson et al., 2006b) of wild-type 
(WT), GABAB(1a)-/- and GABAB(1b)-/- mice as used in the present studies has been described 
previously. In brief, mice were generated using a knock-in point mutation strategy, whereby 
GABAB(1a) and GABAB(1b) initiation codons were converted to stop codons by targeted 
insertion of a floxed neo-cassette. All mutant and WT mice were maintained on a pure inbred 
BALB/c genetic background. GABAB(1a)-/- and GABAB(1b)-/- mice used in the present 
experiments were derived from homozygous breeding (F3-4) of siblings originating from the 
founding heterozygotic mice. Homozygous WT controls for the GABAB(1) isoform mutant 
mice were derived from mating together WT siblings generated from GABAB(1a)+/- and 
GABAB(1b)+/- heterozygous breedings (F3-4). The breeding strategy was applied in accordance 
with the recommendations proposed by The Jackson Laboratory (Bar Harbor, ME) to obviate 
genetic drift and the formation of substrains (http://jaxmice.jax.org/geneticquality/guide-
lines.html). 
Mice were singly housed in macrolon cages with sawdust bedding, tissue paper 
nesting materials and one red, triangular, polycarbonate Mouse House® (Nalgene, Nalge and 
Nunc International, Rochester, NY) per cage. Housing was at a constant room temperature of 
22-24°C in a 12-h light dark cycle with lights on at either 6 A.M. to 6.30 A.M. Food pellets 
and tap water were available ad libitum (except during experimentation, unless stated). 
Separate cohorts of mice were used for each experiment. All mice were drug-naïve before 
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experimentation. Male mice were used in all experiments with the exception of GHB-induced 
hypolocomotion, for which only females were available.  In certain experiments as indicated, 
experimental replication was also carried out in a cohort of female mice. All animal 
experiments were conducted during the light phase with the exception of continuous 
locomotor activity assessments which were made during both the light and dark phases. All 
animal experiments were conducted in accordance with Swiss guidelines, and approved by the 
Veterinary Authority of Basel-Stadt, Switzerland. 
 
Drugs 
All drug solutions were prepared freshly prior to use. L-baclofen (Novartis, Basel, 
Switzerland) and GHB (Novartis) were dissolved in 0.5% methyl cellulose (vehicle) and 
applied p.o. in a volume of 10 ml/kg. 
 
Primary Observation Test 
A battery of behavioural and physiological observations were made as previously described 
(Cryan et al., 2003) to investigate if GABAB(1a)-/- or GABAB(1b)-/- mice had any gross 
differences compared with WT mice. This was important to investigate, as both GABAB(1)- 
and GABAB(2)-deficient mice have been shown previously to develop an enhanced 
susceptibility to seizures (Prosser et al., 2001; Schuler et al., 2001). Mice used in this 
experiment were singly-housed WT, GABAB(1a)-/- and GABAB(1b)-/- mice. The experiment was 
replicated separately in both male and female mice. The mean age (± S.E.M.) of the mice was 
20.0 ± 1.0 weeks for males and 23.1 ± 0.8 weeks for females (n = 11-12 for each genotype 
and gender). The observations quantified were the presence of twitches, tremor, convulsions, 
piloerection, stereotyped behaviour, lacrimation, salivation, ptosis, catalepsy, passivity, falling 
convulsion and ataxia. In addition the frequency and quality of breathing was observed. 
Alterations in skin colour, tail position, pelvic position, limb tonus, abdominal tonus and pupil 
width were observed. The nature of locomotion, motility and rearing in the home cage were 
quantified, as was overall flight and startle reactions. In addition, novelty behaviour was 
observed and a series of reflexes checked, including pinna reflex, toe-pinch, tail-pinch and 
provoked biting. Body temperature was also quantified. This battery of tests has been 
validated in our laboratories to detect stimulant and sedative effects in mice in addition to 
other effects of pharmacological agents.  
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Locomotor Activity of GABAB(1a)-/- , GABAB(1b)-/- and WT Mice in a Novel Environment 
Locomotor activity of mutant and WT mice when placed in a novel environment was 
investigated in two separate experiments with male and female mice, respectively. Horizontal 
locomotor activity of the mice [n = 10-11 for each genotype and sex, mean age (± S.E.M.) 
was 17.5 (± 0.5) and 14.5 (± 0.4) weeks for males and females, respectively] was recorded for 
1 h after individuals were placed into novel enclosure (transparent Plexiglas boxes, 19 x 31 x 
16 cm), with motion detection determined by infrared light beam interruptions along the x- 
and y-axes. Distance travelled was automatically calculated using a TSE Moti system (TSE, 
Bad Homburg, Germany). 
 
Continuous 3-Day Locomotor Activity of Male GABAB(1a)-/- , GABAB(1b)-/- and WT Mice 
Horizontal locomotor activity of age-matched, singly house male mice (WT, n = 9; 
GABAB(1a)-/-, n = 9; GABAB(1b)-/-, n = 6; mean age ± S.E.M., 15.6 ± 0.6 weeks) was 
continuously recorded over 67 h (TSE Moti system). Mice were transferred to new home 
cages at 1 P.M. in the afternoon. Food and water was provided ad libitum, as usual, although 
tissue paper nesting material and the Mouse House were removed. Motion detection was 
determined in the new home cages from the time immediately after re-housing over the 
following 3 dark and 2.5 light cycles, by infrared light beam interruptions along the x- and y-
axes. Distance travelled was automatically calculated using a TSE Moti system (TSE, Bad 
Homburg, Germany). The testing room in which the experiment took place was undisturbed 
during the course of the experiment. 
 
Influence of L-Baclofen on Rotarod Endurance and Body Temperature of GABAB(1a)-/-, 
GABAB(1b)-/- and WT Mice 
The effect of the GABAB receptor agonist, L-baclofen, on motor coordination and body 
temperature GABAB(1a)-/-, GABAB(1b)-/- and WT mice were investigated in two experiments: 
one with male and one with female mice, respectively. Each experiment was conducted with 
two cohorts of mice. In the first cohort, 0 and 12 mg/kg of L- baclofen was examined in age-
matched mutant and WT mice (male mice: n = 19 – 20 per genotype; mean age ± S.E.M., 15.2 
± 0.3 weeks; female mice: n = 18 – 21 per genotype; mean age ± S.E.M., 18 ± 0.3 weeks). In 
the second cohort, 0 and 6 mg/kg of L-baclofen was examined (male mice: n = 9 – 10 per 
genotype; mean age ± S.E.M., 15.2 ± 0.3 weeks; female mice: n = 8 – 10 per genotype; mean 
age ± S.E.M., 25.2 ± 0.5 weeks). 
In the experimental protocol, performance on the fixed-speed rotarod (Dunham and 
Miya, 1957) was combined with the evaluation of rectal temperature within each animal, as 
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described previously (Cryan et al., 2004; Jacobson and Cryan, 2005). The rotarod apparatus 
consisted of a 28 mm diameter rod of approximately 300mm length, which was partitioned 
into 5 lanes of 58 mm wide to accommodate individual mice. The rod was positioned 30 cm 
above a surface and rotated at a constant speed of 12 rpm. Each day the rod lanes were tightly 
lined with fresh paper towelling. Rectal temperature was recorded (ELLAB Instruments 
thermistor probe, Copenhagen, Denmark) from individual mice while hand held near the base 
of the tail against the wall of the home cage. The probe was left in place until steady readings 
were obtained (approximately 15 s). 
Two days prior to testing, the Mouse House and tissue paper nesting materials were 
removed from each cage to reduce possible inter-cage variations in mouse body temperatures 
on the day of testing. On the day before testing mice were acclimatized to the rectal thermistor 
probe by performing a single body temperature measurement and were then trained to walk 
on the rotarod for 300 s. Rotarod training was performed in two to four sessions, depending 
on the innate ability of each animal. The number of falls during training was recorded. Mice 
were returned to the home cage for an interval of approximately 30 min between training 
sessions.  
On the day of testing, mice were moved to the experimental lab at least 2 hours before 
dosing. One hour before dosing, rectal temperature was taken. At time 0 h, rectal temperature 
was taken, then the mice were placed on the rotarod for 300 s to re-establish training and to 
provide an experimental baseline. Each mouse was then immediately dosed with its allocated 
treatment on completing 300 s on the rotarod. Rectal temperature and endurance on the 
rotarod were recorded 1, 2 and 4 h thereafter.  
An index of the degree of hypothermia (summed ΔT) was calculated by totalling the 
differences between control (predose) rectal temperature and the temperatures at 1, 2 and 4 h 
post treatment, respectively, within each animal. An index of the degree of ataxia was 
calculated by determining the difference between cumulative total time on the rotarod 1, 2 and 
4 hours after drug or vehicle application as a proportion of the total possible (i.e. percent 
reduction from 1200 s). 
 
Effect of GHB on Body Temperature of Male GABAB(1a)-/-, GABAB(1b)-/- and WT Mice 
The effect of GHB (1 g/kg) on body temperature has been shown to be GABAB(1) receptor 
dependent (Kaupmann et al., 2003). Therefore, we assessed whether either receptor isoforms 
conferred susceptibility to GHB-induced hypothermia. This dose was selected based on our 
dose-response data obtained in BALB/c mice (Kaupmann et al., 2003), the background strain 
Chapter 3  65 
_________________________________________________________________________________ 
for the GABAB(1) isoform mutant and WT mice. Rectal temperature (ELLAB Instruments 
thermistor probe, as described above) of singly housed, age-matched, male mice (WT, n = 7; 
GABAB(1a)-/-, n = 9; GABAB(1b)-/-, n = 13; mean age ± S.E.M., 27.0 ± 1.7 weeks) was recorded 
1 h before, immediately before, and 30, 60, 120 and 240 min after, p.o. administration of 
GHB [1 g/kg in methyl cellulose (0.5%)] in a volume of 10 ml/kg. 
 
Effect of GHB on Locomotor Activity of Female GABAB(1a)-/-, GABAB(1b)-/- and WT 
Mice 
Previous studies have shown that the motor impairing effects of GHB (1g/kg) are GABAB(1) 
receptor mediated (Kaupmann et al., 2003). Therefore, it was important to assess whether 
either of the GABAB(1) receptor subunit isoforms conferred susceptibility to GHB-induced 
hypoactivity. Singly housed, age-matched, female mice (WT, n = 23; GABAB(1a)-/-, n = 16; 
GABAB(1b)-/-, n = 34; mean age ± S.E.M., 26.7 ± 0.6 weeks) were given GHB (1 g/kg) or 
vehicle (0.5% methyl cellulose) p.o. in a volume of 10 ml/kg. The doses of GHB was selected 
based on previous dose-response studies showing maximal effects at this dose in this 
background mouse strain (Kaupmann et al., 2003). One hour after dosing, mice were placed 
in a transparent Plexiglas boxes (19 x 31 x 16 cm), and motion detection was determined over 
the following hour by infrared light beam interruptions along the x- and y-axes. Distance 
travelled was automatically calculated using a TSE Moti system (TSE, Bad Homburg, 
Germany). 
 
Statistical Analyses 
Because studies that were carried out in both male and female mice were conducted in 
independent experiments, data for each sex were analysed separately. Live-weight and rectal 
temperature as determined in the primary observation test were analysed with one-way 
analysis of variance (ANOVA). Locomotor activity in a novel environment and continuous 3-
day locomotor activity were analysed for the effects of genotype and time using two-way 
repeated measures ANOVA. Summed mean distance travelled during the first 2 and the full 
12 h of the three complete dark cycles and during the 12 h of the two complete light cycles, 
was analysed for the effect of genotype using one-way ANOVA. Basal body temperature (at 
time points -1 and 0 h in the combined rotarod - temperature experiment) were analysed for 
the effect of replicate, genotype and time using three-way ANOVA. Fisher’s least significant 
difference post hoc comparisons were made where indicated by significant ANOVA factors. 
Falls during rotarod training, and body temperature responses to GHB were analysed for the 
effect of genotype in a pair-wise fashion using the Mann-Whitney rank sum method. All 
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variables from the POT, with the exception of live-weight and rectal temperature (see above), 
summed rotarod data (within each baclofen dose) and distance travelled after vehicle or GHB 
treatment (within treatment and time point) were analysed for the effect of genotype using 
Kruskal Wallis one-way ANOVA on ranks. Dunn’s Method post hoc comparisons were made 
where indicated by significant Kruskal Wallis ANOVA factors, with the exception of the 
influence of GHB on locomotor activity, where pair-wise Mann-Whitney Rank Sum 
comparison were used as a post hoc comparison method when appropriate. 
 
3.4 Results 
 
POT 
Unlike GABAB(1)- and GABAB(2)-deficient mice, in which spontaneous seizures were 
observed (Schuler et al., 2001; Gassmann et al., 2004), this phenotype was not behaviourally 
apparent in GABAB(1a)-/- or GABAB(1b)-/- mice. To assess whether ablation of GABAB(1a) or 
GABAB(1b) receptor isoforms had any other effects on gross behaviour and physiology, male 
and female GABAB(1a)-/- or GABAB(1b)-/- mice were subjected to an extensive POT battery.  
Within the male mice, GABAB(1b)-/- mice were significantly heavier than either WT (P 
< 0.01) or GABAB(1a)-/- (P < 0.001) mice, and WT mice were heavier than GABAB(1a)-/- mice 
(P < 0.001). Mean (± SEM) weights of male mice were WT, 32.5 (± 0.6) g; GABAB(1a)-/-, 29.2 
(± 0.5) g; GABAB(1b)-/- , 34.8 (±0.6) g (genotype F2,34 = 23.73, P < 0.001).  
Female GABAB(1b)-/- mice were slightly, but significantly heavier than female WT 
mice (P < 0.01, mean ± S.E.M. weights were 27.6 ± 0.7 g and 24.5 ± 0.7 g, respectively). 
However, there were no differences between the weight of female GABAB(1a)-/- mice (25.9 ± 
0.8 g) and either WT or GABAB(1b)-/- female mice (genotype F2,35 = 4.20, P < 0.05).  
Otherwise the POT battery revealed no significant differences between GABAB(1a)-/-, 
GABAB(1b)-/- and WT mice in any of the other 31 parameters assessed (see Materials and 
Methods). This included body temperature as assessed in the home cage, where mean rectal 
temperature for both the male and female mice was not significantly influenced by genotype, 
respectively (males: mean rectal temperature ± SEM: 35.9 ± 0.13 °C; genotype F2,34 = 0.36, P 
= 0.70; females: mean rectal temperature 36.2 ± 0.15 °C; genotype F2,35 = 1.20, P = 0.32). 
 
Locomotor Activity of GABAB(1a)-/- , GABAB(1b)-/- and WT Mice in a Novel Environment 
Data from one male and one female GABAB(1a)-/- mouse were excluded from analysis as 
statistical outliers. The male mouse travelled 158 m in 1 h, compared with the mean for the 
remaining nine male GABAB(1a)-/- mice of 79.6 ± 5.5. The female mouse travelled 208 m in 1 
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h, compared with the mean for the remaining 10 female mice of 54.1 ± 3.6 m. Both of these 
animals showed intermittent periods of repetitive, stereotypic circling behaviour in the home 
cage, which might have increased locomotor activity during the test. No other signs of 
stereotyped behaviour were observed in any genotype across all other experiments. 
Genotype influenced the pattern of locomotor activity in male mice (time F11, 347 = 
15.39, P < 0.001; genotype F2, 347 = 1.67, P > 0.05; interaction F22, 347 = 1.708, P < 0.05) (Fig. 
1a). Post hoc analysis revealed the male GABAB(1b)-/- mice were more active than WT and 
GABAB(1a)-/- male mice within the first 5 min, and at other time-points within the first 20 min 
of the experiment (Fig. 1a).  
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Fig. 1. GABAB(1b)-/- mice were hyperactive in a novel environment. Distance travelled during 
spontaneous locomotor activity in a novel enclosure by male (a) and female (b) WT, GABAB(1a)-/- (1a-/-) 
and GABAB(1b)-/- (1b-/-) mice. * P < 0.05 vs WT, # P < 0.05 vs 1a-/- , ## P < 0.01 vs 1a-/- .‘]’ denotes 
ANOVA main effects for genotype and time.  
 
Genotype and time influenced the locomotor activity of female mice, with the 
GABAB(1b)-/- mice showing consistently greater distance travelled over the duration of the 
experiment than WT of GABAB(1b)-/- mice, as revealed by a main effect of genotype (time F11, 
347 = 28.27, P < 0.001; genotype F2, 347 = 4.13, P < 0.05; interaction F22, 347 = 0.744, P > 0.05) 
(Fig. 1b). Post hoc analysis revealed that female GABAB(1b)-/- mice were more active over the 
hour than both WT and GABAB(1a)-/- female mice (P < 0.05, respectively). 
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Continuous 3-Day Locomotor Activity of GABAB(1a)-/- , GABAB(1b)-/- and WT Mice 
Male GABAB(1b)-/- mice travelled significantly greater distances that either WT of GABAB(1a)-
/- mice during the 1st h of habituation to a new enclosure, and during the following three dark 
phases, whereas GABAB(1a)-/- mice travelled similar distances to that of WT mice during the 
dark phases (genotype F2, 1607 = 2.62, P = 0.096; time F66, 1607 = 34.08, P < 0.001; interaction 
F132, 1607 = 1.75, P < 0.001) (Fig. 2, a and b). The hyperactivity of the GABAB(1b) mice was 
particularly prevalent during the first 2 h of the dark phase, as the distance travelled (averaged 
over the 3 dark phases and expressed as a proportion the WT mean) during this time was 
154% that of the WT controls (genotype: F2,23 = 6.697, P < 0.01) (Fig. 2c). This pattern of 
behavior was confirmed when assessing data as mean summed distance (within animal) in the 
dark, as GABAB(1b)-/- mice travelled a greater mean distance during the dark phase than either 
WT or GABAB(1a)-/- mice (P < 0.05, respectively; genotype F2, 23 = 3.81, P < 0.05) (Fig. 2d).  
In comparison, during the two complete light phases, the GABAB(1a)-/- mice travelled a greater 
mean distance per light phase than the WT mice (genotype F2, 23 = 4.15, P < 0.05) (Fig 2e). 
 
Influence of L-Baclofen on Rotarod Endurance and Body Temperature of GABAB(1a)-/-, 
GABAB(1b)-/- and WT Mice 
Temperature data from one female GABAB(1a)-/- mouse in the baclofen 12 mg/kg dataset was 
eliminated as a statistical outlier (the two pre-drug body temperature measurements on the day 
of the experiment were less than 35.0 ° C). Rotarod data from one male GABAB(1a)-/- mouse in 
the vehicle-treated dataset were eliminated due to repeated voluntary jumping from the 
rotarod. Data from one female GABAB(1a)-/- mouse at a time-point 4 hours after vehicle dosing 
were lost due to repeated voluntary jumping from the rotarod. 
Body temperature at times -1 and 0 h, as well as rotarod training performance and 
duration on the rotarod at time 0 h of the experiment, did not differ between the two 
experimental cohorts for either of the experiments involving male or female mice 
(temperature: males, cohort F1,175 = 1.399, P = 0.24; females, cohort F1,171 = 0.47, P = 0.50; all 
mice walked for 300 s on the rotarod at time point 0), therefore temperature and rotarod data 
for the two cohorts were pooled (within experiments). 
Mean body temperature before drug treatment was slightly, but significantly, lower in 
female GABAB(1a)-/- mice than either the WT (P < 0.05) or GABAB(1b)-/- mice (P < 0.05), 
although the GABAB(1a)-/- and WT mice were not different from each other [P > 0.05; 
genotype F2,171 = 3.37, P < 0.05; mean temperature ± S.E.M. (°C): WT, 35.87 ± 0.08; 
GABAB(1a)-/-, 35.60 ± 0.08; GABAB(1b)-/-, 35.85 ± 0.06].  
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Figure 2
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Fig. 2. GABAB(1b)-/- mice are hyperactive during the circadian dark phase. Distance travelled during 67 
hours of continuously monitored locomotor activity by male wild-type (WT) and GABAB(1a)-/- (1a-/-) mice 
(a.), and of the WT versus GABAB(1b)-/- (1b-/-) mice (b.). Mean (+ SEM) summed distance travelled by 
WT, 1a-/- and 1b-/- mice in the 2 h immediately after the start of the dark phase, averaged over the 
three dark phases and expressed as a proportion of the WT mean (c.). Mean (+ SEM) summed 
distance travelled per 12 h for male WT, 1a-/- and 1b-/- mice during the three complete dark phases (d.) 
and two complete light phases (e.). * P < 0.05, ** P < 0.01, *** P< 0.001 vs WT; # P < 0.05, ##P < 0.01 vs 
1a-/-. 
 
In contrast, in the experiment with male mice, GABAB(1b)-/- mice had a slightly higher 
mean basal body temperate that either the WT (P < 0.05) or GABAB(1a)-/- mice (P < 0.05), 
although the GABAB(1a)-/- and WT mice were not significantly different from each other [P > 
0.05; genotype F2,175 = 5.11, P < 0.01; mean temperature ± S.E.M. (°C): WT, 35.94 ± 0.10; 
GABAB(1a)-/-, 36.09 ± 0.11; GABAB(1b)-/-, 36.40 ± 0.10]. 
Baclofen produced profound, long lasting hypothermia in male WT mice (male WT: 
baclofen dose F2,149 = 13.74, P < 0.001; time F4,149 = 13.99, P < 0.001; interaction F8,149 = 
16.36, P < 0.001) (Fig. 3a). Baclofen at 12 mg/kg, but not 6 mg/kg, also induced hypothermia 
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in male GABAB(1b)-/- mice (male GABAB(1b)-/-: baclofen dose F2,149 = 5.95, P < 0.01 ; time 
F4,149 = 9.03, P < 0.001 ; interaction F8,149 = 2.95, P < 0.01) (Fig. 3c). In contrast, neither the 6 
nor 12 mg/kg doses of baclofen induced hypothermia in the male GABAB(1a)-/- mice, relative 
to vehicle-treated GABAB(1a)-/- males, at the three postdrug time points measured (male 
GABAB(1a)-/- : baclofen dose F2,139 = 2.78, P = 0.08; time F4,139 = 1.73, P = 0.149; interaction 
F8,139 = 0.61, P = 0.76) (Fig. 3b). When examining the total hypothermic response to baclofen 
over the duration of the experiment, both GABAB(1a)-/- and GABAB(1b)-/- male mice showed an 
attenuated summed ΔT in response to 12 mg/kg baclofen in comparison to the WT mice, 
although neither of the mutant mice strains differed from each other in this regard (males 
summed ΔT: genotype F2,87 = 3.26, P < 0.05; baclofen dose F2,87 = 10.64, P < 0.001, 
interaction F4,87 = 4.66, P < 0.01) (Fig. 3d). 
Baclofen also induced time-dependent hypothermia in female WT mice (female WTs: 
baclofen dose F2,129 = 52.85, P < 0.001; time F4,129 = 18.17, P < 0.001; interaction F8,129 = 
18.11, P < 0.001) (Fig. 3e). Baclofen at 12 mg/kg, but not 6 mg/kg, also induced hypothermia 
in both GABAB(1a)-/- and GABAB(1b)-/- female mice (female GABAB(1a)-/-: baclofen dose F2,154 
= 6.27, P < 0.01; time F4,154 = 4.04, P < 0.01; interaction F8,154 = 5.11, P < 0.001; female 
GABAB(1b)-/-: baclofen dose F2,149 = 4.58, P < 0.05; time F4,149 = 1.14, P = 0.34; interaction 
F8,149 = 3.77, P < 0.001) (Fig. 3, f and g). However, the degree of hypothermia was greatly 
attenuated in both mutant strains of mice in comparison to the WT mice. As for the 
experiment using the male mice, this attenuation was particularly apparent when examining 
the summed hypothermic responses to baclofen. The degree of summed hypothermia in 
response to 12 mg/kg of baclofen was greatly attenuated in both mutant strains of female mice 
in comparison to the WT mice, but did not differ significantly between the two mutant lines 
(females: genotype F2,86 = 26.09, P < 0.001; baclofen dose F2,86 = 50.78, P < 0.001; 
interaction F4,86 = 15.19, P < 0.01) (Fig. 3h). 
It is interesting to note that in the experiments with both male and female GABAB(1b)-/- 
mice, the lower dose of baclofen appeared to induce hyperthermia 1 hour after baclofen 
administration (Fig. 3, c and 3g). In the female mice, post hoc analysis within the 6 mg/kg 
group showed  significant increase in body temperature from the -1 to the 0 h time point (P < 
0.01), and a tendency to further increase from the 0 to the 1 h time point (P = 0.077). In male 
mice, post hoc analysis within the 6 mg/kg baclofen treatment, similar to the females, showed 
a significant increase in body temperature from the -1 to the 0 h time point (P < 0.05). 
However, mean body temperature at time points 0 and 1 h were not significantly different 
from each other (P = 0.144). 
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Fig. 3. Hypothermic responses to baclofen are attenuated in GABAB(1a)-/- and GABAB(1b)-/- mice. Mean 
(± SEM) body temperature of male (a - c.) and female (e - g.) wild-type (WT), GABAB(1a)-/- (1a-/-) and 
GABAB(1b)-/- (1b-/-) mice following vehicle or L-baclofen (6 and 12 mg/kg) administration. Data are also 
presented as mean (± SEM) summed area under the curve (ΔT, calculated within animal) for male (d.) 
and female (h.) WT, 1a-/- and 1b-/- mice. * P < 0.05, ** P < 0.01, *** P< 0.001 vs WT. 
 
During training for the rotarod experiment, the mean number of falls from the rotarod 
during training for male mice was not significantly affected by genotype (P > 0.05 for all the 
pairings; mean ± S.E.M.: WT, 0.73 ± 0.24; GABAB(1a)-/-, 0.43 ± 0.17; GABAB(1b)-/-, 0.67 ± 
0.19). In comparison, female GABAB(1a)-/- mice fell from the rotarod more often during 
training than either WT or GABAB(1b)-/- mice (P < 0.05, for each respective pairing; mean ± 
S.E.M.: WT, 0.15 ± 0.07; GABAB(1a)-/-, 0.94 ± 0.25; GABAB(1b)-/-, 0.13 ± 0.06). On the day of 
testing, however, all mice walked on the rotarod for the allocated 300 s on the first 
experimental time point (immediately prior to dosing), thus indicating they had learned the 
task adequately. 
Baclofen significantly impaired rotarod endurance in male WT mice in a time- and 
dose-dependant manner (male WT: baclofen dose F2, 119 = 6.99, P < 0.01; time F3, 119 = 17.06, 
P < 0.001; interaction F6, 119 = 7.64, P < 0.001) (Fig. 4a). Baclofen similarly reduced rotarod 
endurance in male GABAB(1a)-/- and GABAB(1b)-/- mice by 1 h after dosing, although the 
duration of impairment was shorter than that of the WT mice in both mutant strains of mice 
(GABAB(1a)-/-: baclofen dose F2, 111 = 2.44, P = 0.107; time F3, 111 = 9.63, P < 0.001; interaction 
F6, 111 = 3.72, P < 0.01; GABAB(1b)-/-: baclofen dose F2, 119 = 5.82, P < 0.01; time F3, 119 = 5.60, 
P < 0.01; interaction F6, 119 = 5.63, P < 0.001) (Fig. 4, b and c). Overall, when examining total 
Chapter 3  72 
_________________________________________________________________________________ 
summed endurance on the rotarod, male GABAB(1a)-/- and GABAB(1b)-/- mice performed 
similarly to WT at 0-, 6- and 12-mg/kg doses of baclofen (vehicle, H = 3.30, P = 0.19; 
baclofen 6 mg/kg, H = 4.51, P = 0.162; baclofen 12 mg/kg H = 1.20, P = 0.55) (Fig. 4d).  
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Fig. 4. Ataxic responses to baclofen are attenuated in GABAB(1a)-/- and GABAB(1b)-/- mice. Mean (± 
SEM) endurance on a fixed-speed rotarod (12 rpm, maximum allowed was 300 s per time point) for 
male (a - c.) and female (e - g.) wild-type (WT), GABAB(1a)-/- (1a-/-) and GABAB(1b)-/- (1b-/-) mice following 
vehicle or L-baclofen (6 and 12 mg/kg) administration. Data are also presented as a proportion of the 
total time available (1200 s) which was spent walking on the rotarod by male (d.) and female (h.) WT, 
1a-/- and 1b-/- mice. * P < 0.05, ** P < 0.01, *** P< 0.001 vs WT. 
 
Baclofen also impaired rotarod endurance in female WT mice in a dose and time 
dependent manner (female WT: baclofen dose F2, 103 = 26.96, P < 0.001; time F3, 103 = 17.34, 
P < 0.001; interaction F6, 103 = 15.51, P < 0.001) (Fig. 4e.). Baclofen likewise impaired rotarod 
endurance in female GABAB(1a)-/- and GABAB(1b)-/- mice at 1 h after dosing, although to a 
lesser duration and degree to that of WT in both mutant strains (GABAB(1a)-/-: baclofen dose 
F2, 122 = 8.66, P = 0.001; time F3, 122 = 4.55, P < 0.01; interaction F6, 122 = 5.82, P < 0.001; 
GABAB(1b)-/-: baclofen dose F2, 119 = 3.71, P < 0.05; time F3, 119 = 3.03, P < 0.05; interaction 
F6, 119 = 3.71, P < 0.01) (Fig. 4, f and g). When examining summed endurance, mice of the 
three genotypes treated with either vehicle or 6 mg/kg baclofen showed similar rotarod 
performances (vehicle, H = 4.10, P = 0.129; baclofen 6 mg/kg, H = 2.50, P = 0.81) (Fig. 4h). 
However, post hoc analyses for data at 12 mg/kg of baclofen demonstrated both GABAB(1a)-/- 
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and GABAB(1b)-/- mice had similarly attenuated ataxic responses in comparison with the WT 
mice (P < 0.05; baclofen 12 mg/kg, H = 12.26, P = 0.002) (Fig. 4h). 
 
Effect of GHB on Body Temperature of GABAB(1a)-/-, GABAB(1b)-/- and WT Mice 
All mice responded to GHB with hypothermia, relative to pre-drug application body 
temperature. However, the degree of hypothermia was influenced by genotype. Thirty 
minutes after GHB application, GABAB(1a)-/- mice had a significantly lower mean reduction in 
body temperature than that of the WT mice (P < 0.05) (Fig. 5). One hour after p.o. 
application, both GABAB(1a)-/- and GABAB(1b)-/- mice had attenuated hypothermic responses to 
the GHB compared with WT mice (P < 0.05 for GABAB(1a)-/- and GABAB(1b)-/- mice vs WT, 
respectively) (Fig. 5). Body temperature of the mice before drug administration was not 
influenced by genotype (P > 0.05). 
 
Effect of GHB on Locomotor Activity of GABAB(1a)-/-, GABAB(1b)-/- and WT Mice 
Interestingly, the genotype did not affect the distance travelled for vehicle-treated mice at any 
of the post-drug administration time intervals investigated (P > 0.05). In contrast, in the GHB-
treated mice, genotype influenced the median distance travelled in the 15 to 20 min (H = 6.02, 
P < 0.05), 20 to 25 min (H = 6.25, P < 0.05), 25 to 30 min (H = 9.01, P < 0.05), 30 to 35 min 
(H = 6.93, P < 0.05) and 40 to 45 min intervals (H = 6.61, P < 0.05). Post hoc comparison 
revealed that the GABAB(1b)-/- mice tended to be more active than WT mice during the 15 to 
20 min interval (P = 0.056). However, at the other time intervals, GABAB(1a)-/- mice travelled 
a greater distance than the WT mice (20 – 25 min, P < 0.05; 25 – 30 min, P < 0.01; 30 – 35 
minutes, P < 0.05; 40 – 45 min, P < 0.01) (Fig. 6). This indicated that both GABAB(1a)-/- and 
GABAB(1b)-/- mice were less sensitive to the locomotor suppressing effects of GHB. 
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Fig. 5. Hypothermic responses to GHB were attenuated in GABAB(1a)-/- and GABAB(1b)-/- mice. Mean (± 
SEM) body temperature of male wild-type (WT), GABAB(1a)-/- (1a-/-) and GABAB(1b)-/- (1b-/-) mice 
following administration of GHB (1 g/kg). * P < 0.05 1a-/- vs WT. # P < 0.05 1b-/- vs WT.  
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Fig. 6. Hypolocomotor effects of GHB are attenuated in GABAB(1) isoform-deficient mice. Mean (± 
SEM) distance travelled by female wild-type (WT), GABAB(1a)-/- (1a-/-) and GABAB(1b)-/- (1b-/-) mice 
following administration of vehicle or GHB (1 g/kg). Note: analysis performed with non-parametric 
testing. + P < 0.10 GHB-treated 1b-/- vs WT; * P < 0.05, GHB-treated 1a-/- vs WT. 
 
3.5 Discussion 
 
The Gabbr1 gene is predominantly transcribed into two differentially expressed isoforms, 
GABAB(1a) and GABAB(1b), which differ in sequence primarily by the inclusion of a pair of 
evolutionary-conserved sushi repeats (also known as short consensus repeats) in the 
GABAB(1a) N terminus (Bettler et al., 2004). The recent generation of GABAB(1a)-/- and 
GABAB(1b)-/- mice (Vigot et al., 2006) has opened up new possibilities for understanding the 
functions of these sushi domains. Here we show that GABAB(1a)-/- and GABAB(1b)-/- mice 
possessed normal overt behavioural responses as observed in the primary observation test, as 
well as in basic righting and motor function, as indicated by unimpaired baseline performance 
on the rotarod. In addition, unlike the full GABAB(1)-/- mice (Prosser et al., 2001; Schuler et 
al., 2001), basic observations of the mice suggested that neither GABAB(1a)-/- nor GABAB(1b)-/- 
mice had spontaneous seizures. However, the characteristic hypothermia and motor 
impairment in response to the GABAB receptor agonists L-baclofen or GHB were markedly 
attenuated, and interestingly, to a relatively similarly degree in both GABAB(1a)-/- and 
GABAB(1b)-/- mice compared to WT controls. Moreover, the two mutant lines of mice 
diverged significantly in their baseline behaviour. The GABAB(1b)-/- mice were hyperactive in 
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a novel environment and habituated more slowly than either the WT or GABAB(1a)-/- mice. 
Furthermore, GABAB(1b)-/- mice were more active throughout the dark phase than either the 
GABAB(1a)-/- or WT mice. Finally, the findings of the lack of overt phenotype in the POT, 
similar attenuation of baclofen-induced hypothermia and ataxia in both mutants, and 
hyperlocomotor responses to a novel environment by GABAB(1b)-/- mice were replicated in 
separate experiments with both male and female mice, attesting to the reproducibility of these 
phenotypes.  
GABAB receptors play a crucial role in mediating normal motor responses (Jacobson 
and Cryan, 2005). Further, deletion of the GABAB1 receptor subunit results in a complex 
locomotor response (Mombereau et al., 2004a; Vacher et al., 2006). This includes marked 
hyperlocomotion when exposed to a novel environment whereas in a familiar environment, 
GABAB(1)-/- mice display an altered pattern of circadian activity but no hyperlocomotion 
(Vacher et al., 2006). Therefore, the baseline motor hyperactivity of GABAB(1b)-/- mice in a 
novel environment was not entirely surprising. Although the effect of GABAB(1b) isoform 
deletion on locomotor activity seemed somewhat modest, the magnitude of the effect is more 
apparent when examined as a relative proportion of the WT controls. For example, male 
GABAB(1b)-/- mice travelled approximately 140% of the distance of WT controls in the first 
five minutes of exposure to a novel environment, and 154% of that of wild type mice in the 
first 2 h of the dark cycle. Furthermore, hyperlocomotor responses were demonstrated on four 
occasions with three different cohorts of mice: novelty-induced hyperlocomotion was 
replicated in a separate cohort of female mice; in another cohort of male mice in the 3 day 
locomotor experiment during the 1st h in a new home cage; and hyperlocomotion of 
GABAB(1b)-/- in the dark phase was subsequently demonstrated during the following three dark 
cycles. Together these data suggest that the loss of the GABAB(1b) isoform may contribute to a 
significant degree to the aforementioned hyperlocomotion of GABAB(1)-/- mice. 
Although the locomotor behaviour of GABAB(1a)-/- mice was similar to WT controls in 
the present investigation, in other test systems differences to WT and GABAB(1b)-/- mice have 
been  identified. We have previously shown that GABAB(1a)-/- mice were impaired in an object 
recognition task (Vigot et al., 2006), whereas the GABAB(1b)-/- mice were not. Furthermore, 
GABAB(1a)-/- mice had deficits in the acquisition of conditioned taste aversion (Jacobson et al., 
2006b) and in the generalisation of fear conditioning-induced freezing (Shaban et al., 2006). 
Correspondingly, the GABAB(1a)-/-, but not the GABAB(1b)-/-, mice were also deficient in 
hippocampal (Vigot et al., 2006) and amygdala long-term potentiation (Shaban et al., 2006). 
In addition, Perez-Garci et al., (2006) have also shown specific and differential roles for the 
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GABAB(1a) and GABAB(1b) isoforms in mediating different components of GABAB receptor-
induced inhibition of layer 5 cortical neurons. Together with the hyperactive phenotype in 
locomotor activity of the GABAB(1b)-/- mice shown in the present study, these data show that 
GABAB(1) receptor isoforms have divergent and functionally relevant influences on 
behavioural output and the underlying neurophysiology. 
 Given the phenotypic differences between these two isoform-deficient lines of mice, 
it was interesting to note that although both GABAB(1a)-/- and GABAB(1b)-/- mice both showed 
attenuated responses to the GABAB receptor agonists baclofen, the degree of attenuation was 
largely similar in both mutant strains of mice. In GABAB(1)-/- mice, baclofen does not induce 
the hypothermic or ataxic effects normally seen in WT mice (Schuler et al., 2001; Queva et 
al., 2003). This indicated that the full GABAB receptor heterodimer is necessary for the 
actions of these agonists and, likewise, that the actions of these agonists are specific to the 
GABAB receptor. Results of the present study, however, suggest that neither the GABAB(1a) 
nor GABAB(1b) isoforms are solely responsible for the hypothermic or ataxic actions of  
baclofen. The data also show that neither isoform can fully compensate for the loss of the 
other with regard to agonist-induced responses. To further confirm this we investigated the 
effects of another GABAB receptor agonist, GHB.  We have previously shown that the 
hypothermic and motor-impairing effects of GHB (1g/kg) are completely absent in mice 
lacking the GABAB(1) receptor (Kaupmann et al., 2003).  Here we show that the effects of 
GHB were modestly but significantly attenuated in mice lacking either of the two GABAB(1) 
isoforms.  Thus, we can conclude, as in the case of baclofen, that neither the GABAB(1a) nor 
GABAB(1b) isoforms are solely responsible for the hypothermic or ataxic actions of GHB.  
These in vivo data are in support of a number of recombinant studies demonstrating that 
neither baclofen nor GHB appear to show specificity for either one of the two predominant 
GABAB(1) subunit isoforms (see Bettler et al., 2004).  
Paradoxically, at the lower dose of 6 mg/kg, baclofen seemed to increase body 
temperature in GABAB(1b)-/- mice. Examination of post-hoc statistical comparisons indicated  
that the bulk of the temperature increase of mice in this treatment group occurred between 
time -1 and 0 hours, both of which preceded baclofen injection. Therefore, it seems likely that 
handling stress may have induced the apparent hypothermic responses in these mice. 
However, it should be noted that the GABAB agonist GHB at low doses has been previously 
reported to induced hyperthermia as opposed to hypothermia (Kaufman et al., 1990). 
Therefore, it remains possible that some influence of residual GABAB(1) activity in the 
GABAB(1b)-/- mice may have contributed to a hyperthermic response to baclofen in these mice.  
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Control of body temperature and motor activity is anatomically and neurochemically 
heterogeneous (Cryan et al., 1999; Cryan et al., 2000; Jacobson and Cryan, 2005). Both 
GABAB(1a) and GABAB(1b) isoforms are abundantly expressed throughout the brain, although 
their expression level relative to each other and distribution profile within structures diverges 
in many regions, including in many of those involved in the control of body temperature or 
motor activity and coordination (Benke et al., 1999; Bischoff et al., 1999; Liang et al., 2000; 
Fritschy et al., 2004). Therefore, it may seem reasonable to have expected that, irrespective of 
a lack of specificity of the isoforms for baclofen or GHB, responses to the agonists may yet 
have varied between the two mutant mouse lines. In the present study, however, this was not 
the case. Previously we have demonstrated that genetic background (in the form of different 
mouse strains) can greatly influence hypothermic and ataxic responses to baclofen (Jacobson 
and Cryan, 2005). The present study may indicate that this is not necessarily because of 
overall variations in the relative expression of the GABAB(1) subunit isoforms. Indeed, given 
that baseline body temperatures of the GABAB(1a)-/- and GABAB(1b)-/- mice showed negligible 
differences, it may be that normal homeostasis of body temperature is not specifically 
controlled by one or other of the GABAB(1) subunit isoforms either. This is in contrast to the 
full GABAB(1)-/- mice, where basal body temperature was shown to be approximately 1°C less 
than that of the WT controls (Kaupmann et al., 2003; Queva et al., 2003).  
The lack of differential responses to baclofen and GHB between the GABAB(1) 
isoform-deficient mice may also be in part the result of the complex neural control of body 
temperature and motor activity. For example, when strongly activated by pharmacological 
means, loss of either presynaptic or postsynaptic inhibition in a complex multisynaptic system 
may ultimately appear similar downstream (i.e., appearing as an increase in excitability in a 
convergent output). With regard to the contribution of different cellular components in these 
systems, the prospective roles of interneurons in GABAB receptor agonist-induced 
hypothermia and ataxia are unknown at the present time. Hippocampal and lateral amygdala 
autoreceptor function was preserved in both GABAB(1a)-/- and GABAB(1b)-/- mice (Shaban et 
al., 2006; Vigot et al., 2006), but was completely absent in the GABAB(1)-/- mice (Prosser et 
al., 2001; Schuler et al., 2001). This indicated that in these structures, both isoforms can act as 
autoreceptors. However, GABAergic interneurons synapsing on distal dendrites of layer 5 
cortical neurons appeared to preferentially express the GABAB(1a) isoform, but not the 
GABAB(1b) isoform (Perez-Garci et al., 2006). This shows that different interneuron 
populations may variably express the two GABAB(1) subunit isoforms. Clearly, further studies 
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are needed to evaluate the expression profile and roles of GABAB(1) isoforms autoreceptors in 
GABAB receptor-mediated hypothermia and ataxia. 
In conclusion, GABAB(1a) and GABAB(1b) isoforms are functionally relevant molecular 
variants of the GABAB(1) receptor subunit, which are differentially involved in specific 
neurophysiological processes and behaviors. It is evident from the present study, however, 
that the GABAB receptors agonists baclofen and GHB were unable to pharmacologically 
discriminate these differences, at least with regard to body temperature and motor 
coordination. As the sequence of the GABAB(1a) and GABAB(1b) isoforms differ primarily in 
the N-terminus, and not in the region coding the ligand binding domain (Kaupmann et al., 
1997; Bettler et al., 2004), future studies should focus on strategies to uncover novel 
interaction sites at either receptor isoforms in order to enable specific pharmaceutical 
intervention. 
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4.1 Abstract 
 
Conditioned taste aversion (CTA), is a form of aversive memory where an association is made 
between a consumed substance and a subsequent malaise. CTA is a critical mechanism for the 
successful survival, and hence evolution, of most animal species. The role of excitatory 
neurotransmitters in the neurochemical mechanisms of CTA is well recognized, however, less 
is known about the involvement of inhibitory receptor systems. In particular the potential 
functions of metabotropic GABAB receptors in CTA have not yet been fully explored. 
GABAB receptors are metabotropic GABA receptors that are comprised of two subunits, 
GABAB(1) and GABAB(2), which form heterodimers. The Gabbr1 gene is transcribed into two 
predominate isoforms, GABAB(1a) and GABAB(1b) which differ in sequence primarily by the 
inclusion of a pair of sushi domains (or short consensus repeats) in the GABAB(1a) N-terminus. 
The behavioural function of mammalian GABAB1 receptor isoforms is currently unknown. 
Here, using a point mutation strategy in mice we demonstrate that these two GABAB(1) 
receptor isoforms are differentially involved in critical components of CTA. In contrast to 
GABAB(1b)-/- and wild-type mice, GABAB(1a)-/- mice failed to acquire CTA. On the other hand, 
GABAB(1b)-/- mice, robustly acquired CTA but failed to show any extinction of this aversion. 
The data demonstrate that GABAB receptors are involved in both the acquisition and 
extinction of CTA; however, receptors containing the GABAB(1a) or the GABAB(1b) isoform 
differentially contribute to the mechanisms used to learn and remember the salience of 
aversive stimuli. 
 
4.2 Introduction  
 
Conditioned taste aversion (CTA) is an associative learning phenomenon whereby the 
characteristics of a consumed substance are paired with the memory of a subsequent malaise 
(Bermudez-Rattoni, 2004). CTAs are long-lasting and specific memories which can be 
induced with a single pairing of the conditioned stimulus (CS, being the consumed substance) 
and the unconditioned stimulus (US, the malaise). As such, CTA is a critical mechanism for 
the successful survival, and hence evolution, of most animal species (Bures, 1998a). 
Moreover, because CTA declines reliably with repeated non-reinforced exposure to the CS, 
the use of CTA in the laboratory allows the investigation of the processes involved in both  
the acquisition and extinction of aversive memories (Bahar et al., 2003; Bermudez-Rattoni, 
2004).  
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The importance of excitatory neurotransmitters in the acquisition and extinction of 
CTA is well known (Berman and Dudai, 2001; Bermudez-Rattoni, 2004). In contrast, there is 
a paucity of studies investigating the role of inhibitory neurotransmitters in CTA. Some 
studies have demonstrated that ionotropic GABAA-modulating drugs such as benzodiazepines 
alter the acquisition and certain aspects of extinction of CTA (Roache and Zabik, 1986; 
Delamater and Treit, 1988; Yasoshima and Yamamoto, 2005) whereas the role of GABAB 
receptors is largely uninvestigated. 
GABAB receptors are comprised of two subunits, GABAB(1) and GABAB(2), which 
form heterodimers. The Gabbr1 gene is predominantly transcribed into two differentially 
expressed isoforms, GABAB(1a) and GABAB(1b), which differ in sequence primarily by the 
inclusion of a pair of evolutionary conserved sushi repeats (a.k.a. short consensus repeats) in 
the GABAB(1a) N-terminus (Bettler et al., 2004). The function of the sushi repeats, and hence 
of the different receptor isoforms, has been a mystery until recently. Vigot et al. (2006) 
demonstrated that the sushi repeats define the morphological localization of GABAB 
receptors: the GABAB(1a) isoform was mainly a presynaptic heteroreceptor at glutamatergic 
terminals, whereas the GABAB(1b) isoform was predominantly located postsynaptically. Given 
the importance of GABAergic mechanisms in emotional learning (Akirav, 2006; Davis et al., 
2006) we used GABAB(1a)-/- and GABAB(1b)-/- mice to address the hypothesis that GABAB 
receptor isoforms could play distinctive roles in the acquisition and extinction of aversive 
memories. 
 
4.3 Materials and Methods  
 
Establishment of a Conditioned Taste Aversion Protocol in BALB/c Mice 
Because there are marked strain differences in emotional behaviour in mice (Cryan and 
Holmes, 2005), it was important first to establish an appropriate CTA protocol in the 
background strain of our genetically modified mice. A two-bottle choice CTA protocol was 
validated using singly-housed male mice [BALB/cByJIco (Charles River Laboratories, 
L’Abresele Cedex, France; ~12 weeks of age, n=30]. Mice were trained to drink water from a 
15 ml plastic drinking tube in two 30 - minute sessions (morning and afternoon) per day for 5 
d. Mice were then presented with a saccharin solution (0.5% in tap water) in their drinking 
tube. Thirty minutes after the end of the 30 minute saccharin - drinking period, they were 
injected (i.p., 10 ml/kg) with either vehicle (saline, unconditioned mice) or the malaise-
inducing agent lithium chloride (LiCl; Sigma-Aldrich Chemie, Steinheim, Germany) at a dose 
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of either 3 or 6 mEq/kg (0.3 or 0.6 M LiCl) (conditioned mice). Over the following 7 days, 
mice were presented with both water and the saccharin solution in the morning drinking 
sessions. Drinking tubes containing the saccharin solution were always presented in the same 
spatial order relative to the water tube (e.g. always on the right). Afternoon drinking sessions 
remained water-only throughout the experiment.  
 
Conditioned Taste Aversion in Wild-Type, GABAB(1a)-/- and GABAB(1b)-/- Mice 
The generation of GABAB(1a)-/- and GABAB(1b)-/- has been described previously (Vigot et al., 
2006). Briefly, a knock-in point mutation strategy was adopted, whereby GABAB(1a) and 
GABAB(1b) initiation codons were converted to stop codons by targeted insertion of a floxed 
neo-cassette. Gene targeting constructs and embryonic stem cells were of BALB/c origin. 
Embryonic stem cells were injected into C57BL/6 blastocysts and chimerics crossed with 
BALB/c mice to generate heterozygotic founding mice. The neo-cassette was excised by 
crossing to BALB/c mice expressing Cre recombinase and breeding to homozygosity. 
Consequently, all mutant and wild-type mice were maintained on a pure inbred BALB/c 
genetic background. GABAB(1a)-/- and GABAB(1b)-/- mice used for the evaluation of CTA were 
derived from subsequent homozygous breeding (F5-6) of siblings originating from the 
founding heterozygotic mice. Homozygous wild-type controls for the GABAB(1) isoform 
mutant mice were derived from mating together wild-type siblings generated from 
GABAB(1a)+/- and GABAB(1b)+/- heterozygous breedings (F5-6). The breeding strategy was 
applied in accordance with the recommendations proposed by The Jackson Laboratory (Bar 
Harbor, ME) to obviate genetic drift and the formation of substrains 
((http://jaxmice.jax.org/geneticquality/guidelines.html). 
A similar protocol to that validated in-house (see above) was used to evaluate CTA in 
singly housed male wild-type (n = 19, 29.3 ± 0.6 weeks of age), GABAB(1a)-/- (n = 15, 26.8 ± 
0.6 weeks of age) and GABAB(1b)-/- (n = 18, 26.4 ± 0.6 weeks of age) (Fig. 1). Mice from each 
genotype were allocated to either an unconditioned (saline injection after saccharin 
presentation) or conditioned (6 mEq / kg LiCl after saccharin presentation) treatment. The 
dose of lithium was selected based on the validation experiment. Furthermore, mice were 
subjectively scored in a blind fashion for the presence or absence of malaise behaviour after 
LiCl or saline injections (Hayley et al., 1999; Anisman et al., 2001). Malaise was defined as 
prolonged periods of non-sleeping immobility, piloerection, contraction of the flanks, 
prostrate elongated body posture and/or excessive defecation or diarrhoea. Mice displaying 
malaise behaviour were given a score of 1. Animals not showing malaise behaviour were 
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given a score of 0. Sleeping animals were not scored. For 2 weeks after conditioning, mice 
experienced a once – daily preference test in which they were presented with both saccharin 
and water for 30 minutes. In the afternoons they were given water only for 30 minutes. They 
were then returned to an ad libitum water regime for a further week. Thereafter, animals were 
water-deprived overnight and again presented with the choice of  saccharin or water in the 
morning. This allowed us to assess whether the aversion was altered over 1 week in the 
absence of saccharin exposure. Animals were then returned to an ad libitum water regime for 
an additional week. Thereafter, animals were water deprived overnight and again presented 
with the choice of saccharin or water in the morning with the difference that the spatial order 
of tube presentation was reversed, which allowed us to determine whether or not 
perseverative behaviour was contributing to the choice of drinking fluid. The following day, 
the saccharin or water option was presented again, but in their usual order. 
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Fig. 1. Schematic of a CTA protocol used in GABAB(1) isoform mutant and wild-type mice. 
 
Calculations and Statistical Analyses. 
All drinking tubes were weighed before and after presentation to the mice to obtain the weight 
of fluid consumed. An aversion index (AI) for the saccharin solution was calculated as 
follows: AI (%) = [water intake (g) / [saccharin intake (g) + water intake (g)]] x 100. Data 
were analysed with one-way, two-way or two-way repeated measure ANOVA, followed by 
Fisher’s LSD post hoc comparisons, where appropriate.  
 
4.4 Results 
 
Conditioned Taste Aversion in BALB/c Mice 
BALB/c mice acquired a robust aversion to both 3 and 6 mEq/kg doses of LiCl in comparison 
to the unconditioned (saline-treated) animals (Fig. 2A. LiCl dose F2,29 = 9.87, P < 0.001). 
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Mice treated with LiCl at 3 mEq/kg had extinguished the aversion by 5 d, whereas the mice 
treated with LiCl at 6 mEq/kg took 7 d to extinguish (Fig. 3A, P > 0.05, respectively). 
Therefore, this protocol was chosen as appropriate for detecting alterations in CTA 
acquisition or extinction in genetically modified mice bred on a BALB/c genetic background.  
 
Conditioned Taste Aversion in GABAB(1a)-/-, GABAB(1b)-/- and Wild-Type Mice 
Mice of all three genotypes readily consumed the saccharin solution on the day of 
conditioning (mean ± sem saccharin solution intake: WT, 1.91 ± 0.08 ml; GABAB(1a)-/-, 2.12 ± 
0.13 ml; GABAB(1b)-/-, 1.95 ± 0.09 ml. Genotype; F2,51 = 11.11, P = 0.34).  
GABAB(1a)-/- that received LiCl after saccharin exposure (conditioned) failed to 
acquire an aversion to the saccharin solution, relative to conditioned wildtype and GABAB(1b)-
/- mice (P < 0.01), and showed a preference for the saccharin solution to a level not different 
from that of unconditioned GABAB(1a)-/- , GABAB(1b)-/- or wild-type mice. In comparison, both 
conditioned wild-type and GABAB(1b)-/-  mice developed similar, robust  levels of aversion to 
the saccharin solution, relative to unconditioned controls (P < 0.001), (Fig. 2B. LiCl F1,51 = 
39.77, P < 0.001; genotype F2,51 = 6.57, P < 0.01; interaction F2,51 = 4.60, P < 0.05). The 
failure of the conditioned GABAB(1a)-/- mice to acquire an aversion to the saccharin solution 
was not attributable to insensitivity to LiCl-induced malaise, as indicated by the 
demonstration of malaise behaviour in 100% of the GABAB(1a)-/- mice 1 hour after LiCl 
injections (Table 1). 
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Fig. 2. Acquisition of CTA. A. BALB/c mice acquire CTA to a saccharin solution when paired with 
malaise induced by LiCl at 3 and 6 mEq/kg (***P < 0.001 vs saline). B. The GABAB(1a) receptor isoform 
is essential for acquisition of a CTA (WT, wild-type; 1a-/-, GABAB(1a)-/-; 1b-/-, GABAB(1b)-/;**P < 0.01 vs 
conditioned wild-type; ###P < 0.001 vs unconditioned within genotype).  
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Table 1. LiCl (6 mEq/kg, i.p.) induced malaise to an equivalent degree in wildtype, GABAB(1a)-/- and 
GABAB(1b)-/- mice.  
 Wildtype GABAB(1a)-/- GABAB(1b)-/-
Treatment Saline 
(9) 
LiCl 
(10) 
Saline LiCl Saline LiCl 
(N) (7) (8) (9) (9) 
Time (h) 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
% sick 0 
 
0 
 
0 
 
90 
(9) 
90 
(9) 
67
(6)
0 0 
 
0 
 
100 
(8) 
83 
(6)
57
(4)
11 
(1)
0 
 
0 
 
89 
(8) 
78 
(7)
100 
(# sick)  (7) 
% sleep 11 
(1) 
87 
(8) 
44
(4)
0 
 
0 
 
10
(1)
0 29 
(2)
71
(5)
0 25 
(2)
13
(1)
0 
 
44 
(4) 
38 
(3) 
0 
 
0 
 
22 
(# sleep)   
 
(2) 
Only mice that were awake were scored for the presence or absence of malaise (% sick ). 
 
In striking contrast, although GABAB(1b)-/- mice readily acquired the aversion, they 
failed to show any reduction of this aversion over the following 30 days of the experiment, 
relative to both unconditioned GABAB(1b)-/- mice and to conditioned wild-type and GABAB(1a)-
/- mice (Fig. 3B. Conditioning within GABAB(1b): LiCl F1,323 = 27.39, P < 0.001; time F17,323 = 
2.71, P < 0.001; interaction F17,323 = 0.72, P = 0.78. Genotype within conditioned treatment: 
genotype F2,480 = 7.32, P < 0.01; time F17,480 = 5.06, P < 0.001; interaction F34,480 = 1.90, P < 
0.01). 
Post hoc comparisons revealed significant differences between the conditioned 
GABAB(1b)-/-  and conditioned wild-type mice from day 5 onward (Fig. 3B). This was because 
of extinction in the conditioned wild-type mice, which reached a low level of aversion not 
different to that of unconditioned wild-type mice by day 5 after conditioning (Fig.3B. 
Conditioning within wild-type: LiCl F1,326 = 8.22, P = 0.01; day F17,326 = 5.2, P < 0.001; 
interaction F17,326 = 2.85, P < 0.001). The reversal of drinking tube presentation on day 29 
demonstrated that the GABAB(1b)-/-  mice were not simply drinking from the same tube 
position each day, but were actively avoiding the saccharin solution.  
In the unconditioned mice, there was no effect of genotype on the AI although the 
overall AI decreased over the duration of the experiment until the perseveration test on day 
29, when it was transiently elevated (Fig. 3B .Genotype within unconditioned: F2,434 = 1.49, P 
= 0.25; day F17,434 = 5.04, P < 0.001; interaction F34,434 = 1.08, P = 0.36). 
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Fig. 3. Extinction of CTA. A. Time to extinguish a CTA in BALB/c mice was determined by dose of 
the malaise-inducing agent, LiCl ( P < 0.001, P< 0.01, P < 0.05 vs saline, within day). B. 
Conditioned Deletion of the GABA  receptor isoform profoundly impairs extinction of CTA ( P < 
0.001, P < 0.01, P < 0.05, P < 0.10 vs wildtype). Unconditioned GABA  isoforms do not influence 
the development of preference for a saccharin solution in unconditioned mice
*** ** *
B(1b)
***
** * +
B(1)
. 
 
4.5 Discussion 
 
Our data demonstrate a critical role for GABAB receptors in CTA. Specifically, the two 
GABAB(1) subunit isoforms are differentially involved in the acquisition and extinction of 
CTA. Acquisition of CTA requires the GABAB(1a) isoform, whereas extinction requires the 
GABAB(1b) receptor isoform. 
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It has recently been shown that the presence of specific sushi domains directs 
GABAB(1a) isoforms to a presynaptic localisation and that this localisation is critical for 
cognitive performance as assessed using an object recognition task (Vigot et al., 2006). 
Further, GABAB(1a)-/- mice have impaired hippocampal LTP and lack presynaptic GABAB-
ergic inhibition of glutamatergic excitability (Vigot et al., 2006). Given that glutamate 
signalling is essential for the acquisition of CTA (Yasoshima et al., 2000; Bermudez-Rattoni, 
2004; Akirav, 2006), it therefore seems plausible that GABAB(1a) isoform modulation of 
presynaptic glutamate release may underlie the mechanisms CTA acquisition. The brain 
regions involved in such modulation are unknown presently, because the GABAB(1a) receptor 
isoform is widely expressed throughout the brain (Benke et al., 1999; Bischoff et al., 1999; 
Fritschy et al., 1999).  However, lesion or inactivation of the pontine parabrachial nucleus, 
amygdala or insular cortex disrupts the acquisition of CTA (Bermudez-Rattoni and 
Yamamoto, 1998; Bures, 1998b; Bermudez-Rattoni, 2004) which points to GABAB(1a) 
receptors in these structures as being crucial for CTA acquisition.  
Given the differential localization of GABAB(1) isoforms (Perez-Garci et al., 2006; 
Vigot et al., 2006) the very dissimilar phenotype of GABAB(1b)-/- compared to GABAB(1a)-/- 
mice was not entirely unexpected.  Indeed, unlike GABAB(1a)-/- mice, GABAB(1b)-/- mice 
readily acquired CTA but failed to extinguish the aversion despite repeated unreinforced 
exposures to the CS. Similar to the acquisition of associative learning, its extinction is also 
believed to be a learning process that results from the formation of new memories as opposed 
to simple forgetting (Myers and Davis, 2002; Davis et al., 2006). It has been suggested that 
the study of CTA may have  direct implications for the study of anxiety disorders associated 
with altered emotional learning (Bahar et al., 2003; Bermudez-Rattoni, 2004; Guitton and 
Dudai, 2004; Cryan and Holmes, 2005). Therefore, the understanding of the molecular 
mechanisms that underlie the extinction of established aversive memories would be a 
considerable breakthrough in the treatment and management of anxiety disorders (Ressler et 
al., 2004; Barad, 2005; Davis et al., 2006).  
Until recently, no unique pharmacological or functional properties could be assigned 
to GABAB(1a) or GABAB(1b) (Perez-Garci et al., 2006; Vigot et al., 2006). However, it has 
been proposed that there exists auxiliary proteins that modify receptor activity, pharmacology, 
and localization (Marshall et al., 1999).  Our data clearly show differential functions of 
GABAB(1) receptor isoforms in the acquisition (GABAB(1a)) and extinction (GABAB(1b)) of 
CTA. Thus future studies must focus on uncovering potential novel protein interacting sites at 
either receptor isoforms to enable pharmaceutical intervention. Together, our data 
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demonstrate that isoforms of the GABAB(1) receptor, which differ only in the presence or 
absence of a  pair of sushi repeats at their N-terminal ectodomain, play differential, yet critical 
roles in the evolutionary conserved mechanisms used to learn and remember the salience of 
aversive stimuli.  
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5.1 Abstract 
 
Rationale: Emerging data support a role for GABAB receptors in anxiety. GABAB receptors 
are comprised of a heterodimeric complex of GABAB1 and GABAB2 receptor subunits. The 
predominant neuronal GABAB1 receptor isoforms are GABAB(1a) and GABAB(1b). Recent 
findings indicate specific roles for these isoforms in conditioned fear responses, although their 
influence on behaviour in tests of unconditioned anxiety is unknown. Objective: To examine 
the role of the GABAB(1) isoforms in unconditioned anxiety. Methods: Mice deficient in the 
GABAB(1a) or GABAB(1b) receptor isoforms were examined in a battery of anxiety tests. 
Results: In most tests, genotype did not significantly affect anxious behaviour, including the 
elevated plus maze, marble burying, or stress-induced hyperthermia tests. Corticosterone and  
ACTH levels were similarly unaffected by genotype. Female, but not male, GABAB(1a)-/- and 
GABAB(1b)-/- mice showed increased anxiety relative to wild-type controls in the elevated zero 
maze. In the staircase test, male GABAB(1b)-/- mice defecated more than male GABAB(1a)-/- 
mice, although no other test parameter was influenced by genotype. In the light-dark box, 
female GABAB(1a)-/- mice spent less time in the light compartment compared to the 
GABAB(1b)-/- females whereas male GABAB(1b)-/- mice made fewer light-dark transitions than 
GABAB(1a)-/- males. Conclusions: Specific roles for either GABAB(1) isoform in unconditioned 
anxiety were not explicit. This differs from their contribution in conditioned anxiety, and from 
the anxious phenotype of GABAB1 and GABAB2 subunit knockout mice. The findings suggest 
that the GABAB(1) isoforms have specific relevance for anxiety with a cognitive component, 
rather than for innate anxiety per se. 
 
5.2 Introduction 
 
G-protein coupled γ –aminobutyric acid (GABA) receptors, GABAB receptors, are 
heterodimers comprised of GABAB(1) and GABAB(2) subunits. They are expressed both as 
presynaptic heteroreceptors and also postsynaptically, where they respectively modulate 
neuronal excitability. Heteroreceptors modulate the release of (excitatory) neurotransmitters, 
mainly via actions on presynaptic Ca+2 channels, and postsynaptic GABAB receptors activate 
slow inhibitory postsynaptic potentials via activation of inwardly-rectifying K+ channels. 
GABAB receptors also function as autoreceptors on interneurons. Additionally, GABAB 
receptors are negatively coupled to adenylyl cyclase, through which they influence 
downstream molecular pathways (Bettler et al. 2004; Couve et al. 2000). 
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There is a growing body of evidence indicating that GABAB receptors play a critical 
role in anxiety (Cryan and Kaupmann 2005; Pilc and Nowak 2005). The classic GABAB 
receptor agonist, baclofen, has shown anxiolytic activity in some clinical settings. Baclofen 
reduced anxiety in post-traumatic stress disorder (PTSD) patients (Drake et al. 2003), in 
alcoholics following alcohol withdrawal (Addolorato et al. 2002a; Addolorato et al. 2006; 
Ameisen 2005; Flannery et al. 2004), in panic disorder (Breslow et al. 1989) and in patients 
suffering from acute spinal trauma (Hinderer 1990). Baclofen has also demonstrated 
anxiolytic effects in several preclinical studies including ultrasonic vocalisation in rat pups 
(Nastiti et al. 1991), increased punished drinking (Shephard et al. 1992), elevated plus maze 
(Andrews and File 1993) (but see (Dalvi and Rodgers 1996)) and in the social interaction and 
elevated plus maze tests following withdrawal of dependent rats from either diazepam or 
alcohol (File et al. 1991a; File et al. 1991b; File et al. 1992). GABAB receptor positive 
modulators such as GS39783 also demonstrate an anxiolytic profile in both rats and mice in a 
wide range of tests (Cryan et al. 2004).  
Perhaps the strongest preclinical evidence to date for a role of GABAB receptors in 
anxiety was demonstrated by the phenotype of GABAB receptor-deficient mice. Deletion of 
either the GABAB(1) or GABAB(2) receptor subunits results in a complete loss of typical 
GABAB functions and induces a highly anxious phenotype in mice in exploratory-based tests 
of anxiety (Mombereau et al. 2004a; Mombereau et al. 2004b). For example, GABAB(1)-/- 
mice show profound anxiety relative to wild-type controls in the light-dark box and staircase 
tests (Mombereau et al. 2004a; Mombereau et al. 2004b). Similarly, GABAB(2)-/- mice are also 
anxious in the light dark box (Mombereau et al. 2005).  
The GABAB(1) subunit is predominantly expressed as one of two isoforms: GABAB(1a) 
or GABAB(1b), both of which are transcribed from different promoters of the GABAB(1) gene 
(Steiger et al. 2004) and heterodimerize with the GABAB(2) subunit to form functional 
receptors (Bettler et al. 2004). The primary sequence of the GABAB(1a) isoform differs from 
that of the GABAB(1b) isoform by the inclusion of short-consensus repeats (or “sushi 
domains”) at the N-terminus (Blein et al. 2004). Currently there are no pharmacological tools 
available to dissect the physiological roles of these isoforms. Recently, however, the 
generation of mice deficient in either the GABAB(1a) or GABAB(1b) isoforms has facilitated the 
demonstration of specific and differential roles for the GABAB(1) isoforms. The two isoforms 
localise differentially: the GABAB(1a) isoform was predominantly expressed as a presynaptic 
heteroreceptor in the hippocampus (Vigot et al. 2006) and lateral amygdala (Shaban et al. 
2006). In contrast the GABAB(1b) isoform was predominantly located postsynaptically in these 
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structures (Shaban et al. 2006; Vigot et al. 2006). Both the GABAB(1a) and GABAB(1b) 
isoforms also fulfilled autoreceptor functions in the hippocampus and amygdala (Vigot et al. 
2006)), although in the apical dendrites of layer 5 cortical neurons, the GABAB(1a) isoform 
was shown to be the predominant autoreceptor (Perez-Garci et al. 2006). The GABAB(1) 
isoforms also have differential impacts on neurophysiological processes, such as LTP in the 
hippocampus (Vigot et al. 2006) and amygdala (Shaban et al. 2006). Finally, deletion of either 
isoform demonstrates a divergence of behavioural phenotypes in conditioned aversive 
learning and memory paradigms (Jacobson et al. 2006b; Shaban et al. 2006; Vigot et al. 
2006). Specifically, in a conditioned fear paradigm GABAB(1a)-/- mice showed generalized 
freezing to both paired and unpaired tones (Shaban et al. 2006). In a conditioned taste 
aversion paradigm (CTA), GABAB(1a)-/- mice failed to acquire an aversion to a saccharin 
solution when paired with a lithium chloride-induced malaise, while GABAB(1b)-/- mice 
acquired CTA, but demonstrated a profound failure in the extinction of this aversion 
(Jacobson et al. 2006b).  
It is therefore well-established that GABAB receptors play a role in anxiety, and that 
the GABAB(1) subunit isoforms are functionally relevant molecular variants of the GABAB 
receptor which convey differential behavioural responses in tests of aversive learning and 
memory. However, the influence of the two GABAB(1) isoforms on behaviour in tests of 
unconditioned anxiety is currently unknown. The aim of the present study therefore, was to 
determine the influence of the different GABAB(1) subunit isoforms on innate anxiety-related 
behaviours, using mice deficient in either the GABAB(1a) or GABAB(1b) isoforms.  
 
5.3 Materials and Methods 
 
Animals 
The generation of wild-type, GABAB(1a)-/- and GABAB(1b)-/- mice as used in the present studies 
has been described previously (Vigot et al. 2006) . Briefly, a knock-in point mutation strategy 
was adopted, whereby GABAB(1a) and GABAB(1b) initiation codons were converted to stop 
codons by targeted insertion of a floxed neo-cassette. All mutant and wild-type mice were 
maintained on a pure inbred BALB/c genetic background. GABAB(1a)-/- and GABAB(1b)-/- mice 
used in the present experiments were derived from homozygous breeding of siblings 
originating from the founding heterozygotic mice (F3-4). Homozygous wild-type controls for 
the GABAB(1) isoform mutant mice were derived from mating together wild-type siblings 
generated from GABAB(1a)+/- and GABAB(1b)+/- heterozygous breedings (F3-4). The breeding 
strategy was applied in accordance with the recommendations proposed by The Jackson 
Chapter 5  93 
_________________________________________________________________________________ 
Laboratory to obviate genetic drift and the formation of substrains 
(http://jaxmice.jax.org/geneticquality/guidelines.html). 
Male and female mice were investigated in separate experiments for all tests 
performed with the exception of corticosterone and ACTH levels, in which only male mice 
were used. All mice were singly-housed after achieving at least 8 weeks of age, with the 
exception of those used in the marble burying test that were group-housed 2 – 4 mice per 
cage. Mice were housed in macrolon cages with sawdust bedding, tissue paper nesting 
materials and one red, triangular, polycarbonate Mouse House® (Nalgene) per cage. Housing 
was at a constant room temperature of 22-24°C in a 12 h light : dark cycle with lights on at 6 
– 6.30 am. Food pellets and tap water were available ad libitum (except during 
experimentation). Mice were allowed to settle for a minimum of 1 week after single-housing 
before testing began. All mice were 8 weeks of age or older at testing. All mice were drug-
naïve, and mice used in the stress-induced hyperthermia (SIH), light-dark box (LDB), marble 
burying tests and in the corticosterone and ACTH assessment were experimentally-naïve. 
Mice used in the staircase test were the same as those from the SIH test, with an interval of 
approximately 3 weeks and 5 weeks between tests for the male and female mice, respectively. 
Mice used in the marble-burying test were singly-house immediately following the test and 
subsequently tested in the elevated plus maze after an interval of approximately 5 weeks and 1 
week for male and female mice, respectively. Mice tested with the elevated zero maze had 
been previously exposed to a 5 minute handling period approximately 1 week prior to testing, 
during which basic sensory and sensory-motor characteristics of the mutant mice and wild-
type controls were examined (Jacobson et al. 2006a). All animal experiments were conducted 
during the light phase. All animal experiments were conducted in accordance with Swiss 
ethics guidelines, and approved by the Veterinary Authority of Basel Stadt, Switzerland. 
 
Stress-Induced Hyperthermia (SIH) 
The SIH test is an ideal inclusion in an anxiety test battery as it is not unduly influenced by 
alterations in locomotor activity, and is a translational model across strains and species 
(including mice and humans; see (Bouwknecht et al. 2006). The test procedure for SIH was 
adapted from that reported by Van der Heyden and colleagues (Van der Heyden et al. 1997) 
and was conducted essentially as described by Cryan et al., (2003), with the exception that 
mice in the present study were already singly housed prior to the time of SIH testing. Two 
SIH experiments were conducted, one with male and one with female mice. Age-matched 
(within gender), experimentally-naive male and female wild-type, GABAB(1a)-/- and 
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GABAB(1b)-/- mice (mean age: 10 ± 0.4 weeks for males and 13 ± 0.3 weeks for females, n = 
10 per sex and genotype) were re-housed in new cages overnight in the testing room. They 
had free access to water and food, but were without nesting materials or Mouse Houses®. The 
following day rectal temperature was measured in each mouse twice, i.e. at t = 0 min (T1) and 
t = +15 min (T2). The first measurement of temperature serves as the stressor and results in a 
rapid hyperthermic response. The difference in temperature (T2 − T1) was considered to reflect 
the SIH. Time-points were based on previous experiments which showed that a T2 − T1 
interval of 15 min was optimal in terms of SIH (Spooren et al. 2002). Rectal temperature was 
measured to the nearest 0.1 °C by an ELLAB instruments thermometer (Copenhagen, 
Denmark Model DM 852), by inserting a lubricated thermistor probe model PRA-22002-A 
(ELLAB) 2.2 mm diameter 20 mm into the rectum; the mouse was hand-held at the base of 
the tail during this determination and the thermistor probe was left in place for 15 s. 
 
Staircase Test 
The staircase test in mice (Simiand et al. 1984) allows the distinction between locomotor 
versus anxiolytic responses by comparing the ratio of steps climbed to rearings performed. 
Anxiolysis is thus interpreted when reductions in rearing are accompanied by an unchanged, 
or an increased, number of steps climbed. The test shows pharmacological selectivity for 
anxiolytics, and indeed, locomotor stimulants tend to decrease both parameters in the test 
(Simiand et al. 1984). Additionally, the number of faecal boli and urination spots made by the 
mice are easily quantifiable in this test and provide a further indicator of stress responses 
(Cryan et al. 2003; Gray and Lalljee 1974).  
The test was carried out essentially as previously described (Cryan et al. 2003; 
Simiand et al. 1984). The apparatus comprised an enclosed staircase with five steps made of 
grey plastic. Each step was 2.5 cm in height, 7.5 cm in length and 11 cm in width. The 
apparatus was 45 cm in length, with one end 12 cm and the other 25 cm in height. Mutant and 
wild-type mice utilized in the staircase test in the present study were the same animals as 
those for the SIH test, with the exception that of the wild-type female mice, only 8 rather than 
10 mice were used. Experiments with male and female mice were conducted separately. 
Animals were moved in their home cages to the testing room at least 1 h prior to testing 
commencement. Mice were placed on the bottom level facing away from the stairs. The 
number of steps ascended and rearings made in a 3-min period were observed. The apparatus 
was briefly wiped with a wet paper towel and dried between animals. 
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Light - Dark Box  
The light-dark box test (LDB) is a conflict-based anxiety test whereby the tendency to explore 
a novel environment contrasts against the natural aversion of mice to brightly-lit spaces 
(Crawley 2000). The test was included in the present study as most reliable indictors of 
anxiety, such as light-dark transitions and time spent in the light (in that order) (Crawley and 
Davis 1982; Holmes et al. 2002), are expressed as passive avoidance behaviours, thus 
increasing the range of behaviours used in the present study to evaluate anxiety. The test was 
carried out similarly to that previously described (Cryan et al. 2003; Holmes et al. 2002; 
Mombereau et al. 2004a). The apparatus consisted of a Plexiglas enclosure (44 x 21 x 21 cm) 
divided into two compartments (one light and one dark) by a partition in which there was a 
small opening (12 x 5 cm) at the floor level. The light compartment was open-roofed, with 
walls of transparent Plexiglas and was brightly illuminated by a 60W desk lamp overhead 
(approximately 1000 Lux). The smaller, dark compartment (14 cm width) was closed-roofed 
and was constructed of black Plexiglas. Male and female mice were investigated in separate 
experiments. Age-matched, experimentally-naive wild-type, GABAB(1a)-/- and GABAB(1b)-/- 
mice (mean age: 12 ± 0.4 weeks, n = 10 - 11 per sex and genotype) were individually placed 
in the center of the light compartment, facing away from the partition and allowed to explore 
the apparatus freely for 10 min. The apparatus was cleaned thoroughly between subjects. The 
number of light – dark transitions, time spent in the light compartment, and latency to enter 
the dark, were recorded by a trained observer. 
 
Marble-Burying Test 
The Marble-Burying test was similar to that previously described (Broekkamp et al. 1986; 
Spooren et al. 2000). This test was included as animals who are more anxious must engage in 
active behaviours (defensive marble burying) as opposed to passive behaviours utilized to 
avoid anxiogenic stimuli in the light-dark box and elevated mazes. Male and female mice 
were investigated in separate experiments. Mice were group-housed, age-matched (within 
gender), experimentally-naive male and female wild-type, GABAB(1a)-/- and GABAB(1b)-/- mice 
(Males: mean age, 15.2 ± 0.4 weeks; wild-type n = 14, GABAB(1a)-/- n = 19, GABAB(1b)-/- n = 
26. Females: mean age, 20.6 ± 0.6; wild-type n = 23, GABAB(1a)-/- n = 16, GABAB(1b)-/- n =  
35). Mice were placed individually in small cages (26 × 20 × 14 cm), in which 10 marbles had 
been equally distributed on top of a 5 cm – deep bed of sawdust, and a wire lid placed on top 
of the cage. Mice were left undisturbed for 30 min, after which the number of buried marbles 
(i.e., those covered by sawdust three-quarters or more) were counted. 
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Elevated Plus Maze 
The elevated plus maze is a widely used test for assigning anxiety behaviour in mice (Crawley 
2000; Holmes 2001; Rodgers 1997). Similarly to the light-dark box, the elevated plus maze is 
based on the conflict between exploratory drive and avoidance of the innately-aversive open 
arms, and in the expression of passive behaviours that are employed to avoid the more 
anxiogenic areas of the mazes. However, the tests differ both in the nature of the anxiogenic 
stimuli (heights versus a brightly lit space), and in the starting place of the mice (choice point 
versus maximally anxiogenic area) (Crawley 2000; Rodgers 1997). As such, results between 
the two tests can be expected to vary, and therefore the inclusion of both tests in the present 
study provides a more comprehensive test battery.  Separate experiments were conducted with 
male and female mice. Mice were the same animals as those utilized in the Marble-Burying 
test, with the exception that of the female GABAB(1b)-/- mice, only 34, rather than 35 mice 
were used. The elevated plus maze was carried out as described previously (Cryan et al. 2003; 
Rodgers et al. 1997b). The apparatus comprised two open arms (30 × 5 cm) and two enclosed 
arms (30 × 5 × 15 cm), which extended from a common central platform (5 × 5 cm). The 
configuration formed the shape of a plus sign, with like-arms arranged opposite one another, 
and the apparatus was elevated 60 cm above floor level on a central pedestal. The maze floor 
was made of black Plexiglas, while the side- and end-walls of the enclosed arms were made 
from clear Plexiglas. Grip on the edges of open arms was facilitated by inclusion of a small 
raised edge (0.25 cm) around their perimeter. Animals were transported from the holding 
room to the laboratory at least 1 h before testing. Mice were placed onto the central platform 
facing an enclosed arm. A 6-min trial was performed and, between subjects, the maze was 
thoroughly cleaned. Direct registrations were made by an observer sitting close to the maze 
using the following conventional parameters: number of open and closed arm entries (arm 
entry defined as all four paws entering an arm), time spent on open arms (excluding the 
central platform). 
 
Elevated Zero Maze 
The elevated zero maze is an ideal complementary test to the elevated plus maze. It eliminates 
the central area of the plus maze and provides a continuous circular track to facilitate 
exploration, while maintaining endpoint parameters similar in construct to that of the elevated 
plus maze (Lee and Rodgers 1990; Shepherd et al. 1994). Furthermore, we have previously 
shown that mice lacking the GABAB(1) subunit jumped off the maze in a panic-like response 
(Mombereau et al. 2004a). It was therefore of interest to assess the influence of GABAB(1) 
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receptor isoform deletion on mice in this test. The elevated zero maze test was conduced as 
previously described (Cryan et al. 2004). Male and female mice were investigated in separate 
experiments. Age-matched (within gender), experimentally-naive male and female wild-type, 
GABAB(1a)-/- and GABAB(1b)-/- mice (mean age: 21.2 ± 1.4 weeks for males and 23.8 ± 0.8 
weeks for females, n = 11 - 12 for each sex and genotype) were used. Mice had been 
individually handled for about 5 minutes each one week prior to testing in the elevated zero 
maze. The apparatus was a 5.5 cm-wide circular track constructed of grey Plexiglas with an 
inside diameter of 34 cm, a midtrack circumference of approximately 121 cm, and an 
elevation of 40 cm. It consisted of two open quadrants with a raised, 2-mm edge and two 
closed quadrants with walls 11 cm high. Mice were placed in one of the closed quadrants 
designated as the starting quadrant and were allowed to investigate the zero maze for a period 
of 5 min. During this time, an observer scored mice on several anxiety-related variables as 
identified in previous studies (Cryan et al. 2004; Shepherd et al. 1994; Tarantino et al. 2000). 
These included time spent in both open and closed quadrants, number of transitions between 
quadrants, latency to leave the closed quadrant, stretch-attend postures (SAP, elongated body 
posture with at least snout over open/closed divide) into the open quadrant, rearing, and head 
dips.  
 
Corticosterone and ACTH 
In order to investigate the effects of deletion of the GABAB(1a) or GABAB(1b) isoforms on 
hypothalamic-pituitary-adrenal (HPA) axis activity, corticosterone and adrenocorticotropic 
hormone (ACTH) levels at 0700 – 0800 hr were measured in trunk blood of male, 
experimentally-naïve wild-type (n = 9), GABAB(1a)-/- (n = 9) and GABAB(1b)-/- (n = 6) male 
mice (mean age (± SEM) 15.6 ± 0.6 weeks). Home cages for each individual mouse were 
removed from the housing room one at a time to another room where mice were decapitated 
immediately on arrival and trunk blood collected into EDTA-treated 1.5 ml  tubes (Milian 
S.A., Meyrin, Switzerland). Blood samples were kept on ice for up to about 20 min until 
centrifugation at 10 000 rpm for 15 min in a refrigerated centrifuge (4 °C). The plasma 
fraction was collected and stored at -80 °C until subsequent analysis for corticosterone and 
ACTH. Plasma corticosterone and ACTH concentrations were measured using commercially 
available radioimmunoassay kits (ICN Biomedicals, Costa Mesa, CA, USA). 
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Statistical Analyses 
As studies which were carried out in both male and female mice were conducted in 
independent experiments, data for each sex were analysed separately. Corticosterone levels 
and the number of steps taken in the staircase test were analyzed using one-way Analysis of 
Variance (ANOVA). Parameters measured within the SIH , staircase, light-dark box, elevated 
plus maze tests and ACTH data were analyzed using Kruskal-Wallis one-way Analysis of 
Variance on Ranks, followed by Dunn’s Method post hoc comparisons where indicated by 
significant ANOVA factors. 
 
5.4 Results 
 
Stress-Induced Hyperthermia (SIH) 
SIH was not influenced significantly by genotype in either of the experiments using male or 
female mice (Fig 1a and b; H = 4.25, P = 0.12 and H = 1.64, P = 0.44 for males and females, 
respectively). In the male mice the first temperature recording, T1, tended to be higher for the 
GABAB(1a)-/- mice (Fig 1a; H = 5.27, P = 0.072), although in the female mice this trend was 
not apparent (Fig 1b; H = 3.582, P = 0.17). The second temperature recording, T2, was not 
significantly influenced by genotype in either the male or female mice (Fig 1a and b; H = 
2.24, P = 0.33 and H = 3.40, P = 0.18 for male and female mice, respectively). 
 
Staircase Test 
The number of steps taken, incidence of rearing and the ratio of steps to rears in the staircase 
test were not significantly affected by genotype in either of the experiments using male or 
female mice (Males: steps F2,29 = 0.26, P = 0.772; rears H = 0.96, P = 0.62; ratio H = 0.88, P 
= 0.64. Females: steps F2,27 = 0.996, P = 0.38; rears H = 3.61, P = 0.17; ratio H = 1.25, P = 
0.536; Fig 2a and b).  
With regard to physiological indicators of stress (Fig 2a and b), genotype significantly 
influenced the number of faecal boli produced by male mice during the test (H = 14.13, P < 
0.001). Post hoc comparisons demonstrated the GABAB(1b)-/- mice defecated more than 
GABAB(1a)-/- mice (P < 0.01), although neither mutant strain differed from the wild-types in 
this regard (P > 0.05). Faecal boli production was not significantly affected by genotype in the 
female mice, as was also the case for the number of urine spots produced by male or female 
mice (Females faecal boli H = 2.37, P = 0.31; males urination score H = 3.73, P = 0.16; 
females urination score H = 3.74, P = 0.154). 
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Fig. 1. Stress-Induced Hyperthermia (SIH). Genotype did not significantly influence SIH or rectal 
temperature at the two time points measured in experiments with (a) male (n = 10 per genotype) or (b) 
female (n = 10 per genotype) wild-type (WT), GABAB(1a)-/- (1a-/-) or GABAB(1b)-/- (1b-/-) mice. Bars 
represent means + SEM. First rectal temperature recording (T1), second rectal temperature recording 
taken 15 min later (T2), temperature difference between T1 and T2 (ΔT).  
 
Light - Dark Box 
In the experiment with male mice, three wild-type mice, one GABAB(1a)-/- and one 
GABAB(1b)-/- mouse made no transitions during the test – all of their time in the test was spent 
in the light compartment in which they were initially placed, and the latency to enter the dark 
side was therefore greater than the 600 sec duration of the test. As a consequence, absolute 
data values for latency for these mice were not determined. Furthermore, data from these mice 
may have introduced bias in other test measures such as time in the light compartment and 
light-dark transitions, therefore these mice were excluded from statistical analysis.  
Genotype influenced the number of light-dark transitions in male mice (H = 6.48, P = 
0.039, Fig. 3a). Post hoc comparisons revealed that male GABAB(1b)-/- mice conducted 
significantly less light-dark transitions than GABAB(1a)-/- mice (P < 0.05), although neither 
mutant differed from the wild-type controls in this regard.  The latency to enter the dark 
compartment and the total time spent in the light compartment were not significantly 
influenced by genotype in the male mice (Latency: H = 1.55, P = 0.46; Time in light: H = 
2.26, P = 0.32; Fig. 3a). 
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Fig. 2. Staircase. Deletion of GABA  or GABA  receptor subunit isoforms did not influence the 
number of ascending steps taken (Steps), incidence of rearing (Rears), the ratio between these two 
parameters (Ratio) or the amount of urination in the staircase test in experiments with (a) male (n = 
10 per genotype) and (b) female (n = 10 per genotype) mice, although male GABA  mice 
defecated more than GABA  male mice. Bars represent means  SEM.  P < 0.05 for GABA  
vs GABA . Wild-type (WT), GABA  (1a ), GABA  (1b ). 
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In the experiment with female mice, some mice also failed to enter the dark 
compartment (two wild-type, one GABAB(1a)-/- and two GABAB(1b)-/- mice) and were therefore 
excluded from statistical analysis. The number of light-dark transitions made by female mice 
was not significantly affect by genotype (H = 1.99, P = 0.37, Fig. 3b). However, GABAB(1b)-/- 
female mice spent more time in the light compartment than GABAB(1a)-/- female mice (P < 
0.05, Fig. 3b), although neither mutant genotype differed significantly from the wild-types (H 
= 6.58, P = 0.037, Fig. 3b). As for the experiment conducted with the male mice, latency to 
enter the dark compartment was not significantly affected by genotype in the female mice (H 
= 0.71, P = 0.70). 
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Fig. 3. Light-Dark Box. In male mice (a), GABAB(1b)-/- (1b-/-) mice made fewer transitions between the 
light and dark compartments (Transitions) relative to the GABAB(1a)-/- (1a-/-) mice (n = 10 per genotype). 
In a separate experiment with female mice (b), GABAB(1b)-/- mice spent more time in the light 
compartment (Time in light) than GABAB(1a)-/- mice (n = 10 – 11 per genotype). Genotype did not 
influence the time take for mice of either sex to initially enter the dark compartment (Latency). Bars 
represent means + SEM. # P < 0.05 for GABAB(1a)-/- vs GABAB(1b)-/-. Wild-type (WT).  
 
Marble Burying Test 
The number of marbles buried in the experiments with either male or female mice were not 
significantly affected by genotype (H = 0.33, P = 0.85 and H = 2.49, P = 0.29 for males and 
females, respectively; Table 1). 
 
Table 1. Mean (± SEM) number of marbles buried by male (wild-type n = 14, GABAB(1a)-/- n = 19, 
GABAB(1b)-/- n = 26) and female (wild-type n = 23, GABAB(1a)-/- n = 16, GABAB(1b)-/- n =  35) wild-type and 
GABAB(1) isoform-deficient mice .  
 
 Wild-type GABAB(1)-/- GABAB(1b)-/-
Males 7.6 (± 0.6) 7.4 (± 0.6) 7.3 (± 0.4) 
Females 6.7 (± 0.5) 6.6 (± 0.6) 7.5 (± 0.3) 
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Elevated Plus Maze 
Genotype did not significantly influence any of the measured parameters in the elevated plus 
maze in the experiments involving the male or the female mice. The number of open arm 
entries for male (H = 0.71, P = 0.70) or female mice (H = 2.62, P = 0.27) was not affected by 
genotype, nor were closed arm entries for male or female mice ((H = 0.91, P = 0.63; H = 0.71, 
P = 0.70 for males and females respectively), nor the total number of arm entries (H = 0.87, P 
= 0.65; H = 1.67, P = 0.44 for males and females, respectively). With regard to total arm 
entries, some mice made only one or no arm entries during the experiment. In female mice, 
this was the case for 4 of the 23 wild-type, 1 of the 16 GABAB(1a)-/- and 9 of the 35 
GABAB(1b)-/- mice. In the experiment with male mice, all of the wild-type and GABAB(1a)-/- 
mice made more than one arm entry, while 2 of the 26 GABAB(1b)-/- males made one or no 
arm entries. The ratio of the number of open to closed arm entries was not affected by 
genotype in the experiments with either sex (H = 2.16, P = 0.34 and H = 0.87, P = 0.65 for 
males and females, respectively). Finally, the amount of time spent on the open arms by the 
mice in each respective experiment was not significantly affected by genotype (H = 2.35, P = 
0.31 and H = 2.05, P = 0.36 for males and females, respectively; Table 2) 
 
Table 2. Parameters measured in the elevated plus maze were not significantly influenced by deletion 
of the GABAB(1a) or GABAB(1b) isoforms. Data are means (± SEM) 
  Males   Females  
 
(n) 
Wild-type 
(14) 
GABAB(1a)-/-
(19) 
GABAB(1b)-/-
(26) 
Wild-type 
(23) 
GABAB(1a)-/-
(16) 
GABAB(1b)-/-
(34) 
Open arm 
entries 
5.0 
(± 1.0) 
4.8 
(± 0.6) 
4.3 
(±0.6) 
3.3 
(± 0.5) 
3.3 
(± 0.7) 
2.3 
(± 0.3) 
Closed arm 
entries 
7.9 
(± 1.4) 
6.4 
(± 1.0) 
5.8 
(± 0.8) 
3.6 
(± 0.7) 
4.0 
(± 0.9) 
3.4 
(± 0.6) 
Ratio open : 
closed 
entries 
0.39 
(± 0.03) 
0.48 
(± 0.05) 
0.44 
(± 0.04) 
0.49 
(± 0.06) 
0.52 
(± 0.06) 
0.49 
(± 0.1) 
Total arm 
entries 
12.9 
(± 2.3) 
11.2 
(± 1.4) 
10.1 
(± 1.3) 
6.9 
(± 1.1) 
7.3 
(± 1.4) 
5.7 
(± 0.8) 
Time open 
(s) 
109.1 
(± 13.3) 
153.3 
(±20.3) 
135.8 
(± 16.8) 
103.0 
(± 18.2) 
137 9 
(± 25.8) 
110.1 
(± 20.7) 
  
Elevated Zero Maze 
In the experiment with male mice, the latency to enter the open side, time spent on the open 
side, the number of head dips over the side of the open areas and number of rears were not 
significantly affected by genotype (H = 1.98, P = 0.371; H = 0.62, P = 0.733; F2,34 = 1.75, P = 
0.19 and H = 1.18, P = 0.55, respectively). There was a tendency for genotype to influence the 
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distance travelled in the maze (line crossings: H = 5.50, P = 0.064), and the number of SAPs 
performed by the mice (F2,34 = 2.577, P = 0.092; Figure 4a). 
In the experiment with female mice, genotype significantly influenced the majority of 
parameters measured in the elevated zero maze. The latency to enter the open sided area of 
the maze (H = 11.39, P < 0.01) was significantly longer in both GABAB(1a)-/- and GABAB(1b)-/- 
mice than in the wild-type mice. Both mutant strains also performed significantly less head 
dips over the maze open sides (F2,35 = 21.07, P < 0.001) and rearings (H = 13.52, P = 0.001) 
than the wild type mice. Genotype also influenced the time spent on the open sided areas (H = 
11.60, P < 0.01) and the number of line crossings (H = 9.09, P < 0.05), and post-hoc 
comparisons revealed a significant difference between GABAB(1b)-/- mice and wild-types in 
these parameters. The mutants did not differ significantly from each other in post hoc 
comparisons of the aforementioned parameters. The only parameter measured in the elevated 
zero maze that was not significantly influence by genotype in the female mice was the number 
of SAPs (F2,35 = 0.80, P = 0.46; Figure 4b).  
 
 
 
 
 
Fig. 4. Elevated Zero Maze. In male mice (a) deletion of either the GABAB(1a) or GABAB(1b) isoforms 
did not significantly influence the time taken to enter an open-sided quadrant (Latency), time spent in 
the open-sided quadrants (Time in open), ambulation in the maze (Line crossings), or the ethological 
parameters: incidence of dipping the head over the open sides (Head dip), rearing (Rears) and the 
number of stretch-attend postures (SAP) performed into the open quadrants (n: WT = 12, 1a-/- = 11, 
1b-/- = 12). In a separate experiment with female mice (b) genotype influenced all elevated zero maze 
parameters measured with the exception of SAPs (n: WT = 12, 1a-/- = 12, 1b-/- = 12). Bars represent 
means + SEM. * P < 0.05, ** P < 0.01 vs wild-type (WT).  GABAB(1a)-/- (1a-/-), GABAB(1b)-/- (1b-/-). 
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Basal Corticosterone and ACTH 
Mean plasma corticosterone appeared to be slightly elevated in the GABAB(1a)-/- mice 
compared to the GABAB(1b)-/- mice (Fig. 6a), however, ‘genotype’ did not achieve statistical 
significance (F2,12 = 1.91, P = 0.17). Two data points were removed from the ACTH dataset 
as statistical outliers: one from the GABAB(1a)-/- mice (922 pg/ml) and one from the 
GABAB(1b)-/- mice (1176 pg/ml). The genotype did not significantly influence basal ACTH 
levels (Fig 6b; H = 1.93, P = 0.38).  
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Fig. 5. Hypothalamic-Pituitary-Adrenal Axis Characteristics. Deletion of GABAB(1a) or GABAB(1b) 
isoforms did not significantly influence plasma corticosterone (a) or ACTH (b) of male mice as 
measured within 1 hour of the start of the circadian light phase (Basal) (n: wild-type = 9, GABAB(1a)-/- = 
9, GABAB(1b)-/- = 6). Bars represent means + SEM. 
 
5.5 Discussion 
 
The present study aimed to determine the influence of GABAB(1) subunit isoform deletion on 
innate, unconditioned anxiety-related behaviours in mice. To this end, GABAB(1a)-/-, 
GABAB(1b)-/- and wild-type control mice were investigated in a comprehensive battery of 
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anxiety tests that employed a number of different types of experimental endpoints including 
autonomic, passive and active avoidance and ethological parameters. The test-battery 
approach has been advocated for the detecting of genuine differences in anxiety phenotypes in 
mutant mice, as reliance on fewer tests may give rise to erroneous interpretations depending 
on specific idiosyncrasies of individual tests or mutations (Cryan and Holmes 2005). Overall, 
the present study demonstrated that the constitutive genetic deficiency of either the GABAB(1a) 
or GABAB(1b) isoform did not, for the most part, result in an alteration of innate, 
unconditioned anxiety (Table 3). 
 
Table 3. Summary of results for the behavioural assessment of innate anxiety in GABAB(1a)-/- and 
GABAB(1b)-/- mice. X = no alteration in phenotype, ↓ = anxiolytic-like phenotype, ↑ = anxiogenic-like 
phenotype, relative to wild-type controls.  
 
Paradigm Endpoint Males Females 
 Parameter Category GABAB(1a)-/- GABAB(1b)-/- GABAB(1a)-/- GABAB(1b)-/-
Stress-induced 
hyperthermia      
 SIH Autonomic x x x x 
Staircase      
 Steps Passive avoidance x x x x 
 Rears Ethological x x x x 
 Ratio Combined x x x x 
 Boli and urine Autonomic x x x x 
Light dark box      
 Latency Active avoidance x x x x 
 Time in light Passive avoidance x x x x 
 Transitions Passive avoidance x x x x 
Marble burying      
 Marbles buried Active avoidance x x x x 
Elevated plus maze      
 Open arm Passive avoidance x x x x 
 Closed arm Passive avoidance x x x x 
 Ratio Passive avoidance x x x x 
 Total arm Passive avoidance x x x x 
 Time open Passive avoidance x x x x 
Elevated zero maze      
 Latency Passive avoidance x x ↑ ↑ 
 Time open Passive avoidance x x x ↑ 
 Line X Passive avoidance x x x ↑ 
 Head dips Ethological x x ↑ ↑ 
 Rears Ethological x x ↑ ↑ 
 SAP Ethological x x x x 
Basal corticosterone Autonomic x x - - 
Basal ACTH Autonomic x x - - 
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No anxiety-related phenotype was detected for either the GABAB(1a)-/- or GABAB(1b)-/- 
mice, in experiments with either gender, in the SIH, marble burying and elevated plus maze 
paradigms. Furthermore, in male mice at least, genotype did not influence the levels of  HPA 
axis hormones (Table 3). In the staircase, light-dark box and elevated zero maze tests, 
GABAB(1b)-/- mice showed some minor differences in behaviour when compared with 
GABAB(1a)-/- mice. However, given that neither mutant differed from the control wild-type 
mice in these measures, or for that matter in the majority of the response parameters measured 
in these tests, one cannot place too much credence on such subtle effects with relation to 
anxiety-related behaviours 
Deletion of either GABAB(1) subunit isoforms significantly influenced a number of 
parameters in the elevated zero maze in female mice. Locomotor activity can influence 
aspects of performance in exploratory-based tests of anxiety (Cryan and Holmes 2005); for 
example, a hyperactive phenotype may falsely suggest anxiolysis, and likewise, hypoactivity 
anxiogenesis. GABAB(1b)-/- mice (both females and males) have previously been demonstrated 
to be hyperactive in a novel environment, while the distance traveled by GABAB(1a)-/- mice 
was not different to that of the wild-type controls (Jacobson et al. 2006a). However, these 
observations are at odds with the reductions in exploratory activity by both mutant strains 
relative to the wild-types in the elevated zero maze in the present study, as indicated by an 
increased latency to enter the open sided area in both female mutant genotypes and by the 
reduced line crossings made by the GABAB(1b)-/- females. Furthermore, the ethological 
measures of head-dipping and rearing were also reduced in both GABAB(1a)-/- and GABAB(1b)-
/- female mice in this test. Reductions in the parameters of latency to enter an innately 
aversive area, head-dipping over the edges of elevated apparatuses and rearing, have been 
interpreted as heightened anxious responses in various apparatuses, including the elevated 
zero maze (Belzung 1999; Homanics et al. 1999; Rodgers 1997; Rodgers and Johnson 1995; 
Shepherd et al. 1994). The elevated zero maze is considered a more sensitive test than the 
elevated plus maze, mainly due to the elimination of the central square of the elevated plus 
maze, which can produce difficulties in data interpretation (Lee and Rodgers 1990; Shepherd 
et al. 1994), and to the facilitation of locomotor exploration given by the circular track of the 
zero maze, thus eliminating corners in which the mice may barricade themselves (Rodgers 
1997; Shepherd et al. 1994).The present findings therefore suggest a subtle, sex-specific role 
for the GABAB(1) isoforms in innate anxiety. It should be noted, however, that in the light-
dark box test, GABAB(1b)-/- female mice spent an increased amount of time in the light side 
relative to the GABAB(1a)-/- female mice, an anxiolytic-like response. Together with the data 
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from other anxiety paradigms where no robust anxiety phenotype was observed, these results 
indicate that the influence of GABAB(1) isoforms on anxiety in female mice is most likely 
highly dependent on the environment. 
Failure to enter the dark compartment of the light-dark box was shown by a small 
number of both male and female mice, and occurred to a reasonably similar level in wild-type 
and mutant mice. The proportion of mice of each genotype making 0 or 1 total arm entries in 
the elevated plus maze was also similar to that of the light dark box, although only in female 
mice. These behaviours may reflect ‘freezing’, neophobic avoidance of newly-discovered 
compartments, or failure to explore extensively enough to find additional compartments 
(Rodgers 1997), and thus may indicate anxiety in these animals. As genotype did not 
significantly influence these behaviours, they may be a consequence of the background strain. 
The BALB/c substrains have previously been reported as anxious in comparison to other 
mouse strains (Belzung 1999; Belzung and Griebel 2001; Cryan and Holmes 2005; Griebel et 
al. 2000). It could therefore be posited that innate anxiety may have been near-maximal in the 
background strain for the GABAB(1) isoform mutant mice, and thus further increases in 
anxiety induced by the genetic manipulations may be difficult to detect (Crawley et al. 1997). 
However, this was certainly not the case with either of the GABAB(1)-/- or GABAB(2)-/- mice, 
both of which were also maintained on a BALB/c background (Gassmann et al. 2004; Schuler 
et al. 2001), and both of which show profoundly increased anxiety relative to wild-type 
controls in exploratory anxiety tests (Mombereau et al. 2004a; Mombereau et al. 2005; 
Mombereau et al. 2004b). GABAB(1)-/- mice were substantially more anxious than wild-types 
in the light-dark box (Mombereau et al. 2004a; Mombereau et al. 2004b) and staircase tests 
(Mombereau et al. 2004a), while in the elevated zero maze, all GABAB(1)-/- mice jumped from 
the maze, a response indicating heightened flight or panic behaviour (Mombereau et al. 
2004a). Clearly this indicates that the tests used are suitable to detect increases in anxious 
behaviours in the BALB/c strain. 
The anxious phenotype of the aforementioned GABAB(1)-/- mice differs considerably 
from that of the specific GABAB(1) isoform-deficient mice in the present study. Both 
GABAB(1)-/- and GABAB(2)-/- mice show spontaneous seizures, hyperalgesia, hyperlocomotion, 
memory impairments and significantly elevated exploratory anxiety (Gassmann et al. 2004; 
Mombereau et al. 2004a; Mombereau et al. 2005; Mombereau et al. 2004b; Schuler et al. 
2001). In these mutant mice, classical GABAB receptor agonist responses are abolished 
(Gassmann et al. 2004; Kaupmann et al. 2003; Schuler et al. 2001). In contrast, there is only 
partial GABAB receptor loss in the GABAB(1a) and GABAB(1b)-/- mice (Vigot et al. 2006), and 
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some residual agonist-induced function remains, albeit blunted, in both the GABAB(1a)-/- and 
GABAB(1b)-/- mice (Jacobson et al. 2006a; Perez-Garci et al. 2006; Shaban et al. 2006; Vigot et 
al. 2006). In combination with the lack of overt anxious phenotype of the GABAB(1) isoform 
mutant mice in the present study, these findings together demonstrate that at least some 
heterodimeric GABAB receptor function is essential for the prevention of an increase in 
anxiety behaviour, and furthermore, that the presence of either the GABAB(1a) or GABAB(1b) 
isoforms can fulfil this task.  
The indistinct innate anxiety phenotype of GABAB(1b)-/- and GABAB(1b)-/- mice 
demonstrated in the present study contrasts with their reported phenotypes in aversive taste 
memory (Jacobson et al. 2006b) and conditioned freezing paradigms (Shaban et al. 2006). 
GABAB(1a)-/- mice did not acquire a CTA to a saccharin solution paired with LiCl-induced 
malaise, while GABAB(1b)-/- mice acquire CTA well, but were profoundly impaired in the 
extinction of this aversion (Jacobson et al. 2006b). In conditioned freezing, GABAB(1a)-/- mice 
show subsequent generalized freezing to sound cues irrespective of whether or not they were 
paired with high-intensity (0.9mA) foot shocks during conditioning (Shaban et al. 2006). In 
theory, it should not necessarily be expected that conditioned and unconditioned tests of fear 
and anxiety should demonstrate similar phenotypes, or indeed, even to produce similar 
phenotypes within each of these categories (Rodgers 1997). Certainly, dissociations between 
aversive conditioning and exploratory anxiety has also been reported for other mutant mice, 
such as forebrain-selective glycine transport 1 (GlyT1)-deficient mice (Yee et al. 2006) and 5-
HT1A receptor knockout mice (Klemenhagen et al. 2006), although it should be noted that in 
each of these studies only one unconditioned anxiety paradigm was utilized. However, the 
differentiation between conditioned and unconditioned responses appears particularly clearly 
delineated with GABAB(1) isoform deficient mice. CTA is well known as an aversive, 
associative learning and memory paradigm (Akirav 2006; Akirav et al. 2006; Berman and 
Dudai 2001; Bermudez-Rattoni 2004; Lamprecht et al. 1997; Welzl et al. 2001) and has 
recently been applied to the study of anxiety disorders associated with altered emotional 
learning (Cryan and Holmes 2005; Guitton and Dudai 2004; Yasoshima and Yamamoto 
2005). Conditioned freezing in rodents is thought to model emotive cognition aspects of 
human anxiety disorders such as post-traumatic stress disorder and panic disorder (Barad 
2005; Cryan and Holmes 2005; Delgado et al. 2006; Ledgerwood et al. 2005; Ressler et al. 
2004). It should also be noted that the GABAB(1a) isoform has been demonstrated as necessary 
for both hippocampal (Vigot et al. 2006) and amygdala (Shaban et al. 2006) long-term 
potentiation, and the ability to discriminate successfully between novel and familiar objects in 
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a mouse object recognition paradigm – a task which requires the presence of an intact 
hippocampus (Broadbent et al. 2004; Clark et al. 2000). Together these findings suggest that 
the GABAB(1a) and GABAB(1b)  isoforms of the GABAB(1) subunit have specific relevance for 
anxiety with a cognitive component, rather than for innate anxiety per se. Indeed, it remains 
possible that the specific and differential deficiencies in emotive learning and memory in 
these mutant mice could be a product predominantly of cognitive impairments, rather than 
one of emotive processing in itself. 
In conclusion, previous studies have demonstrated that genetic ablation of all 
functional GABAB receptors results in increases in unconditioned anxiety behaviour (Cryan 
and Kaupmann 2005). Results of the present study suggest that this not due to the specific loss 
of either one of the predominant GABAB(1) subunit isoforms, and that the role for the isoforms 
in innate anxiety is relatively indistinct. In contrast, these isoforms appear to be more 
explicitly involved in anxious behaviours that are associated with a cognitive component. 
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6.1 Abstract 
 
GABAB receptors are heterodimers of GABAB1 and GABAB2 receptor subunits. The 
predominant GABAB1 receptors isoforms are GABAB1a and GABAB1b. There is accumulating 
evidence for a role of GABAB receptors in depression. In preclinical studies, GABAB receptor 
antagonists induce antidepressant-like responses, and GABAB1 and GABAB2 deficient mice 
show an antidepressant-like profile in the forced swim test (FST). However, the contribution 
of GABAB1 isoforms to the antidepressant-like behavior is unknown. We therefore studied 
mutant mice deficient in either the GABAB1a or GABAB1b receptor isoforms in the FST. As 
there is strong evidence for interactions between GABAB receptor and the serotonergic 
system, and 5-HT1A receptors are implicated in depression and antidepressant actions, we also 
evaluated 5-HT1A receptor function in these mice. Both male and female GABAB1a-/- mice 
showed an antidepressant-like profile in the FST, relative to wild-types. GABAB1b-/- deficient 
mice were without a phenotype in this test. Further, GABAB1a-/- mice demonstrated 
profoundly blunted hypothermic and motoric responses to the 5-HT1A receptor agonist 8-OH-
DPAT. In addition, 8-OH-DPAT-induced corticosterone and ACTH release was specifically 
attenuated in GABAB1a-/- mice. Interestingly, 5-HT1A  receptor  binding sites, as detected by 
autoradiography with [3H]-MPPF and [3H]-8-OH-DPAT, were largely unaffected by 
genotype. The data indicate that the GABAB1a isoform, but not the GABAB1b isoform, may 
underlie GABAB receptor-related antidepressant-like effects. We conclude that GABAB 
receptors containing the GABAB1a isoform  regulate the serotonergic system and contribute to 
the neurobiological mechanisms underlying depression. 
 
6.2 Introduction  
 
GABAB receptors are heterodimers of GABAB(1) and GABAB(2) subunits. There are two 
predominant isoforms of the GABAB(1) receptor subunit expressed in brain, GABAB(1a) and 
GABAB(1b), both of which heterodimerize with the GABAB(2) subunit to form functional 
receptors (Bettler et al. 2004; Cryan and Kaupmann 2005). Both isoforms are encoded by the 
same gene, Gabbr1, and are generated by different promoter usage (Steiger et al. 2004). The 
isoforms differ in sequence primarily by the inclusion of an extended N-terminus (‘short 
consensus repeats’ or ‘sushi domains’) on the GABAB(1a) isoform (Kaupmann et al. 1998a).  
A hypothesis for the role of GABAB receptors in the mechanisms underlying 
depression and the action of antidepressants was first proposed over 20 years ago (Pilc and 
Lloyd 1984). This followed the observation that after chronic (but not acute) treatment of rats 
Chapter 6  112 
_________________________________________________________________________________ 
with antidepressants of varied mechanisms of action, GABAB receptor binding in the frontal 
cortex was up-regulated (Pilc and Lloyd 1984). Other animal studies have since demonstrated 
similar findings on GABAB receptor function or expression following antidepressant 
administration (Gray and Green 1987; Sands et al. 2004b) or models of antidepressant 
electroconvulsive shock therapy (Gray and Green 1987; Lloyd et al. 1985). This includes the 
enhancement of hypothermia induced by GABAB receptor activation via the prototypic 
agonist baclofen, a classic indicator of GABAB receptor function (Gray et al. 1987). However, 
further advances have been hampered by a lack of tools with which to probe the molecular 
diversity of the GABAB system. 
Accumulating recent evidence has demonstrated that GABAB receptor antagonists 
may be an attractive target for the development of antidepressants (Cryan and Kaupmann 
2005; Slattery and Cryan 2006). Specifically, genetic deletion of either the GABAB(1) or 
GABAB(2) receptor subunits induced an antidepressant-like phenotype in the forced swim test 
(FST) in mice (Mombereau et al. 2004a; Mombereau et al. 2005). Furthermore, GABAB 
receptor antagonists show antidepressant-like actions in the rat and mouse FST (Mombereau 
et al. 2004a; Nowak et al. 2006; Slattery et al. 2005a) and in the learned helplessness 
(Nakagawa et al. 1999; Nowak et al. 2006), olfactory bulbectomy and chronic mild stress 
paradigms (Nowak et al. 2006). The mechanisms underlying the antidepressant-like 
behavioral effects of GABAB receptor antagonists have been shown to depend on an 
interaction with the serotonergic system (Slattery et al. 2005a), as it was abolished by pre-
treatment with the tryptophan hydroxylase inhibitor para-chlorophenylalanine.  
GABAB receptors are expressed both presynaptically and postsynaptically, where they 
modulate neuronal excitability through inhibition of neurotransmitter release via interactions 
with Ca+2 channels, and inhibitory post synaptic potentials via interactions with inwardly-
rectifying K+ (GIRK) channels, respectively (see (Bettler et al. 2004) for a review). Activation 
of GABAB receptors with baclofen either systemically or locally has been shown to modulate 
5-HT  release at the level of the raphé nuclei and in postsynaptic structures (Abellan et al. 
2000a; Abellan et al. 2000b; Tao et al. 1996). 
Currently, no GABAB(1) isoform-selective ligands exist, and so to date 
pharmacological analysis of the physiological roles of GABAB(1a) and GABAB(1b) receptor 
isoforms has been impossible. However, recently the generation of mice deficient in these two 
isoforms (Vigot et al. 2006) has enabled such investigations. Studies with these mice have 
facilitated the demonstration of distinct behavioral and physiological roles for the GABAB(1a) 
and GABAB(1b) isoforms such as locomotor activity (Jacobson et al. 2006a), recognition 
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memory (Vigot et al. 2006), conditioned taste aversion (Jacobson et al. 2006b) and 
conditioned fear (Shaban et al. 2006). The influence of the specific isoforms on depression 
related behaviors, however, has not been investigated to date.  
Given the interactions between the 5-HT and GABAB receptor systems, and the 
aforementioned specific phenotypes of  GABAB(1) isoform-deficient mice, we hypothesized 
that the GABAB(1) isoforms may have differential influences on the 5-HT system and 5-HT-
related behavior of relevance to depression. Dysregulation of the 5-HT system is accompanied 
by alterations in 5-HT receptor function, and in particular by 5-HT1A autoreceptor 
desensitization – which has been proposed as an important mechanism by which 
antidepressants exert their effects (see Blier and Ward 2003 for a review). In the present study 
we therefore aimed to test our hypothesis using GABAB(1a)-/- and GABAB(1b)-/- mice in a 
classic test of antidepressant-like function, and in paradigms designed to probe pre- and 
postsynaptic 5-HT1A receptor function. 
 
6.3 Materials and Methods  
 
Animals 
The generation (Vigot et al. 2006) and breeding strategy (Jacobson et al. 2006a; Jacobson et 
al. 2006b) of wild-type, GABAB(1a)-/- and GABAB(1b)-/- mice used in the present studies have 
been described previously. Briefly, a knock-in point mutation strategy was adopted, whereby 
GABAB(1a) and GABAB(1b) initiation codons were converted to stop codons by targeted 
insertion of a floxed neo-cassette. All mutant and wild-type mice were maintained on a pure 
inbred BALB/c genetic background. Mutant mice were derived from homozygous breeding of 
siblings originating from the founding heterozygotic mice (F3-F6). Homozygous wild-type 
controls for the GABAB(1) isoform mutant mice were derived from mating together wild-type 
siblings generated from GABAB(1a)+/- and GABAB(1b)+/- heterozygous breedings (F3-F6).  
Mice were singly-housed in macrolon cages with sawdust bedding, tissue paper 
nesting materials and one Mouse House® (Nalgene) per cage. Housing was at a constant 
room temperature of 22-24°C in a 12 h light:dark cycle with lights on at 6-6.30 am. Food 
pellets and tap water were available ad libitum (except during experimentation). Testing 
began a minimum of about 3 weeks after single-housing. Experiments investigating body 
temperature responses to (±)8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) were 
conducted with the mice while in their home cages. In these and the forced swim test (FST) 
and hypothalamic-pituitary-adrenal (HPA) axis experiments, mice were moved to an 
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experimental room a minimum of 1 hour beforehand. In experiments necessitating euthanasia, 
mice were moved, individually in their home cages, to another room where they were 
immediately decapitated. Male mice were used in all experiments. In certain experiments as 
indicated, experimental replication was also carried out in a cohort of female mice. All animal 
experiments were conducted in accordance with the Swiss guidelines and regulations, and 
approved by the Veterinary Authority of Basel Stadt, Switzerland. 
 
Drugs 
The 5-HT1A receptor agonist (±)8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; Cat 
No. H-8520, Sigma-Aldrich) was prepared freshly each day in saline. A dose of 0.5 mg/kg 
was used in all experiments that involved 8-OH-DPAT. This dose was selected on the basis of 
previous studies showing that 0.5 mg/kg of 8-OH-DPAT was optimal for the production of 
hypothermia in mice (Gardier et al. 2001; Young et al. 1994),  including mice of the BALB/c 
strain (Man et al. 2002; McAllister-Williams et al. 1999). All 8-OH-DPAT and vehicle 
injections were delivered subcutaneously at the back of the neck in a volume of 10 ml/kg.  
 
Forced Swim Test (FST) 
Wild-type, GABAB(1a)-/- and GABAB(1b)-/- were investigated for duration of immobility in a 
FST in two separate experiments conducted with male and female mice. Ten mice of each 
genotype for each gender were used. The mean (± SEM) age at testing of the mice was 10.6 
(± 0.3) weeks of age for male mice, and 14.2 (± 0.3) for the female mice. The FST was 
conducted as previously described (Cryan et al. 2003; Mombereau et al. 2004a). Briefly, 
cylinders (21 cm diameter x 45 cm high) were filled to a depth of 15 cm with water adjusted 
to a temperature of 23-25°C. Mice were then placed into the cylinders where they remained 
for a duration of 6 minutes. The test sessions were recorded on video tapes from a camera 
positioned directly above the cylinders. The amount of time mice spent immobile in the last 4 
minutes of the test, that is when making only those movements necessary to keep their heads 
above water, were scored manually from video tapes by a trained observer blind to the 
animals genotypes.  
 
5-HT1A Receptor Activation, Hypothermia and Behavior 
Male Mice. Wild-type, GABAB(1a)-/- and GABAB(1b)-/- mice (n = 5 per genotype, mean (± 
SEM) age = 31.2 (± 0.8) weeks) were investigated for their body temperature responses to the 
5-HT1A receptor agonist, 8-OH-DPAT. All mice received 8-OH-DPAT (0.5 mg/kg, s.c.). A 
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baseline body temperature measurement was taken immediately prior to 8-OH-DPAT 
administration to serve as a within-animal pre-drug control. Body temperature was 
subsequently measured 30, 60, 90 and 120 minutes after 8-OH-DPAT administration. Body 
temperatures were measured to the nearest 0.1 °C using an ELLAB instruments thermometer 
(Copenhagen, Denmark Model DM 852) and lubricated thermistor probe (ELLAB model 
PRA-22002-A,  2.2 mm diameter) inserted 20 mm into the rectum while the mouse was 
gently hand-held at the base of the tail. The thermistor probe was left in place for 15 s until a 
stable recording was obtained.  
Female Mice. Only GABAB(1a)-/- (n = 17) and GABAB(1b)-/- (n = 16) female mice 
(mean (±SEM) age = 28.4 (± 0.8) weeks) were available at the time of experimentation. 
Consequently, the objective of this experiment was to verify whether or not the different 
responses to 8-OH-DPAT of the two mutant strains, as seen with the male mice, was also 
present in a cohort of female mice. Due to the absence of wild-type controls, the experimental 
design was altered to include both vehicle (saline) and 8-OH-DPAT treatments (0.5 mg/kg, 
s.c) for each genotype. Pre-treatment baseline temperatures were also obtained, enabling each 
mouse to serve as its own control. Body temperature was recorded as described above, 
immediately before injection with either vehicle or 8-OH-DPAT, and then again 30, 60, 90 
and 120 minutes after injection.  
 
Influence of 5-HT1A Receptor Activation on Behavior 
We took advantage of the 8-OH-DPAT hypothermia experiments to evaluate the behavioral 
responses of the mice to the 8-OH-DPAT treatment. As such, the presence or absence of a flat 
body posture was recorded for male and female mice in the aforementioned experiments, 30-
50 minutes after treatment. 
 
Influence of 5-HT1A Receptor Activation on Indicators of Hypothalamic-Pituitary-
Adrenal (HPA) Axis Activity  
Male mice only were used in this experiment (n: WT = 25, GABAB(1a)-/- = 21, GABAB(1b)-/- = 
22). The mean (±SEM) age of the mice was 20.9 (± 0.5) weeks. Mice were allocated to 8-OH-
DPAT (0.5 mg/kg) or vehicle (saline) treatments. Mice were injected 30 minutes before 
sacrifice by decapitation and trunk blood was collected into 1.5 ml tubes pre-prepared with 
EDTA (Milian S.A., Meyrin, Switzerland). The tubes were held on ice until centrifugation 
within 25 minutes of collection (10 000 rpm, 15 minutes, 4 ° C). The plasma supernatant was 
collected and stored at -80 ° C until analysis for corticosterone and adrenocorticotropin 
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hormone (ACTH) concentration using commercially available radioimmunoassay kits (ICN 
Biomedicals, Costa Mesa, CA, USA). 
 
5-HT1A Receptor Autoradiography 
Brains of experimentally-naïve male wild-type, GABAB(1a)-/- and GABAB(1b)-/- (n = 6 per 
genotype, mean age 15.9 ± 0.7 weeks) were harvested immediately after decapitation and 
stored at -80°C. Brains were subsequently cut in 10 μm sections with a microtome-cryostat 
and thaw-mounted on poly-l-lysine coated slides. Sequential brain sections at regions of 
interest (see Fig. 6a and b) were analysed for 5-HT1A receptor binding by autoradiographic 
analysis as described below, based on previously published methods with the 5-HT1A receptor 
antagonist [3H]MPPF ((2'-methoxy)-phenyl-1-[2'-(N-2"-pyridinyl)-p-fluorobenzamido]ethyl-
piperazine) (Hensler 2002; Kung et al. 1996), and with the 5-HT1A receptor agonist [3H]8-
OH-DPAT (Hoyer et al. 1992; Palacios et al. 1993). 
[3H]MPPF autoradiography. Sections were pre-incubated for 30 min at room 
temperature in a 170 mM Tris-HCl buffer (pH 7.6), then incubated for a further 90 min in the 
same buffer supplemented with 10 nM [3H]MPPF (71.6 Ci/mmol; Perkin Elmer). Non-
specific binding was determined in a set of adjacent slides by incubation in the presence of 10 
µM 5-HT. Sections were then washed twice for 5 min in ice-cold incubation buffer followed 
by a brief dip in ice-cold water. Finally, sections were dried under a stream of cold air. 
Autoradiograms were generated by exposing the labeled sections to BioMax MR Films 
(Eastman Kodak Company, Rochester, NY) for a period of 8 weeks. 
[3H]8-OH-DPAT autoradiography. Sections were pre-incubated for 30 min at room 
temperature in a buffer solutions containing 170 mM Tris-HCl (pH 7.6), 4 mM CaCl2, 0.01% 
ascorbic acid, 1 µM pargyline and 1 µM fluoxetine. Sections were then incubated for 60 min 
in the same buffer supplemented with 2 nM [3H]8-OH-DPAT (230 Ci/mmol; Amersham). 
Non-specific binding was determined in a set of adjacent slides by incubation in the presence 
of 10 µM 5-HT. Sections were then washed twice for 5 min in ice-cold incubation buffer 
followed by a brief dip in ice-cold water. Sections were finally dried under a stream of cold 
air. Autoradiograms were generated by exposing the labeled tissues to BioMax MR Films 
(Eastman Kodak Company, Rochester, NY) for a period of 3 weeks. 
 
Statistics 
As data from male and female mice were derived from separate experiments, they were 
analyzed separately within each gender. Immobility in the forced swim test, [3H]MPPF and 
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[3H]8-OH-DPAT binding within the brain regions investigated, were analyzed using 1-way 
analysis of variance (ANOVA).  Body temperatures of male and female mice in the 8-OH-
DPAT experiments were analyzed, respectively, using a 2-way repeated measures ANOVA. 
Fishers LSD post hoc comparisons were made where indicated by significant ANOVA terms. 
Corticosterone and ACTH data did not meet assumptions for parametric testing. These 
data were therefore analyzed within genotype for the effect of treatment using pair-wise 
Mann-Whitney Rank Sum Tests, and within treatment for the effect of genotype using 
Kruskal-Wallis 1-way ANOVA on Ranks. Dunn’s post hoc comparisons were made where 
indicated by significant terms in Kruskal-Wallis 1-way ANOVAs.  
 
6.4 Results 
 
Forced Swim Test 
Male mice. Genotype significantly affected immobility time of male mice in the forced swim 
test (F2,27 = 9.227, P = 0.001, Fig. 1a). Post hoc comparisons revealed that the GABAB(1a)-/- 
mice had significantly reduced immobility scores relative to wild-type mice, to more than half 
that of the wild-type controls (58% decrease). The GABAB(1a)-/- mice also had a significantly 
lower mean immobility score than the GABAB(1b)-/- mice (p < 0.05). Mean immobility score of 
the GABAB(1b)-/- mice, however, did not differ from that of wild-type controls (P > 0.05). 
Female mice. FST immobility in female mice was similarly affected by genotype 
(Genotype: F2,27 = 5.798, P<0.01), and likewise, post hoc tests showed the GABAB(1a)-/- mice  
had a lower mean immobility than the wild-type controls (44% decrease, P < 0.05) and 
GABAB(1b)-/- mice (P < 0.01; Fig 1b). Female GABAB(1b)-/- mice did not differ from the wild-
type controls in this regard.  
 
8-OH-DPAT, Hypothermia and Behavior 
Male Mice. Genotype significantly influenced body temperature responses to 8-OH-DPAT 
(Genotype: F2,74 = 4.712, P < 0.05. Time: F2,74 = 31.396, P < 0.001. Interaction: F2,74 = 6.589, 
P < 0.001. Fig. 2). Post hoc comparison within each of the wild-type and GABAB(1b)-/- 
genotypes showed profound, long-lasting hypothermia in response to 8-OH-DPAT, relative to 
pre-drug temperatures (Wild-type: P < 0.001 for Time 0 versus 30 and 60 min. GABAB(1b)-/-: 
P < 0.001 for Time 0 versus 30 and 60 min, P < 0.01 for Time 0 versus 90 min). Body 
temperature had returned to a level not different from that measured before 8-OH-DPAT 
administration by 90 minutes in the wild-type mice, and by 120 min in the GABAB(1b)-/- mice 
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(P > 0.05). In contrast, GABAB(1a)-/- mice failed to demonstrate any significant hypothermia in 
response to 8-OH-DPAT relative to their own pre-drug body temperatures (P > 0.05 for Time 
0 versus all other time-points). Likewise, body temperature of GABAB(1a)-/- mice was 
significantly higher than that of the wild-type or GABAB(1b)-/- mice 30 and 60 minutes after 8-
OH-DPAT  administration (P < 0.001, Fig. 2).  
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Fig. 1. Duration of  immobility in the Forced Swim Test of (a.) male and (b.) female wild-type (WT), 
GABAB(1a)-/- (1a-/-) and GABAB(1b)-/- (1b-/-) mice (n = 10 per genotype). *P < 0.05 versus WT; ##P < 0.01 
versus 1b-/-. 
 
Female mice. As for the male GABAB(1a)-/- mice, female GABAB(1a)-/- mice did not 
demonstrate hypothermia in response to 8-OH-DPAT (within GABAB(1a)-/-: Treatment F1,64 = 
2.978, P = 0.112; Time F4,64 =30.101, P < 0.001; Interaction F4,64 = 4.284, P < 0.01; Fig. 3). 
Post hoc analyses revealed that vehicle-treated GABAB(1a)-/- mice showed an increase in body 
temperature 30 minutes after injection relative to that taken at the start of the experiment (P < 
0.001). 8-OH-DPAT-treated GABAB(1a)-/- mice, in comparison, demonstrated neither an 
increase nor decrease in body temperature at 30 minutes post injection (P > 0.05), and as 
such, their mean temperature was lower than that of the vehicle-treated GABAB(1a)-/- mice at 
this time (P < 0.01, Fig. 3). However, 60 minutes after injection, the mean body temperature 
of  8-OH-DPAT-treated GABAB(1a)-/- mice had also risen in comparison to that recorded pre- 
drug (P < 0.001), and was no longer different to that of vehicle treated mice (P > 0.05). 
GABAB(1b)-/- female mice demonstrated a similar pattern of response to the male 
GABAB(1b)-/- and wild-type mice with regard to hypothermic responses to 8-OH-DPAT 
(within GABAB(1b)-/-: Treatment F1,69 = 16.810, P = 0.001; Time F4,69 = 20.343, P < 0.001; 
Interaction F4,69 = 17.837, P < 0.01; Fig. 3). That being a profound, long-lasting hypothermia 
with 8-OH-DPAT relative to both their own mean pre-drug body temperature (at 30 and 60 
minutes, P < 0.001, respectively) and to vehicle-treated mice of the same genotype at the 
same time points (P < 0.001 at 30 and 60 min post-injection, respectively, Fig. 3).  
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Fig. 2. Body temperature of male GABAB(1a)-/- (1a-/-), GABAB(1b)-/- (1b-/-) and wild-type (WT) mice (n = 5 
per genotype) before (Time = 0 min) and after a single administration (arrow head) of (±) 8-OH-DPAT 
(0.5 mg/kg s.c.). ***P < 0.001 versus WT; ###P < 0.001 versus 1b-/-. All mice received 8-OH-DPAT. Note 
also that mean body temperatures at times 30 and 60 min differed significantly from that taken pre-
drug within both WT and 1b-/- mice (P < 0.001) and for 1b-/- at time 90 min (P < 0.01). 
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Fig. 3. Body temperature of female GABAB(1a)-/- (1a-/-, n = 17) and GABAB(1b)-/-  (1b-/-, n = 16) mice 
before (time 0) and after administration  (arrow head)  of either (±) 8-OH-DPAT (0.5 mg/kg, s.c) or 
saline vehicle. ***P < 0.001, **P < 0.01, +P < 0.10 versus vehicle-treated mice within genotype and time-
point. Note also that mean temperatures at time 30 min increased significantly from that taken pre-
drug for vehicle-treated GABAB(1a)-/- mice, and at 60, 90 and 120 minutes post drug for vehicle and 8-
OH-DPAT-treated GABAB(1a)-/- mice (P < 0.001 vs Time 0 min for each time-point within treatment).  8-
OH-DPAT-treated GABAB(1b)-/- mice had significantly lower body temperature relative to that take pre-
drug at time 30 and  60 min (P < 0.001, respectively).  
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Influence of 5-HT1A Receptor Activation on Behavior 
The behavioral activities of mice of the three genotypes differed after 8-OH-DPAT 
administration. In the male mice, only one of the GABAB(1a)-/- mice showed a flat body 
posture after 8-OH-DPAT. In contrast, 3 out of 5 mice of each of the wild-type and 
GABAB(1b)-/- genotypes had flat body postures after 8-OH-DPAT.  
The number of female GABAB(1a)-/- mice showing a flat body posture after vehicle 
(saline) or 8-OH-DPAT treatment was zero in both groups. In comparison, 5 of the 8 
GABAB(1b)-/- female mice treated with 8-OH-DPAT had flat body postures, and one of these 
mice also showed twisting motions of the tail while in a flat posture. None of the vehicle-
treated GABAB(1b)-/- female mice had a flat body posture.  
 
 
Influence of 5-HT1A Receptor Activation on Indictors of Hypothalamic-Pituitary-
Adrenal (HPA) Axis Activity  
Treatment with 8-OH-DPAT significantly increased plasma corticosterone in each of the three 
genotypes (Wild-type T = 66, P < 0.001; GABAB(1a)-/- T = 85, P < 0.01; GABAB(1b)-/- T = 187, 
P < 0.001; Fig. 4a). However, GABAB(1a)-/- mice had a significantly attenuated corticosterone 
response to 8-OH-DPAT in comparison with wild type mice (H = 6.638, P < 0.05, Fig. 4a). 
There was no significant differences in plasma corticosterone between the genotypes of 
vehicle-treated mice (H = 0.792, P = 0.673; Fig. 4a).  
Two ACTH data points were eliminated from analysis as statistical outliers, one from 
the wild-type vehicle group (3680 pg/ml) and the other from the wild-type 8-OH-DPAT-
treated group (1287pg/ml).  
8-OH-DPAT increased plasma ACTH in the wild-type mice (T = 59.00, P < 0.001, 
Fig. 4b). There was a tendency for 8-OH-DPAT to increase ACTH in GABAB(1b)-/- mice as 
well (T = 155, P = 0.066). However, no significant effect of 8-OH-DPAT treatment on plasma 
ACTH concentration was detected for GABAB(1a)-/- mice (T = 122, P = 0.559).  
Plasma ACTH levels in vehicle treated mice were not significantly affected by 
genotype (H = 1.808, P = 0.405). However, within the mice treated with 8-OH-DPAT, 
GABAB(1a)-/- mice had a lower ACTH levels than either wild type or GABAB(1b)-/- mice (P < 
0.05, respectively). The GABAB(1b)-/- mice did not differ significantly from the wild-type 
controls in this regard (H = 7.334, P > 0.05; Fig 4b). 
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Fig. 4. Mean (+ SEM) plasma corticosterone (a.) and ACTH (b.) responses to vehicle (saline, s.c.) or 
(±) 8-OH-DPAT (0.5 mg/kg, s.c.) in male wild-type (WT, n = 25), GABAB(1a)-/- (1a-/-, n = 21) and 
GABAB(1b)-/- (1b-/-, n = 22) mice. ###P < 0.001, +P < 0.10  versus vehicle within genotype; *P < 0.05 
versus WT within 8-OH-DPAT; §P < 0.05 versus 1b-/- within 8-OH-DPAT-treated mice. 
 
 
5-HT1A Receptor Autoradiography 
Few differences were apparent between wild-type, GABAB(1a)-/- and GABAB(1b)-/- mice in 5-
HT1A receptor autoradiographic binding over most of the brain regions analyzed (see Fig. 5 
for representative images). 5-HT1A receptor antagonist ([3H]MPPF) and agonist ([3H]8-OH-
DPAT) binding densities, respectively, were not significantly affected by genotype in the 
caudate putamen, nucleus accumbens, cerebral cortex, dorsal endopiriform nucleus, dorsal or 
ventral hippocampus (or the CA1 region of the dorsal hippocampus), amygdala nuclei, medial 
or posterior hypothalamus, amgydalohippocampal area, dorsal and median raphé nuclei or the 
entorhinal cortex (P > 0.05 for ANOVA factor ‘Genotype’, Fig. 6 a and b).  
Small but significant differences were apparent with [3H]MPPF binding in the lateral 
septum (Genotype F2,17 = 3.73, P < 0.05) and medial septum (limb of the diagonal band) 
(Genotype F2,17 = 3.834, P < 0.05). Post hoc comparisons revealed a slightly higher mean 
binding density in the lateral septum of GABAB(1a)-/- mice in comparison with GABAB(1b)-/-  
mice (P < 0.05), but not versus wild-type mice (P > 0.05, Fig. 6a). In the medial septum, mean 
[3H]MPPF binding density was higher in the GABAB(1a)-/- mice than either the wild-type or 
GABAB(1b)-/- mice, which did not differ from each other in this regard (Fig. 6a). However, 
[3H]8-OH-DPAT binding densities in either the medial or lateral septum were not 
significantly influenced by genotype (P > 0.05). 
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Fig. 5. Representative autoradiograms of 5-HT1A receptor antagonist ([3H] MPPF; a.) and agonist ([3H] 
8-OH-DPAT; b.) binding in wild-type, GABAB(1a)-/- and GABAB(1b)-/- mice (n = 18) in the hippocampus 
(Hpc) and dorsal raphé nucleus (DRN).   
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Fig. 6. Density of 5-HT1A receptor binding sites in different brain regions in wild-type, GABAB(1a)-/- and 
GABAB(1b)-/- male mice (n = 18) as determined using (a.) and [3H] 8-OH-DPAT (b.) autoradiography. *P 
< 0.05 versus wild-type, #P < 0.05 versus GABAB(1b)-/-. 
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6.5 Discussion  
 
The present study demonstrated that constitutive genetic ablation of the GABAB(1a) isoform, 
but not the GABAB(1b) isoform, produced an antidepressant-like phenotype in the FST. This 
finding was replicated in separate cohorts of both male and female mice, attesting to the 
robustness of the phenotype. The present study also demonstrated that GABAB(1a)-/- mice, but 
not GABAB(1b)-/- mice, showed a profound desensitization to the hypothermic and behavioral 
effects of 5-HT1A receptor activation, as assessed using the agonist 8-OH-DPAT. This finding 
was replicated in two different experimental protocols with male and female mice. Similarly, 
in GABAB(1a)-/- mice, but again not in GABAB(1b)-/- mice, HPA activation in response to 5-
HT1A receptor stimulation were attenuated. Furthermore, the influence of GABAB(1a) isoform 
ablation on 5-HT1A receptor desensitization appeared to be largely independent from the level 
of 5-HT1A receptor expression. These finding indicate that the GABAB(1) isoforms have a 
differential involvement in antidepressant-like effects in the FST, and in functional 
interactions with the 5-HT1A receptor.  
The FST in the mouse is one of the most widely used paradigms for assessing 
antidepressant-like behaviour (Cryan and Holmes 2005; Cryan and Mombereau 2004; Petit-
Demouliere et al. 2005).  We have previously shown that mice lacking functional GABAB 
receptors have an antidepressant-like effect in this test (Mombereau et al. 2004a; Mombereau 
et al. 2005) which confirms the antidepressant-like effects of pharmacological antagonism of 
GABAB receptors in the FST (Mombereau et al. 2004a; Nowak et al. 2006; Slattery et al. 
2005a). The results of the present study demonstrate that the GABAB(1a) isoform is important 
for mediating the GABAB receptor-mediated antidepressant-like effects in the FST. It is 
important to note that we have previously shown that GABAB(1a)-/- mice did not show 
differences in locomotor activity from that of wild-type controls (while, in contrast, 
GABAB(1b)-/- mice were hyperactive) (Jacobson et al. 2006a). This indicates that the reduced 
of immobility in the FST of GABAB(1a)-/- mice in the present study was not a non-specific 
effect due to enhanced locomotor activity.   
Previously we have shown that the antidepressant-like behavioral effects of GABAB-
receptor antagonists depends on an interaction with the serotonergic system (Slattery et al. 
2005a). Of all the 5-HT receptors, the 5-HT1A receptor is perhaps the most important for 
influencing the antidepressant response both clinically and in animal models (Cryan and 
Leonard 2000). In particular, 5-HT1A autoreceptor desensitization is thought to contribute to 
antidepressant actions in humans and in animal models (see (Blier and Ward 2003; De Vry 
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1995; Hensler 2003) for reviews). This is further supported in the clinic by the enhancement 
of antidepressant onset of action and efficacy by combining SSRIs with a 5-HT1A antagonist, 
the latter being proposed to act as a mimic of 5-HT1A desensitization (Artigas et al. 1996; 
Blier et al. 1997). Therefore it seemed likely that altered 5-HT1A function may contribute to 
the antidepressant like phenotype of  GABAB(1a)-/- mice. Indeed, our data suggest that the 
phenotype of GABAB(1a)-/- mice in the FST was a result of 5-HT1A autoreceptor 
desensitization, leading to dysregulated 5-HT release 
5-HT1A receptors are expressed both as presynaptic autoreceptors on serotonergic cell 
bodies in the raphé nuclei, and at postsynaptic and extrasynaptic sites in limbic structures of 
the forebrain (see (Hensler 2006) and (Hoyer et al. 2002) for reviews). It is well known that 
activation of 5-HT1A receptors induces hypothermia in a range of different species including 
mice, rats and humans (for examples, see (Blier et al. 2002; Cryan et al. 1999; Larsson et al. 
1990; Millan et al. 1993; Rausch et al. 2006)). In mice, this phenomenon is largely thought to 
be mediated by the presynaptic autoreceptors on serotonergic cell bodies in the dorsal raphé 
nucleus (DRN) (Bill et al. 1991; Goodwin et al. 1985; Martin et al. 1992). In the present 
study, 8-OH-DPAT completely failed to induce hypothermia in GABAB(1a)-/- mice, thus 
suggesting that these mice have altered presynaptic 5-HT1A autoreceptor function. 
GABAB(1a) and GABAB(1b) receptors have recently been shown to localize to 
differential synaptic sites in the hippocampus, amygdala and layer 5 cortical neurons. 
GABAB(1a) was predominantly the heteroreceptor, while GABAB(1b) was mostly postsynaptic 
(Perez-Garci et al. 2006; Shaban et al. 2006; Vigot et al. 2006). In addition, in the 
hippocampus and amygdala, both isoforms were expressed as autoreceptors (Shaban et al. 
2006; Vigot et al. 2006), while in layer 5 of the cortex , the GABAB(1a) isoform was expressed 
as an autoreceptor, but not GABAB(1b) (Perez-Garci et al. 2006).  In situ hybridization studies 
suggest that GABAB(1a) is the prevalent GABAB(1) isoform in the DRN (Bischoff et al. 1999). 
Most 5-HT cell bodies in the dorsal and medial raphé nuclei are co-positive for GABAB(1) 
(Abellan et al. 2000a; Varga et al. 2002). This suggests that it is the GABAB(1a) isoform which 
is predominantly expressed on serotonergic cell bodies in the DRN. 
GABAB and 5-HT1A receptors are both coupled via G-proteins to GIRK2 channels in 
the DRN (Innis et al. 1988), and hypothermic responses to either baclofen or 8-OH-DPAT are 
similarly attenuated in GIRK2-/- mice (Costa et al. 2005). Furthermore, in serotonin 
transporter-deficient (5-HTT-/-) mice, the capacity of baclofen or 5-HT1A receptor agonists to 
inhibit 5-HT cell firing was reduced, as was agonist-stimulated [35S] GTPγS binding by both 
of these receptors (Fabre et al. 2000; Mannoury la Cour et al. 2001; Mannoury la Cour et al. 
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2004). These studies provide evidence that these receptors share G-proteins in the DRN, 
leading  Mannoury la Cour et al., (2004) to speculate that in 5HTT-/- mice, desensitization of 
5-HT1A and GABAB receptor agonist-induced responses was due to a down-regulation of the 
G-protein pool shared by both of these receptors. In the present study there was a lack of, or 
negligible, influence of deletion of the GABAB(1a) (or GABAB(1b) for that matter) isoforms on 
5-HT1A receptor binding density as determined with either a 5-HT1A receptor agonist or 
antagonist, despite the demonstrated complete loss of presynaptic 5-HT1A receptor 
physiological function in the GABAB(1a)-/- mice. It will therefore be of interest in future 
studies to investigate downstream 5-HT1A receptor signalling mechanisms in GABAB(1a)-/- 
mice. Interestingly, other studies using treatments that enhance serotonergic transmission 
have shown reductions in 5-HT1A receptor-dependent G-protein coupling which were 
independent of changes in 5-HT1A receptor ligand autoradiographic binding (Castro et al. 
2003; Hensler 2002; Sim-Selley et al. 2000).  
In contrast with presynaptic mediation of 5-HT1A receptor-induced hyperthermia, 
stimulation of the postsynaptic 5-HT1A receptors is thought to mediate agonist-induced 
stimulation of the HPA axis (Bagdy 1996; Bluet Pajot et al. 1995; Feldman et al. 2000) and 
behaviors characterizing serotonin-syndrome, such as a flat body posture and abnormal tail 
motions (Berendsen et al. 1991; Green and Backus 1990; Hamon 2000). The attenuation of 8-
OH-DPAT-induced behavioral responses typical of the serotonin syndrome and attenuated 
HPA activation in GABAB(1a)-/- mice suggests that postsynaptic 5-HT1A receptors, albeit to a 
much lesser extent than presynaptic receptors, may also be desensitized.   
Overall the present study has indicated that GABAB(1) isoforms show differential roles 
in the mediation of FST behavior and of 5-HT1A receptor function at pre- and postsynaptic 
sites. Further work is needed to investigate the ultrastructural expression of the GABAB(1) 
isoforms in the serotonergic system, particularly at the level of the DRN. Our data identify an 
interaction of GABAB receptors containing the 1a isoform with the serotonergic system and 
suggest that the GABAB(1a) isoform may be a potential therapeutic target for the development 
of novel antidepressants. 
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7.1 Abstract 
 
The GABAB receptor is a heterodimer of GABAB(1) and GABAB(2) subunits. There are two 
isoforms of the GABAB(1) subunit: GABAB(1a) and GABAB(1b). Recent studies with mutant 
mice suggest a differential role for the two GABAB(1) isoforms in behavioural processes. As 
pharmacological and genetic studies have implicated GABAB receptors in cognition we 
investigated the behaviour of GABAB(1a)-/- and GABAB(1b)-/- mice in different types of 
cognitive paradigms. GABAB(1a)-/- and GABAB(1b)-/- mice were both impaired relative to 
wildtype controls in a continuous spontaneous alternation behavior test of working spatial 
memory. In contrast to the reported phenotype of GABAB(1)-/- mice, however, neither 
GABAB(1a)-/- nor GABAB(1b)-/- mice were deficient in a passive avoidance task. On the other 
hand, GABAB(1a)-/- mice were impaired in familiar and novel object recognition. We conclude 
that GABAB(1) isoforms contribute differentially to GABAB receptor-mediated cognitive 
processes. 
 
7.2 Introduction 
 
GABAB receptors are metabotropic GABA receptors formed by the heterodimerization of 
GABAB(1) and GABAB(2) subunits. They modulate excitability as presynaptic hetero- and 
autoreceptors that inhibit the release of neurotransmitters. They are also expressed 
postsynaptically, where they induce inhibitory postsynaptic potentials via activation of 
inwardly-rectifying potassium channels (reviewed in (Bettler et al. 2004)).  
Many studies with GABAB receptor ligands have implicated the GABAB receptor in 
cognitive processes (reviewed in (Bowery et al. 2002)). GABAB receptor antagonists 
improved performance in a number of different cognitive tests, for example hippocampal-
dependent spatial learning and memory (Helm et al. 2005; Nakagawa and Takashima 1997; 
Staubli et al. 1999), and passive (Mondadori et al. 1994; Mondadori et al. 1993) and active 
avoidance (Getova and Bowery 1998). In contrast, GABAB receptor agonists generally (but 
not always (Castellano et al. 1993; Escher and Mittleman 2004)) impair learning and memory 
in these tasks (see (Bowery et al. 2002)). In addition, deletion of the GABAB(1) receptor 
subunit profoundly impaired passive avoidance performance in a gene dose-dependent 
manner (Schuler et al. 2001). 
The GABAB(1) subunit is predominantly expressed in the CNS as one of two isoforms: 
GABAB(1a) or GABAB(1b) (Kaupmann et al. 1998a). Currently no isoform-specific ligands 
exist with which to dissect their influences on cognitive processes. Recently, however, mutant 
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mice deficient in either the GABAB(1a) or GABAB(1b) isoforms have been generated (Vigot et 
al. 2006). We have previously reported that mice deficient in the GABAB(1a) isoform were 
impaired in hippocampal LTP and in an object recognition task (Vigot et al. 2006). 
GABAB(1a)-/- mice also did not discriminate between paired and unpaired tones in a 
conditioned fear paradigm (Shaban et al. 2006), and failed to acquire a conditioned taste 
aversion (CTA) to a novel saccharin solution paired with a LiCl-induced malaise (Jacobson et 
al. 2006b). GABAB(1b)-/- mice, in contrast, acquired CTA normally, but failed to extinguish 
their aversion up to 30 days later (Jacobson et al. 2006b). These studies indicate that the 
GABAB(1) isoforms convey specific and differential components of cognitive processes. 
However, the impact of the GABAB(1) isoforms on other types of cognitive processes has yet 
to be elaborated on.  
In this study, we utilized GABAB(1a)-/- and GABAB(1b)-/- mice to examine the influence 
of the isoforms in three different types of cognitive paradigms. We first aimed to assess novel 
and familiar object recognition, thus replicating our previous findings with a larger cohort of 
mice (Vigot et al. 2006). We also examined the mice in a test indicative of spatial working 
memory, namely continuous spontaneous alternation behaviour (SAB). Finally passive 
avoidance was investigated for comparison with the reported impairment of GABAB(1)-/-  mice, 
lacking  both GABAB(1) isoforms (Schuler et al. 2001).  
 
7.3 Methods and Materials  
 
The generation of GABAB(1a)-/-, GABAB(1b)-/- and wildtype mice has been described previously 
(Jacobson et al. 2006b; Vigot et al. 2006). Briefly, a point mutation knock-in strategy was 
adopted whereby initiation codons for the respective isoforms were replaced with stop 
codons. Mice were generated and maintained on a pure BALB/c genetic background. Mice 
were housed with sawdust bedding, tissue paper nesting materials and one Mouse House® 
(Nalgene, Nalge Nunc International, Rochester, NY) per cage. Housing was at a temperature 
of 22-24°C in a 12 h light : dark cycle with lights on at 6.30 am. Food pellets and tap water 
were available ad libitum (except during experimentation). All experiments were conducted 
during the light cycle, using male mice only. All animal experiments were conducted 
according to the Swiss recommendations and guidelines and approved by the Basel-Stadt 
Cantonal Veterinary Authority. 
Experimentally naïve, singly-housed male wildtype (n =19), GABAB(1a)-/- (n = 15) and 
GABAB(1b)-/- (n = 18) mice (mean age 24 (± 0.4) weeks) were tested in an object recognition 
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task as previously described (Vigot et al. 2006). The test was based on the original principles 
of Ennaceur and Delacour, which relies upon the natural tendency of rodents to attend to a 
novel object more than to a familiar one (Ennaceur and Delacour 1988). Briefly, mice were 
habituated overnight to a new cage (22 x 37 x 15 (h) cm, containing sawdust bedding and ad 
libitum standard food and water). The following day at time = 0 min a clean PVC disc (2 (h) x 
5 (d) cm) was placed for 3 min in the centre of the cage. The disc was then removed and 10 
min later replaced by a new, identical clean disc. This was repeated at time = 24 h. At time = 
24 h + 10 min, a clean grey PVC cone (6 (h) x 5 (d) cm) was placed in the cage. All objects 
were presented for a duration of 3 min and were handled only with tissue paper to prevent 
contamination with odours. All sessions were recorded on video. The frequency of stretch 
attend postures (SAP, defined as head and shoulders extended towards the object) was scored 
at least twice for each mouse by a trained observer blinded to the animals’ genotypes. The 
mean of duplicate scores for each animal were used for analysis. Data from one GABAB(1a)-/- 
mouse was eliminated due to stereotypic circling behaviour during the test which was 
unrelated to its attention towards the objects. Data were analysed within genotype using a 1-
way repeated measures analysis of variance (ANOVA), followed by Fisher LSD post hoc 
comparisons as appropriate.  
In a separate cohort of mice, continuous SAB was assessed in a Y-maze constructed 
from 3 walled arms (8 cm-long, 6 cm-wide) in a radial arrangement each ending in a 10 cm 
square. A clean sheet of paper was placed under the maze and the walls wiped clean for each 
mouse, to reduce odour traces between animals. Wildtype (n = 12), GABAB(1a)-/- (n = 9) and 
GABAB(1b)-/- (n = 9) singly-housed mice (mean age 21 (± 0.6) weeks) were placed 
individually into the Y-maze facing the end wall of a randomly allocated arm, and allowed to 
explore for 5 minutes. The order of the arms (1, 2 or 3) visited were recorded. Overlapping 
triplets of 3 arm visits that included each of the three arms was counted as 1 complete 
spontaneous alternation. The number of alternations performed was divided by the total 
number of arms visited minus 2 (i.e. the number of total possible alternations) to obtain % 
spontaneous alternation (%SA). Data were analyzed as using 1-way ANOVA for the effect of 
genotype followed by Fishers LSD post hoc comparisons. Additionally, within each genotype, 
the difference between mean %SA was assessed against the chance score (50%) using a one-
sample T-test. 
A one-trial step-through passive avoidance paradigm was performed as previously 
described (Schuler et al. 2001; Venable and Kelly 1990). Briefly, wildtype (n = 23), 
GABAB(1a)-/- (n = 17) and GABAB(1b)-/- (n = 18) singly-housed mice (aged 23 (± 0.6) weeks) 
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were placed in the light side of a two-compartment trough-shaped apparatus. The barrier 
between the compartments was opened, the time taken to break a photobeam located 10.5 cm 
inside the dark compartment was recorded automatically (training latency) and a 0.5 mA foot 
shock (Campden Instruments 521 C Source Shock, rectangular current wave) immediately 
delivered though the floor and walls. The shock duration was a maximum of 5 s or until the 
animal escaped back into the light side. Animals with a training latency >150 s were not 
shocked and were excluded from further testing (one wildtype and two GABAB(1a)-/- mice). 
The retention test was performed 24 hours later and was identical to the training trial except 
no shock was delivered. Maximum latency allowed in the retention test was 300 s. Data were 
analysed using a 2-way repeated measures ANOVA.  
 
7.4 Results and Discussion 
 
In the object recognition test, SAPs of wildtype mice were affected by time (the three disc 
presentations) and novelty (cone presentation) (F3,72 = 9.45, P < 0.001; Fig. 1). The number of 
SAPs to the disc was decreased after a 10-min interval (P < 0.001) indicating that the mice 
remembered the object. Interestingly, the number of SAPs to the disc was also reduced 24 h 
later (P < 0.001). In our  previous study, wildtype mice did not demonstrate recognition of the 
familiar disc after a 24-h interval (Vigot et al. 2006). Using a greater number of animals in the 
present study (n = 19 in this study versus 7 previously), it was clear that a more persistent 
memory trace of the object occurred in the wildtype mice. When presented with the novel 
cone at 24 hr 10 min, the number of SAPs increased relative to the disc at maximum 
recognition (i.e. to the 10 min disc presentation, P < 0.001) and to the disc presented at time = 
24 h (P < 0.01), indicating that the mice recognised the cone as a novel object.  
In contrast, no significant alterations were seen in the number of SAPs performed by 
GABAB(1a)-/- mice, irrespective of the delay between presentation of  familiar objects, or of the 
novelty of the object (F3,55 = 0.70, P = 0.56; Fig. 1). This indicated that the GABAB(1a)-/- mice 
failed to recognise a familiar object, or to discriminate between the novel and familiar objects. 
This finding replicates that of our previous study (Vigot et al. 2006).  
The number of SAPs made by GABAB(1b)-/- mice towards the objects was influenced 
by time and novelty (F3,71 = 7.35, P < 0.001; Fig. 1). Like the wild type mice, and in 
accordance with our previous findings, GABAB(1b)-/- mice recognised the familiar disc after a 
10-min delay, as indicated by a reduction in the number of object-oriented SAPs (P < 0.001). 
However, similar to our original findings (Vigot et al. 2006), the present study indicated that 
the GABAB(1b)-/- mice did not, on average, maintain a persistent memory trace of the disc (P = 
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0.43). In accordance with our previous findings, however, the ability of the GABAB(1b)-/- mice 
to discriminate between a familiar object (disc at 10 min) and a novel one (cone at 24 h 10 
min) was intact (P = 0.001).  
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Fig. 1. Number of stretch attend posture performed in an object recognition task by wildtype (n = 19), 
GABAB(1a)-/- (n = 14) and GABAB(1b)-/- (n = 18) mice towards a disc at initial presentation (Time = 0:00), 
to the same (clean) disc 10 min and 24 hr later (Time = 0:10 and 24:00, respectively) and to a novel 
cone-shaped object (Time 24:10). ***P < 0.001 vs Time 0:00 within genotype; ###P < 0.001, ##P < 0.01 
versus Time 0:10 within genotype.  
 
In the SAB test, both GABAB(1) isoform mutant strains were impaired relative to 
wildtype controls in the proportion of completed alternations (% SAB; F2,27 = 5.067, P < 0.05; 
Fig. 2). When examined against a chance performance score of 50%, wildtype (P< 0.001) and 
GABAB(1b)-/- mice (P < 0.05) performed significantly better than chance, whereas the 
GABAB(1a)-/- mice did not (P = 0.196). The number of arms entered, a measure of locomotor 
activity, was higher in the GABAB(1b)-/- mice than either the wildtype or GABAB(1a)-/- mice (P 
< 0.001 and P < 0.05, respectively; Fig. 2). Increased locomotor responses to a novel 
environment have been previously reported for GABAB(1b)-/- mice (Jacobson et al. 2006a). 
However, the greater number of arms visited by the GABAB(1b)-/- mice in this study did not 
improve the proportion of correct alternations in the SAB test. Although there are criticism of 
continuous SAB as a cognitive task per se (Hughes 2004), results of the present study suggest 
that both the GABAB(1) isoforms may have a role in working spatial memory. Further 
delineation of the roles of the isoforms in other more comprehensive tests of spatial working 
and reference memory are therefore warranted.  
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Fig. 2. Percentage of correct alternations (a.), number of correct alternations and total number of arms 
visited (b.) by wildtype (n = 12), GABAB(1a)-/- (n = 9) and GABAB(1b)-/- (n = 9) mice in a Y-maze 
continuous spontaneous alternation task. ***P < 0.001, **P < 0.01, * P < 0.05 versus wildtype; #P < 
0.05 versus GABAB(1b)-/-. 
 
In passive avoidance training all mice vocalized on receiving the shock, indicating that 
pain sensory modalities were functional in both isoform-deficient mutant strains. Latency to 
enter the dark side was greater at retention testing than during training, although there was no 
effect of genotype on either training or retention latency (Genotype F2,107 = 0.55, P = 0.58; 
Training F1,107 = 77.11, P < 0.001; Interaction F2,107 = 0.30, P = 0.74; Fig. 3). This indicated 
that the memory of the shock received in the dark compartment was functional in both mutant 
strains. This finding contrasts with that of the aforementioned GABAB(1)-/- mice, which lack 
both functional isoforms and show profound memory deficits in the retention phase of this 
test (Schuler et al. 2001). It should be noted however, that in GABAB(1)-/- mice, GABAB 
receptor agonist-induced responses are completely abolished (Kaupmann et al. 2003; Schuler 
et al. 2001). In contrast, in the GABAB(1a)-/- and GABAB(1b)-/- mice the loss of GABAB 
receptor function is partial (Vigot et al. 2006), and some GABAB receptor agonist-induced 
functions remain in both of these mutant strains (Jacobson et al. 2006a; Perez-Garci et al. 
2006; Shaban et al. 2006; Vigot et al. 2006). Together these findings indicate that 
heterodimeric GABAB receptor function is essential for the retention of passive shock-
avoidance training, and that this may be accomplished with either one of the GABAB(1) 
isoforms.  
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Fig. 3. Latency of wildtype (n = 23), GABAB(1a)-/- (n = 17) and GABAB(1b)-/- (n = 18) mice to enter the 
dark compartment during training and 24 h later during retention testing in a one-trial step-through 
passive avoidance paradigm.  
 
The present study indicated that the GABAB(1) isoforms contribute differentially to 
distinct cognitive capabilities. Currently it is difficult to speculate about the neuronal and 
molecular mechanisms underlying these differences. The hippocampus is implicated in 
spontaneous alternation (Lalonde 2002), object recognition (Broadbent et al. 2004; Clark et al. 
2000) and passive avoidance (Impey et al. 1998; Stubley-Weatherly et al. 1996). As the 
GABAB(1a)-/- mice are deficient in hippocampal LTP (Vigot et al. 2006), an impairment in this 
mutant in all three of these tasks could have been expected, although this was not the case as 
passive avoidance capabilities were preserved in these mice. However, it is also clear that 
learning can occur in mice in the absence of LTP (reviewed in (Bannerman et al. 2006)). 
Other brain regions are of course also important in all these tasks, for example the rhinal 
cortices are crucial for both passive avoidance (for example, (Phillips and LeDoux 1995)) and 
object recognition learning (reviewed in (Steckler et al. 1998)). GABAB(1) isoforms, however, 
are widely expressed throughout the brain, and the isoforms diverge in expression profile both 
between and within various structures, including within the anatomical divisions of the 
hippocampus and neocortex (Bischoff et al. 1999). Furthermore, the ultrastructural expression 
of the GABAB(1) isoforms differs markedly. In the hippocampus and lateral amygdala the 
GABAB(1a) isoform is a presynaptic heteroreceptor at glutamatergic terminals, while 
GABAB(1b) is mostly postsynaptically located, and both are autoreceptors (Shaban et al. 2006; 
Vigot et al. 2006). This pattern is preserved to a certain degree in layer 5 pyramidal cortical 
neurons, with the exception that the autoreceptor is predominantly the GABAB(1a) isoform 
(Perez-Garci et al. 2006).  
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To summarise, the present study demonstrated that the GABAB(1a) isoform is essential 
for object recognition and discrimination, while the GABAB(1b) isoform may be required more 
for either the retrieval or long-term storage of this type of memory. Impairments of both 
isoform-deficient mice in continuous SAB indicate that further examination of spatial 
working memory are warranted, and may confirm that both isoforms contribute to this 
cognitive capability. In contrast, although previous research has demonstrated that complete 
GABAB receptor heterodimers are required for effective passive avoidance performance, the 
present study shows that the presence of either of the GABAB(1) isoforms is sufficient for 
normal performance. Future research may benefit from pursuit of development of isoform-
specific ligands ultimately for the development of cognitive therapeutics. We conclude that 
the GABAB(1a) and GABAB(1b) isoforms are molecular variants of the GABAB receptor system 
which contribute differentially to specific components of GABAB receptor-mediated cognitive 
functioning.  
 
Acknowledgements 
This work was supported by the National Institutes of Mental Health/National Institute on 
Drug Abuse grant U01 MH69062 (LHJ, KK, JFC) and the Swiss Science Foundation (3100-
067100.01, BB). The authors thank Dr. Annick Vassout for discussions and Erich Müller, 
Christine Hunn and Charlotte Huber for expert technical assistance. 
 
Chapter 8  136 
_________________________________________________________________________________ 
Chapter 8 
 
General Discussion 
 
 
The experiments described in this thesis demonstrated an important role for the GABAB(1) 
isoforms, GABAB(1a) and GABAB(1b), in specific aspects of aversive memory and depression-
related behaviour and neuropharmacology, but not in innate anxiety. Preparatory work 
underlined the necessity of including multiple experimental endpoints in the study of GABAB 
receptor function using in vivo pharmacological approaches, and established the influence of 
genetic background on GABAB receptor-mediated responses. Importantly, it was demonstrated 
that the BALB/c mouse strain was appropriate for carrying the GABAB(1) isoform genetic 
mutations. Initial studies with GABAB(1) isoform-deficient mice showed GABAB(1a) and 
GABAB(1b) isoforms diverged in their influences on locomotor responses to novelty and 
circadian activity, although the GABAB receptor agonists baclofen or GHB were not specific 
for either isoform and were unable to discriminate these differences.  
In tests related to anxiety and depression, the two isoforms had profound, differential 
effects impacts on the acquisition (GABAB(1a)) and extinction (GABAB(1b)) of aversive 
memories. These effects, however, were not accompanied by differences in innate anxiety. The 
GABAB(1a) isoform was specifically implicated in depression-related behaviour, most probably 
mediated via its striking interactions with the serotonergic system. Finally, the GABAB(1) 
isoforms were differentially implicated in distinct cognitive tasks.  
Together these studies have demonstrated that the GABAB(1) isoforms are functionally 
important variants of the GABAB receptor, with specific relevance in depression and to 
aversive learning and memory processes that may underlie cognitive symptoms in anxiety 
disorders. 
 
 
8.1 The Utility of GABAB(1a)-/- and GABAB(1b)-/- Mice  
 
Prior to initiation of the research outlined in this thesis, no specific functions had been 
assigned to the GABAB(1) receptor isoforms (see General Introduction). Genetic-based 
manipulation of the machinery involved in the translation of the isoform proteins represented 
an elegant molecular strategy with great potential for determining the in vivo functions of the 
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isoforms (Huang 2006; Vigot et al. 2006). The result of this approach was the demonstration 
that GABAB(1) isoforms localised specifically to presynaptic heteroreceptor and postsynaptic 
sites, as well as fulfilling autoreceptor functions. This immediately illustrated why it had not 
previously been possible to delineate differential functions of GABAB(1) isoforms. Cellular 
assays lack the necessary morphological organisation, and application of GABAB receptor 
ligands in electrophysiological bath preparations of tissue from normal wildtype animals 
(Shaban et al. 2006), or to normal wildtype animals in in vivo studies, will affect both the 
GABAB(1) isoforms at all of their different sites. Thus, genetic manipulation of mice probably 
represented the only method available for determining the functions of the individual 
GABAB(1) isoforms, and particularly with regard to assessment of the behavioural impact of 
the isoforms.  
In the generation of GABAB(1) isoform deficient mice, a specific concern was the 
potential to generate an epileptiform phenotype similar to that observed in the full GABAB(1)-/- 
and GABAB(2)-/- mice. Both of these mutant strains show overt, spontaneous epileptiform and 
audiogenic seizures (Gassmann et al. 2004; Prosser et al. 2001; Queva et al. 2003; Schuler et 
al. 2001). When generated on a C57BL/6 or 129 mouse strain genetic background, the life-
span of GABAB(1)-/- mice was very short - only a few weeks - due to the seizures, and limited 
their application in behavioural studies (Prosser et al. 2001; Queva et al. 2003). However, on a 
BALB/c background GABAB(1)-/- mice had a much longer life-span – well into adulthood 
(thus enabling behavioural studies), although seizure activity was still present (Gassmann et 
al. 2004; Schuler et al. 2001). Before generation of GABAB(1) isoform specific mice, it was 
unknown whether or not one of the isoforms may have been responsible for the epileptiform 
activity. Therefore GABAB(1) isoform-deficient mice were generated on a BALB/c 
background in case an epileptiform phenotype accompanied either one of the mutations. 
Choice of a BALB/c background would further allow comparisons with other aspects of the 
GABAB(1)-/- and GABAB(2)-/- phenotypes. Ultimately, by observation, it appeared that neither 
of the GABAB(1) isoform-specific mutants demonstrated overt clonic-tonic seizures, although 
confirmation by EEG analysis has yet to be conducted. Indeed, GABAB(1a)-/- and GABAB(1b)-/- 
mice were viable, healthy, bred relatively normally and, in a comprehensive test battery, 
demonstrated no gross morphological or sensory-motor deficiencies (Chapter 3). This 
indicated they were applicable to behavioural research.  
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BALB/c Mice as the Background Strain for Studying GABAB(1)Receptor Isoform 
Function 
 
The importance of the background strain in the phenotypic analysis of mutant mice is well 
known (Crawley 2000; Crawley et al. 1997; Tarantino and Bucan 2000). With regard to the 
aims of this thesis, the BALB/c genetic background is particularly well suited for anxiety- and 
depression-related research. They show higher levels of anxiety than other strains in several 
anxiety paradigms such as the light-dark box and open field test (Griebel et al. 2000; Kim et 
al. 2002), leading to speculations that the BALB/c strain may be a relevant strain to model 
trait, pathological anxiety (Belzung and Griebel 2001). In addition, BALB/cJ mice have a 
high baseline sensitive in many models used in depression-related research (see (Jacobson and 
Cryan 2007)), and are broadly responsive to selective serotonin reuptake inhibitor (SSRI) 
antidepressants in both acute (Crowley et al. 2005; Lucki et al. 2001) and chronic (Dulawa et 
al. 2004) tests, although there are a few findings to the contrary (see (Cervo et al. 2005) and 
see (Jacobson and Cryan 2007) for a review). The BALB/cJ background for the GABAB(1) 
isoform deletion was therefore ideally suited for the aims of this thesis, to determine the roles 
of the isoforms in anxiety and depression-related behaviour.   
It should be noted, however, that some BALB/c substrains may not be ideal 
backgrounds for cognition research. At the very least, test protocols which are effective in 
other strains may require significant adaptation for use with BALB/c strains (Jacobson and 
Cryan, unpublished observations). Performance of BALB/cJ in the Morris water maze 
(MWM) reference spatial memory paradigm has been reported as intermediate, but poor in 
the BALB/cByJ substrain (Francis et al. 1995; Zaharia et al. 1996) (reviewed in (Schimanski 
and Nguyen 2004)) -  although interestingly, BALB/cByJ pups cross-fostered by C57BL/6 
mothers were not impaired in the MWM (Zaharia et al. 1996). Similarly, reported 
performance of BALB/cByJ in cued and contextual conditioned fear vary from intermediate 
(Balogh and Wehner 2003; Bolivar et al. 2001) to poor (Schimanski and Nguyen 2005). Care 
must be taken also with the BALB/cJ strain in object recognition tests. In a recent study 
BALB/cJ mice showed intense, long-lasting interest in a novel object relative to other strains 
(Kim et al. 2005). The object, a Styrofoam cube wrapped in paper, gave many hours of 
entertainment to the BALB/cJ mice, which showed perseverative responses towards it and 
were highly industrious in gnawing and stripping the paper from it. In traditional object 
recognition tasks, a reduction of time spent ‘exploring’ the object is thought to reflect 
familiarity, and thus recognition memory of the object (Ennaceur and Delacour 1988). Clearly 
with BALB/cJ mice in such a task, evaluations must be made circumspectly. With this in 
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mind, an appropriate object recognition protocol was adopted and successfully used in 
BALB/c mice in this thesis. 
With regard to GABAB(1) isoform deletions, perhaps one of the most important things 
to assess in BALB/c mice as the background strain for the mutations was their native GABAB 
receptor function. Classic in vivo probes of GABAB receptor function, motor incoordination 
and hypothermic responses, varied within and between mouse strains (Chapter 2) 
demonstrating that genetic background has a strong effect on the responses to the GABAB 
receptor agonist, baclofen. These studies also demonstrated that hypothermic and ataxic 
responses to GABAB agonists are influenced by independent genetic loci, and therein 
highlighted the necessity of including more than one experimental endpoint in an in vivo 
assessment of GABAB receptor function. Indeed, the BALB/c strain showed both 
hypothermic and ataxic response to baclofen, and was thus validated as an appropriate strain 
for carrying the GABAB(1) isoform genetic mutations. Inappropriate strains would have 
included NMRI, which showed very low ataxic and hypothermic responses to baclofen, or the 
C3H, which showed ataxia, but no demonstrable hypothermia to the agonist. 
Overall, the BALB/cJ background strain was appropriate for carrying the GABAB(1) 
isoform deletions and for anxiety- and depression-related behavioural research. This strain 
provided a safeguard from a possible epileptic phenotype, levels of normal GABAB receptor 
function that would allow identification of a loss of GABAB function, and sensitivity in tests 
of anxiety and depression.  
Clearly genetic mutations, in the appropriate background strain, represent a powerful 
tool in gene-to-phenotype research. However, some general caveats in the use of genetically 
modified mice, as mentioned in the introduction, are worth revisiting. Behavioural analysis of 
genetically modified mice can be influenced by developmental compensations, effects on 
other gene products, and/or altered endocrine and neuronal feedback loops (Cryan and 
Holmes 2005; Pfaff 2001; Phillips et al. 2002). Further, epigenetic and environmental factors, 
such as maternal care, need to be considered (Holmes et al. 2005). These alterations may 
results in ectopic expression of other proteins which may markedly influence behaviour (Pfaff 
2001). Pleiotropy, where one gene which has many (sometimes seemingly unrelated) effects, 
and overlap of individual genes, are common occurrences that may add to the complexities of 
phenotypic analysis in genetically modified animals (Pfaff 2001). 
Overcoming of compensations in constitutive modifications may be addressed by cre-
lox conditional mutation techniques for controlling time and/or tissue dependent expression of 
the mutation (Huerta et al. 2000; Iwasato et al. 2000; Tsien et al. 1996). Indeed, cre-lox 
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conditional mutation techniques have been developed for the GABAB(1) receptor subunit 
(Haller et al. 2004). Alternatively, much interest has been generated in the potential of RNA 
interference (RNAi), as a means to effectively knockdown genes in the adult mouse brain 
(Thakker et al. 2006; Thakker et al. 2004; Thakker et al. 2005). However, whether or not 
these techniques are applicable for conditional, selective knock-down of GABAB(1a) or 
GABAB(1b) proteins has yet to be investigated.  
Overall, the generation of viable, GABAB(1a)-/- and GABAB(1b)-/- mice opened new 
opportunities for behavioural research into the roles of the GABAB(1) isoforms. Indeed, 
studies in this thesis have demonstrated that GABAB(1a)-/- and GABAB(1b)-/- mice are highly 
useful tools for the in vivo assessment of GABAB(1) isoform functions, and were appropriate 
for addressing the hypothesis that these isoforms would have a differential impact on specific 
behaviours relevant to anxiety and depression.  
 
8.2 GABAB(1) Isoforms and GABAB Receptor Function 
 
GABAB Receptor Agonists: Baclofen and GHB   B
 
Amongst the first studies conducted with GABAB(1a)-/- and GABAB(1b)-/- mice, responses to 
baclofen or GHB in GABAB(1) isoform-deficient mice were assessed and found to be similarly 
attenuated in both mutant strains (Chapter 3). This demonstrated that, in support of in vitro 
findings (Brauner-Osborne and Krogsgaard-Larsen 1999; Green et al. 2000; Kaupmann et al. 
1998a; Malitschek et al. 1998), baclofen does not have preferential specificity for the isoforms. 
Furthermore, either GABAB(1a) or GABAB(1b) may compensate to a certain degree for the loss 
of the other to produce baclofen-induced hypothermia or ataxia. These findings also suggested 
that response variation in the different mouse strains with baclofen (Chapter 2) was therefore 
unlikely to be a product of grossly dissimilar expression of the GABAB(1a) and GABAB(1b) 
isoforms per se. It was interesting to note that the baclofen-induced hypothermic response was 
almost completely blocked in both GABAB(1a)-/- and GABAB(1b)-/- mice, whereas baclofen-
induced motor-incoordination was attenuated to a lesser degree in both mutant strains. This 
confirmed the conclusions from Chapter 2 that both of these responses are under divergent 
genetic control, and that it is important to investigate more than one agonist-induced response 
in genetically modified animals. 
GABAB(1a)-/- and GABAB(1b)-/- mice are ideally suited for the testing of possible 
isoform-selective ligands in the hypothermia/ataxia in vivo assay. Selective, isoform-specific 
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agonists, for example, should induce hypothermia and/or ataxia in only one of the two mutant 
strains. GABAB(1a)-/- and GABAB(1b)-/- mice will therefore be valuable tools for the assessment 
of putative GABAB(1) isoform-specific ligands in the future.  
 
GABAB(1) Isoforms and Baseline Locomotor Behaviour 
 
GABAB(1a)-/- and GABAB(1b)-/- mice diverged significantly in their locomotor behaviour, 
although baseline body temperature was not greatly affected by isoform deletion. In particular, 
GABAB(1b)-/- mice were hyperactive in a novel environment and in the circadian dark phase 
(Chapter 3). In the hippocampus, amygdala and L5 neocortex, the GABAB(1b) isoform is 
predominantly expressed postsynaptically (Perez-Garci et al. 2006; Shaban et al. 2006; Vigot 
et al. 2006). Postsynaptic GABAB receptors are coupled to Kir3 channels (Luscher et al. 1997) 
and Kir3.2 and GABAB receptors are co-localised at excitatory postsynaptic sites in the 
hippocampus (Kulik et al. 2006). Thus, it seems likely that the GABAB(1b) isoform may be 
coupled to Kir3 channels, at least in these regions. 
Kir3 channels are strongly implicated in motor function, as is well illustrated by the 
phenotype of the weaver mutant mouse which have a mutation in the Kir3.2 subunit (Patil et al. 
1995) and show pronounced motor impairments including ataxia, trembling and locomotor 
hyperactivity (Rakic and Sidman 1973a; b). Genetic deletion of Kir3.2 in mice induces 
hyperactivity in a novel environmental and in the (early) circadian dark phase (Blednov et al. 
2001; Blednov et al. 2002). The novelty-induced and circadian hyperlocomotion phenotypes of 
Kir3.2-/- mice are similar to that of the GABAB(1b)-/- mice (Fig. 1), and together with the 
aforementioned colocalisation studies, suggests the same Kir3.2 mediated-mechanisms may 
underlie these phenotypes in both mutants. 
Dopaminergic neurons in the VTA are of prime importance in mediating the 
hyperlocomotor effects of dopamine and dopaminergic agents (Kalivas and Stewart 1991). 
Both Kir3.2 channels (Murer et al. 1997) and GABAB receptors are expressed on dopaminergic 
cell bodies in the VTA (Kalivas 1993). There is evidence to suggest that VTA dopaminergic 
neurons are under tonic inhibitory control by GABAB receptors, as local application of GABAB 
receptor antagonists increased VTA extracellular dopamine levels (Giorgetti et al. 2002), and 
systemic application increased the firing rate of VTA dopaminergic neurons (Erhardt et al. 
2002). In contrast, activation of GABAB receptors decreases the excitability and firing rate of 
VTA dopaminergic neurons and reduced dopamine release in the nucleus accumbens (Chen et 
al. 2005; Lacey 1993; Olpe et al. 1977; Westerink et al. 1996; Wirtshafter and Sheppard 2001). 
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Furthermore, baclofen, or the GABAB positive modulator GS39783, dose dependently 
attenuated acute cocaine-induced hyperlocomotion (Lhuillier et al. 2006). Together these 
findings may indicate that tonic inhibition of VTA dopaminergic neurons may be compromised 
in GABAB(1b)-/- mice, mediated by a coupling failure with the Kir3.2 channel, and thus may 
underlie their hyperlocomotor phenotype.  
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Fig. 1. Kir3.2-/- mice are hyperactive in a novel environment (A), and during the dark phase (B). Kir3.2+/- 
mice were also hyperactive in the dark phase (C). From Blednov et al., Psychopharmacology (2002) 
159:370–378. Similarly, GABAB(1b)-/- mice are hyperactive in a novel environment (males, D; females, 
E); and during the dark phase (males only, F). From Chapter 3; Jacobson et al., J Pharmacol Exp Ther 
(2006) 319 (3):1317-1326 .  
 
Further investigations are clearly needed to characterise the influence of the GABAB(1) 
isoforms on the dopaminergic system. In addition, research into the influence of either isoform 
in addiction related research, in which the GABAB receptor has been firmly implicated (for a 
recent example see (Lhuillier et al. 2006), and see (Bettler et al. 2004; Bowery et al. 2002; 
Roberts 2005) for reviews), should yield interesting results.   
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8.3 GABAB(1) Isoforms, Anxiety and Cognition 
 
Aversive Learning and Memory 
 
GABAB(1a)-/- and GABAB(1b)-/- mice showed profound differences in aversive learning and 
memory, as assessed in a conditioned taste aversion test (CTA; Chapter 4). GABAB(1a)-/- mice 
failed to acquire CTA, which is probably not entirely surprising given the phenotype of these 
mice in other cognitive tasks. For example, in an object recognition task, GABAB(1a)-/- mice 
were unable to remember familiar objects or to distinguish between novel and familiar objects 
(Chapter 7, Table 1). Therefore their acquisition failure in the CTA task could reflect either a 
failure to make, or consolidate, an association between the saccharin (the conditioned stimulus; 
CS) and the malaise (the unconditioned stimulus; US), or indeed to recognize the saccharin as 
familiar at all.  
GABAB(1b)-/- mice, in contrast, showed a profound failure to extinguish CTA. One 
factor which may influence the rate of extinction is the strength of the original association 
(Nolan et al. 1997; Reilly and Bornovalova 2005). As a constitutive germline mutant, loss of 
the GABAB(1b) isoform in GABAB(1b)-/- mice was also present at CTA acquisition. It could 
therefore be posited that the extinction failure of the GABAB(1b)-/- mice may have origins from 
a stronger acquisition, rather than a failure in extinction per se. GABAB(1b)-/- mice however, did 
not show a stronger aversion to saccharin at acquisition testing than wild-type mice, although 
as both were near ceiling aversion levels any such differences may not have been apparent. 
There was certainly no indication that GABAB(1b)-/- mice showed enhanced learning in other 
cognitive tasks (for example in working spatial or 24 hour consolidation of object recognition 
memory, both of which were impaired in GABAB(1b)-/- mice; Chapter 7, Table1).  
To test the possibility of an enhanced CTA acquisition in GABAB(1b)-/- mice, a LiCl 
dose response experiment could be conducted, as different LiCl doses influenced the rate of 
extinction in the background BALB/c strain (Chapter 4). Alternatively a step-wise CTA 
acquisition protocol could be used to by using repeat CS-US pairings with low levels of LiCl. 
The rate of CTA acquisition could then be compared with wild-type mice. The ideal method 
for testing the impact of the GABAB(1b) isoform on extinction learning alone would be selective 
antagonism of the GABAB(1b) isoform after a successful CTA acquisition but before extinction 
training. In the absence of isoform selective antagonists,  this could be addressed by either cre-
lox conditional mutation techniques (Haller et al. 2004) or isoform-specific RNAi (Thakker et 
al. 2004; Thakker et al. 2005). CTA would be the ideal partner in such approaches, as in the 
absence of unreinforced CS exposures (i.e. extinction training), CTA shows remarkable 
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persistence (sometimes even for the lifetime of an animal) (Bures 1998a). This would allow 
sufficient time to produce a level of protein knockdown between CTA acquisition and the 
initiation of extinction training without greatly compromising the level of pre-extinguished 
aversion.  
The alternative hypothesis for the extinction failure of GABAB(1b)-/- mice is of course 
that they were unable to learn extinction, or perhaps to modify the original aversive trace 
through an extinction learning processes. A specific aversive memory extinction failure per se 
would represent a strong case for the promotion of the GABAB(1b) isoform as a target in anxiety 
disorders where persistence of aversive memory prevails, such as PTSD and specific phobia 
(Davis and Myers 2002; Davis et al. 2006; Ressler et al. 2004).  
Other methods for investigating aversive memory have been examined with GABAB(1) 
isoform-deficient mice. In a conditioned fear paradigm, GABAB(1a)-/- mice demonstrated a 
modest acquisition of conditioned freezing to a tone paired with a 0.6 mA footshock (CS+) 
versus an unpaired tone (CS-) (~38% versus ~20% freezing, respectively) (Shaban et al. 2006). 
This contrasts with the failure of GABAB(1a)-/- mice to acquire CTA (Chapter 4). Indeed as 
GABAB(1a)-/- mice were also impaired in object recognition and discrimination (Chapter 7, 
Table 1), it would therefore not have been surprising if GABAB(1a)-/- mice were unable to 
discriminate between two tones. Tones by themselves can induce freezing in mice in the 
absence of associative learning (Kamprath and Wotjak 2004). It would have been interesting to 
determine whether or not the two tones used in the Shaban study produced variable levels of 
freezing when presented in the absence of conditioning, in case this may have contributed to 
differences seen between the CS+ and CS- induced freezing. Alternatively, it may also have 
been informative to compare the acquisition of fear conditioning using either of the two tones 
as the CS+. When fear conditioned with a 0.9 mA footshock however, GABAB(1a)-/- mice no 
longer distinguished between the CS+ and CS-, although when the shock intensity was further 
increased to 1.35 mA, wild-type mice also failed to discriminate between the CS+ and CS- 
(Shaban et al. 2006). This indicated that GABAB(1a)-/- mice generalized at a lower shock 
intensity than wild type mice. It is unclear at the present time precisely how shifting of the 
generalization threshold in GABAB(1a)-/- mice relates to the accompanying loss of associativity 
of cortico-LA presynaptic LTP also seen in this mutant (Shaban et al. 2006). Further studies to 
fully investigate this phenomenon, perhaps in combination with in vivo recordings, promise to 
be very enlightening.  
GABAB(1b)-/- mice, in contrast to their successful acquisition of a CTA (Chapter 4), 
failed to acquire conditioned freezing at all (Shaban et al. 2006). However, as GABAB(1b)-/- 
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mice have a hyperlocomotor phenotype (Chapter 3), it is possible that this may interfere with 
the behavioural expression of freezing. 
 
 
Innate Anxiety 
 
Given the differential influences of the GABAB(1) isoforms on conditioned aversive learning in 
CTA (Chapter 4), and previous findings that mice deficient in GABAB(1) or GABAB(2)  subunits 
have a highly anxious phenotype in exploratory paradigms (Mombereau et al. 2004a; 
Mombereau et al. 2005; Mombereau et al. 2004b), it was of interest to examine unconditioned 
anxiety in GABAB(1a)-/- and GABAB(1b)-/- mice. However, in a comprehensive battery of 
unconditioned anxiety tests, including autonomic, active and passive behavioural readouts, 
there was no evidence for a specific influence of either isoform (Chapter 5). This indicated that 
the GABAB(1) isoforms themselves do not have a defining role in innate anxiety.  
One of the main differences between the GABAB subunit- and GABAB isoform-
deficient mice is that GABAB(1)-/- and GABAB(2)-/- mice show a loss of all GABAB receptor 
function (Gassmann et al. 2004; Schuler et al. 2001; Shaban et al. 2006), where as residual 
agonist-induced function remains, albeit blunted, in both the GABAB(1a)-/- and GABAB(1b)-/- 
mice (Chapter 3; Perez-Garci et al. 2006; Shaban et al. 2006; Vigot et al. 2006). In particular, 
GABAB autoreceptor function is preserved in GABAB(1a)-/- and GABAB(1b)-/- mice in the 
hippocampus and amygdala, but not in GABAB(1)-/- mice (Shaban et al. 2006; Vigot et al. 
2006). Both the (ventral) hippocampus and amygdala are strongly implicated in anxiety and 
fear, (see (Bannerman et al. 2004) for a review). Although it is currently unknown what 
influences GABAB autoreceptor function in these structures may exert on anxious behaviours, 
these findings suggest that further investigations into this area may be warranted. 
Finally, it is worth noting that other endophenotypes of anxiety disorders have yet be 
investigated in GABAB(1) isoform-deficient mice (see Table 2, General Introduction). These 
include panic behaviour in response to a predator as a model of the “sudden onset of intense 
fearfulness” characteristic of panic disorder; examination of social interactions with unfamiliar 
conspecifics, to model “anxiety provoked by social situations, leading to avoidance behaviour” 
in social phobia; and ultrasonic vocalizations in pups separated from their mothers, to model 
separation anxiety. Examining these endophenotypes may be instructive avenues of study in 
future research.  
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Cognition 
 
Studies with GABAB(1a)-/- and GABAB(1b)-/- mice have demonstrated that GABAB(1) isoforms 
have distinctly different roles in specific cognitive tasks.   
GABAB(1a)-/- mice were impaired in a range of tasks reliant on working memory 
(Chapter 7, Table 1). In tasks requiring long term memory, CTA acquisition was profoundly 
impaired, although passive avoidance was spared in these mice. Passive avoidance however is 
reliant on many different cognitive components, including spatial, procedural and associative 
elements (Crawley 2000), and thus there may have been compensation in these different 
processes to facilitate passive avoidance. It is interesting to note that in the studies by Vigot et 
al., (2006), GABAB(1a)-/- mice were impaired in hippocampal LTP, and showed evidence for a 
loss of AMPA silent synapses. Long-term maintenance of LTP is dependent, at least in part, on 
the recruitment of additional AMPA receptors containing the GluR1 subunits into activated 
synapses (see (Malinow and Malenka 2002)). Of note, mice deficient in the GluR1 subunit of 
the AMPA receptor show a loss of hippocampal LTP, profound deficits in working spatial 
memory, but preservation of spatial reference memory (for examples see  (Reisel et al., 2002; 
Schmitt et al., 2003; Zamanillo et al. 1999), and see (Bannerman et al. 2006) for a review). It 
may therefore be of interest to broadly assess both spatial working and reference memory in 
GABAB(1a)-/- mice, to determine whether or not a similar phenotype to GluR1-/- mice is 
demonstrated in that spatial reference memory is spared. 
GABAB(1b)-/- mice show a different cognitive phenotype to that of the GABAB(1a)-/- 
mice. GABAB(1b)-/- mice, like GABAB(1a)-/- mice, are moderately impaired in spontaneous 
alternating behaviour, and in long term familiar object recognition. However, they differ from 
the GABAB(1a)-/- in preservation of short term familiar object recognition and novel object 
discrimination, and in CTA acquisition. Clearly CTA extinction cannot be compared with 
GABAB(1a)-/- mice. However, a question that arises with the failure of CTA extinction in 
GABAB(1b)-/- mice is whether or not it may also be accompanied by broader deficits in reversal 
learning. This would certainly be of great interest to evaluate from a cognitive science basis, 
and could be assessed in tests of reversal learning in spatial reference memory tasks. 
The mechanisms underlying the cognitive phenotypes of GABAB(1a)-/- and GABAB(1b)-/- 
mice have yet to be investigated. It will be interesting to examine the influence of these 
isoforms, and in particular the postsynaptically expressed GABAB(1b) isoform, on downstream 
signalling pathways related to memory. GABAB receptors couple to adenylyl cyclase (Bettler 
et al. 2004) and influence the mitogen-activated protein kinase (MAPK) pathway (Ren and 
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Mody 2003). GABAB receptors may therefore modulate cognitive processes via the cAMP-
PKA-CREB or MAPK signalling pathways, both of which are strongly implicated in learning 
and memory (see (Abel and Kandel 1998; Arnsten et al. 2005; Berman and Dudai 2001; Silva 
et al. 1998)). This is supported by the finding that the GABAB receptor antagonist SGS742 
improved hippocampal-dependant spatial reference memory and reduced basal hippocampal 
CRE-binding (Helm et al. 2005). Clearly this will be an important series of studies for future 
investigation.  
 
Table 1. Summary of cognitive phenotypes of GABAB(1a)-/- and GABAB(1)-/- mice 
 
Paradigm Classification GABAB(1a)-/- GABAB(1b)-/-
Continuous spontaneous 
alternating behaviour 
Working memory 
Spatial 
Impaired Moderately 
impaired 
10 minute delay familiar object 
recognition 
Working memory 
Recognition 
Impaired OK 
Novel object discrimination Working memory 
Recognition 
Impaired OK 
24 hour delay familiar  object 
recognition 
Reference memory 
Recognition 
Impaired Impaired 
Passive Avoidance Reference memory 
Conditioned place 
avoidance 
OK OK 
CTA acquisition Reference memory 
Associative aversive 
learning 
Impaired OK 
CTA extinction Reference memory 
Extinction learning 
? Impaired 
 
 
GABAB(1) Isoforms: Emotional Learning & Memory  Versus Leaning & Memory 
 
As GABAB(1a)-/- or GABAB(1b)-/- mice showed no innate anxiety phenotype, and a range of 
different cognitive impairments, the possibility that deficits in conditioned aversive learning 
and memory could be product of a cognitive phenotype, rather than a deficit in emotional 
learning and memory per se, bears some consideration. In aversive learning and memory 
paradigms however, evidence exists both “for” (CTA) and “against” (passive avoidance) 
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specific roles for the GABAB(1) isoforms in emotive cognition. At least four considerations 
arise from this observation: 
1) If GABAB(1) isoforms play specific roles in emotional learning and memory, that are distinct 
from their effects on non-emotional learning and memory, they are not unique. Indeed, mice 
deficient in the cannabinoid receptor CB1 which show impairments in extinction of 
conditioned freezing (Kamprath et al. 2006; Marsicano et al. 2002) are not impaired in 
appetitive (Holter et al. 2005) or spatial learning (C.T. Wotjak, Max Planck, Munich, pers. 
comm.); 
2) If GABAB(1) isoforms do have a specific role in emotional learning and memory, then the 
specific processes of acquisition (GABAB(1a)-/-) and extinction (GABAB(1b)-/-) of aversive 
memories can occur independently of innate anxiety (at least with regard to the GABAB1 
receptor isoforms); 
3) In mutant mice which have deficits in both non-emotional and emotional aspects of 
cognition, it will be difficult to comprehensively dissect the former from the later, given the 
multimodal cognitive constructs in many of these tasks; 
4) A specific role in non-emotional learning and memory processes does not preclude an 
important impact in the modulation of aversive memory. The most well-known example in this 
category is a pharmacological agent: D-cycloserine, a partial agonist at the NMDA receptor 
strychnine-insensitive glycine site and a cognitive enhancer, which speeds extinction learning 
in both animal models and in clinical studies, although it is without intrinsic anxiolytic activity 
in itself (Ressler et al. 2004; Walker et al. 2002).  
 
8.4 GABAB(1) Isoforms and Depression 
 
The GABAB(1a) isoform demonstrated a clear and specific involvement in depression-related 
behaviour (Chapter 6). This was illustrated by an antidepressant-like phenotype in the FST and 
by profound desensitization of presynaptic 5-HT1A receptors. Desensitization of 5-HT1A 
autoreceptors has been strongly implicated in the action of antidepressants, as evidence in 
many animal studies and in clinical trials (Artigas et al. 1996; Blier et al. 1997; Blier and Ward 
2003; Cryan and Leonard 2000; De Vry 1995; Hensler 2003). Intriguingly, the expression of 
the 5-HT1A receptor itself was unaffected in GABAB(1a)-/- mice. Immunohistochemistry, 
autoradiography and in situ hybridisation studies suggest that GABAB(1a) isoforms are probably 
colocalised on 5-HT cell bodies in the raphae nuclei (Abellan et al. 2000a; Abellan et al. 
2000b; Bischoff et al. 1999; Serrats et al. 2003). Together with the demonstration of reduced  
baclofen-stimulated G-protein binding in 5-HT transporter-deficient (5-HTT-/-) and 5-HT1A-/- 
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mice (see (Fabre et al. 2000; Mannoury la Cour et al. 2001; Mannoury la Cour et al. 2004)), 
these findings may support a dysregulation in G-protein cross-talk between GABAB(1a) and 5-
HT1A receptors on serotonergic cell bodies as a mechanism underlying the 5-HT1A receptor 
desensitisation in GABAB(1a)-/- mice. Alternatively, or additionally, contributions to the 5-HT1A 
desensitisation could arise from a loss of GABAB(1a,2) receptor-mediated inhibition of 5-HT 
release, leading to increased 5-HT at the level of the DRN (and, for that matter, in postsynaptic 
structures), and thus a direct 5-HT-mediated desensitisation of DRN 5-HT1A receptors (Adell et 
al. 2002). This latter mechanism is supported by evidence for postsynaptic 5-HT1A receptor 
desensitisation in GABAB(1a)-/- mice (Chapter 6). This included a loss of hypolocomotor, ataxic 
and serotonin syndrome responses. Interestingly, attenuated in vivo responses to 5-HT1A 
receptor activation has also been demonstrated following chronic antidepressant treatment in 
the clinic (Lesch et al. 1990; Rausch et al. 2006). 
GABAB(1a)-/- and GABAB(1b)-/- mice are ideally suited for use in further studies to 
elucidate the mechanisms involved in interactions between the 5-HT and GABAB receptors. 
Such studies would ideally involve an ultrastuctural analysis of the GABAB(1) isoform 
expression in the raphé nuclei, the influence of GABAB(1a) isoform deletion on 5-HT1A receptor 
G-protein coupling, and the baseline and stimulated release profile of 5-HT in GABAB(1a)-/- 
mice. 
There is growing evidence that abnormalities in the 5-HT1A receptor system in early 
life is responsible for the expression of pathological behaviour in the adult, rather than 
dysregulation of the adult 5-HT1A receptor per se (Ansorge et al. 2004; Gross and Hen 2004). 
For example, neonatal rescue of 5-HT1A receptor function in conditional 5-HT1A receptor 
knockout mice reversed the anxiety phenotype normally seen in these mutants, but not when 
the rescue was performed in adult mice (Gross et al. 2002). In addition, the abnormal sleep 
architecture of adult 5-HTT-/- mice, which show high levels of extracellular serotonin and a 
profound desensitization of presynaptic 5-HT1A receptors, was rescued by transient treatment 
of the neonate with the 5-HT synthesis inhibitor pCPA, or the 5-HT1A receptor silent 
antagonist WAY100635 (Alexandre et al. 2006). In this regard, it is interesting to note that the 
GABAB(1a) isoform is highly expressed in the neonate and subsequently decreases during 
development (Fritschy et al. 1999; Malitschek et al. 1998). This raises the possibility that the 
GABAB(1a) isoform may have a developmental role in the maturation of the 5-HT receptor 
system. Given the efficacy of serotonin depletion and 5-HT1A receptor blockade on neonatal 
rescue of 5-HTT-/- mice, it may therefore be of interest to conduct a similar study in 
GABAB(1a)-/- mice. Analysis of sleep architecture of GABAB(1) isoform-deficient mice has not 
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been conducted to date. However, GABAB receptors influence circadian rhythm (for 
examples see (Colwell et al. 1993; Gillespie et al. 1997; Moldavan et al. 2006; Ralph and 
Menaker 1989)), and GABAB(1a)-/- mice demonstrated a subtle increase in circadian locomotor 
activity during the light-phase (Chapter 3) – which, although not a measure of sleep per se, at 
least indicated that while moving, these mice were not asleep.  
Altered sleep patterns are an endophenotype of anxiety and a classic diagnostic 
criterion in depression. Furthermore, in humans, sleep deprivation is one of the few fast acting 
antidepressant treatments available, and paradoxical (REM) sleep is altered by many 
antidepressant medications (Adrien 2002; Wirz-Justice and Van den Hoofdakker 1999). In a 
recent study, mice selectively bred for high levels of immobility in the tail suspension test 
were found to display lighter and more fragmented sleep and decreased REM sleep latency, 
abnormalities that resemble those observed in depressed patients (El Yacoubi et al. 2003). 
Sleep disturbances in fear conditioned rats (Jha et al. 2005; Pawlyk et al. 2005) and mice 
(Sanford et al. 2003a; Sanford et al. 2003b) have also been reported. These studies suggest 
that investigating sleep patterns in mice will be of great use in anxiety- and depression-related 
research. Further studies on the impact of GABAB receptor manipulations on sleep and 
depression-related behaviours in mice are an interesting direction for future investigations.  
Studies on the effects of GABAB(1a) isoform deletion on brain-derived neurotrophic 
factor (BDNF) may also be warranted. GABAB receptor antagonists have been shown to 
increase the concentration of brain-derived neurotrophic factor (BDNF) and nerve growth 
factor (NGF) in the hippocampus and cortex (Froestl et al. 2004; Heese et al. 2000). BDNF in 
particular has been propose to contribute to the actions of antidepressants (see (Duman et al. 
1997) and (Berton and Nestler 2006) for reviews). As such it is plausible that induction of  
BDNF could contribute to the antidepressant effects of GABAB(1a) isoform deletion .  
Both anxiety disorders and major depression (see Tables 1 and 2, General Introduction) 
are characterised by deficits in attention. Given the impact of the GABAB(1a) isoform in 
particular on tests of working memory, and in depression-related behaviour and serotonergic 
neurotransmission, assessment of attention in GABAB(1a)-/- mice would be of interest to 
investigate in the future. This would probably be best assessed in the 5-choice serial reaction 
time task, in which mice must pay attention to five holes into which they can poke their nose to 
obtain a reward when, and only when, a hole is (randomly) illuminated. This task has recently 
be validated in C57BL/6 and DBA/2 mice, which were both able to do the task, although strain 
differences were apparent (Patel et al. 2006), and was applied in a study of galanin-
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overexpressing transgenic mice to demonstrate that the known cognitive deficits in these mice 
were not a product of deficits in attention (Wrenn et al. 2006). 
Finally, with regard to depression-related behaviour, GABAB(1a)-/- and GABAB(1b)-/- 
mice have yet to be examined in tests that model the induction of depression-related behaviour. 
Perhaps the most ideally suited test, despite it’s criticisms (Cryan and Mombereau 2004; Cryan 
and Slattery 2007), would be the chronic mild stress assay. In a shuttle-box learned 
helplessness paradigm, propensity to develop a state of behavioural despair per se may be 
difficult to delineate from specific and differential cognitive impairments in the isoform-
deficient mice (for example in spatial working memory). A test such as olfactory bulbectomy, 
in contrast,  may be biased by the hyperlocomotor phenotype of the GABAB(1b)-/- mice. Chronic 
mild stress, in comparison, would allow assessment of the propensity of the isoform-deficient 
mice to develop stress-induced, depression-related behaviours relatively independently of overt 
spatial memory impairments or hypolocomotion. Furthermore, the background strain for the 
GABAB(1a)-/- and GABAB(1b)-/- mice, BALB/c, respond sensitively to chronic mild stress with 
alterations in fur state, grooming and increased conspecific aggression ((Ducottet and Belzung 
2004; 2005; Mineur et al. 2003; Pothion et al. 2004). The inclusion of these additional, 
sensitive parameters to the normal hedonic endpoint in chronic mild stress (sucrose 
preference), may add considerably to the power of this test for the detection of real differences 
between GABAB(1) isoform mutants and wildtype controls (see (Jacobson and Cryan 2007) for 
a review).  
Studies presented in this thesis represent the ‘tip of the iceberg’ with regard to the 
GABAB(1) isoforms in depression-related research. There is much work yet to be done in order 
to further define the underlying mechanisms and the full extent of the impact of the GABAB(1a) 
isoform, in particular, in endophenotypes of depression. However, these findings clearly 
identify a strong  interaction of GABAB receptor heterodimers containing the 1a isoform with 
the serotonergic system and suggest that the GABAB(1a) isoform may be a potential therapeutic 
target for the development of novel antidepressants. 
  
8.5 Perspectives 
 
Research presented in this thesis demonstrated that the two isoforms of the GABAB(1) receptor 
subunit, GABAB(1a) and GABAB(1b), are functionally distinct molecular variants of the GABAB 
receptor. Furthermore, these isoforms have particular and differential relevance in the 
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formation and persistence of aversive memory and depression-related behaviour and 
neurobiology.  
Overt phenotypes of mice deficient in the GABAB(1a) isoform included: failures in the 
acquisition of aversive memory, antidepressant-like phenotype in the mouse FST, pre- and 
postsynaptic desensitization of 5-HT1A receptors including attenuated HPA responses to 5-
HT1A receptor stimulation, and deficits in working spatial and recognition memory and in 
reference recognition memory.  
The phenotype of GABAB(1b)-/- mice included novelty-induced and circadian 
psycholocomotor disturbances, profound failures in the extinction of aversive memories, 
impaired spatial working memory and deficits in the consolidation of recognition memory.  
These phenotypes provide convincing evidence that GABAB(1) receptor isoforms are 
specifically and differentially implicated in endophenotypes of depression, and indeed, despite 
a lack of impact on innate anxiety, in endophenotypes of anxiety-related disorders. It is of 
further interest to note that many of these endophenotypes presented in isoform- deficient mice  
are common to both depression and anxiety-related disorders. Future studies will also be able 
to focus on using these mice to delineate the contribution of the isoforms to other pathologies 
where GABAB has been implicated, such as addiction, epilepsy, schizophrenia, pain, food 
intake and gastroesophageal reflux disease (Bowery 2006; Buda-Levin et al. 2005; Foltin 2005; 
Lhuillier et al. 2006; Mizukami et al. 2002; Patel et al. 2001; Paterson et al. 2004; Slattery et al. 
2005b; Treiman 2001). 
Clearly, the influence of the GABAB receptor on physiology and behaviour are defined 
by the location of the receptor, which includes heterosynaptic, postsynaptic and autoreceptor 
locations. It is this differential expression profile which determines the functions that may be 
ascribed to the GABAB receptor. This is delineated to a great degree by the differential 
trafficking of the GABAB(1a) and GABAB(1b) isoforms.  
Perhaps the greatest challenge ahead for the GABAB(1) receptor isoforms will be the 
development of isoform specific ligands. Given that the ligand binding domain for the 
GABAB(1a) and GABAB(1b) isoforms are both coded from the same region of the Gabbr1 gene, 
it seems unlikely that targeting this site will yield selective ligands. The molecular 
architecture of the two isoforms themselves suggest the sushi domains, or their interacting 
proteins, as a possible targets for manipulating GABAB(1) isoform trafficking. As pre- and 
postsynaptic GABAB receptors, by nature of their location, have different interacting proteins 
and effector systems, targeting of proteins interacting at the GABAB receptor C-terminus may 
provide a amenable therapeutic target for the GABAB(1) isoforms (Marshall 2005). Finally 
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siRNA treatments may ultimately offer a method for specific targeting GABAB(1) isoforms 
(Hoyer and Dev 2006). Although GABAB(1) isoforms will be a complex target for the 
development of pharmacotherapies, data generated in this thesis demonstrate that these efforts 
should be worth it. It is hoped that one day the GABAB(1) isoforms may contribute in the 
development of treatments for psychiatric disorders such as depression and anxiety, and the 
cognitive dysfunctions associated with them. 
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